StudyID,InsuranceEnrollment,OtherInsurance,Height,Weight,BMI,HasBenignBreastDisease,BenignBreastDisease,BenignBreastDiseaseDiagnosisDate,BenignBreastDiseaseComments,HasCarcinoma,CarcinomaDiagnosis,Carcinoma,CarcinomaDiagnosisDate2,CarcinomaComments,BreastCancerDiagnosisDate,BreastCancerDiagnosis,ClinicalStageT,ClinicalStageN,ClinicalStageM,PathologicalStageT,PathologicalStageN,PathologicalStageM,SimpleStage,L,R,B,M,Histology,HistologyOther,TumorGrade,Ki67Value,Ki67,RS,ERPositiveCells,ERStainingIntensity,PRPositiveCells,PRStainingIntensity,IHC,ISH,HistologyComments,RecurrenceType,RecurrenceDate,RecurrenceSite_,RecurrenceComments,ImagingDetailNumber,DenseBreasts,TumorSizeAtDiagnosis,ImagingDetailsComments,SurgicalHistoryNumber,BiopsyTimepoint,BiopsyTissueSize,TumorSizeAtBiopsy,SurgicalTimepoint,SurgicalTumorSize,SurgicalMargins,SurgicalHistoryComments,OncotypeDXScore2,MammaprintScore,PDL1Status,GuardantTestingID,NGSTestingID,SignateraTestID,OtherMolecularTest
BCSB0001,,Blue Cross PPO,180.3,98.9,30.4,No,,,,Yes,,Ductal carcinoma in situ,5/1/2019,"grade 2, 8mm",5/1/2019,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,,," ER+, PR-, HER2-",70,2,0,0,0,Unknown,"ER+, PR- , HER2-",,,,,,,,,,,,,,,,,12,,,,,,
BCSB0001,,Blue Cross PPO,180.3,98.9,30.4,No,,,,Yes,,Ductal carcinoma in situ,5/1/2019,"grade 2, 8mm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.6,,,,,,,,,,12,,,,,,
BCSB0001,,Blue Cross PPO,180.3,98.9,30.4,No,,,,Yes,,Ductal carcinoma in situ,5/1/2019,"grade 2, 8mm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.4,0.8,prior to ANY treatment including surgery,0.6,0.6,,12,,,,,,
BCSB0003,,,170.2,113.4,39.1,Yes,Fibrocystic Breast Changes,8/24/2018,Right,No,,,,,8/24/2018,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,,X,,,Ductal,,3,80,High," ER-, PR-, HER2-",0,0,0,0,1,Unknown,ER- PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0003,,,170.2,113.4,39.1,Yes,Fibrocystic Breast Changes,8/24/2018,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,,,,,,,,,,,,,,,,
BCSB0003,,,170.2,113.4,39.1,Yes,Fibrocystic Breast Changes,8/24/2018,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3.2,1.6,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0004,,Kaiser Foundation Health Plan,165.1,79.4,29.1,No,,,,Yes,,Ductal carcinoma in situ,12/19/1979,"GRADE: 3
",11/1/2017,Invasive ductal carcinoma,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage IIa,X,,,,Ductal,,3,,," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0004,,Kaiser Foundation Health Plan,165.1,79.4,29.1,No,,,,Yes,,Ductal carcinoma in situ,12/19/1979,"GRADE: 3
",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,,,,,,,,,,,,,,,,
BCSB0004,,Kaiser Foundation Health Plan,165.1,79.4,29.1,No,,,,Yes,,Ductal carcinoma in situ,12/19/1979,"GRADE: 3
",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,1.3,"after surgical intervention, but before chemo or radiation",2.1,0.8,,,,,,,,
BCSB0006,,,154.9,59.9,25,No,,,,Yes,,Ductal carcinoma in situ,1/2/2015,Left,1/2/2015,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,,X,,,,Ductal,,,12,Low," ER+, PR+, HER2-",99,3,99,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,14,,,,,,
BCSB0006,,,154.9,59.9,25,No,,,,Yes,,Ductal carcinoma in situ,1/2/2015,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,14,,,,,,
BCSB0006,,,154.9,59.9,25,No,,,,Yes,,Ductal carcinoma in situ,1/2/2015,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.1,"after surgical intervention, but before chemo or radiation",1.2,0.5,,14,,,,,,
BCSB0008,,,160,77.6,30.3,Yes,Adenosis,10/4/2017,Right,Yes,,Ductal carcinoma in situ,9/27/2017,"LEFT, GRADE 2",9/27/2017,Invasive lobular carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,N2: Ipsilateral axillary LN(s) fixed,M0: No distant metastasis,Stage IIIa,X,,,,Lobular,,2,26.7,High," ER+, PR+, HER2-",93,3,1.5,2,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0008,,,160,77.6,30.3,Yes,Adenosis,10/4/2017,Right,Yes,,Ductal carcinoma in situ,9/27/2017,"LEFT, GRADE 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,,,,,,,
BCSB0008,,,160,77.6,30.3,Yes,Adenosis,10/4/2017,Right,Yes,,Ductal carcinoma in situ,9/27/2017,"LEFT, GRADE 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3.6,1.1,"after surgical intervention, but before chemo or radiation",2.9,1,,,,,,,,
BCSB0009,,,157.5,102.1,41.2,No,,,,Yes,,Ductal carcinoma in situ,9/9/2020,Right,8/10/2020,Mixed IDC+ILC (50 -90% each component),,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage IIb,,X,,X,,,2,31,High," ER+, PR+, HER2-",99,3,98,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0009,,,157.5,102.1,41.2,No,,,,Yes,,Ductal carcinoma in situ,9/9/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.7,,,,,,,,,,,,,,,,
BCSB0009,,,157.5,102.1,41.2,No,,,,Yes,,Ductal carcinoma in situ,9/9/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.7,"after surgical intervention, but before chemo or radiation",4,0.6,,,,,,,,
BCSB0010,,,154.9,54.4,22.7,Yes,Fibroadenoma,12/23/2014,,No,,,,,1/31/2018,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,1,10,Low," ER+, PR+, HER2-",100,3,20,2,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,17,,,0,,,ctDNA not detected in Guardant testing.
BCSB0010,,,154.9,54.4,22.7,Yes,Fibroadenoma,12/23/2014,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.6,,,,,,,,,,17,,,0,,,ctDNA not detected in Guardant testing.
BCSB0010,,,154.9,54.4,22.7,Yes,Fibroadenoma,12/23/2014,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.4,"after surgical intervention, but before chemo or radiation",1.7,0.3,,17,,,0,,,ctDNA not detected in Guardant testing.
BCSB0015,,Kaiser,157.5,78.5,31.6,Yes,Breast Cysts,9/6/2016,benign 1.8 cm oval cyst in the left breast at 9 o'clock,Yes,,Ductal carcinoma in situ,8/22/2016,"Right Breast, 2 cm multifocal, grade 2",8/1/2016,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage IIb,,X,,,Ductal,,1,,," ER+, PR+, HER2-",95,3,90,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0015,,Kaiser,157.5,78.5,31.6,Yes,Breast Cysts,9/6/2016,benign 1.8 cm oval cyst in the left breast at 9 o'clock,Yes,,Ductal carcinoma in situ,8/22/2016,"Right Breast, 2 cm multifocal, grade 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3,,,,,,,,,,,,,,,,
BCSB0015,,Kaiser,157.5,78.5,31.6,Yes,Breast Cysts,9/6/2016,benign 1.8 cm oval cyst in the left breast at 9 o'clock,Yes,,Ductal carcinoma in situ,8/22/2016,"Right Breast, 2 cm multifocal, grade 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,3.3,"after surgical intervention, but before chemo or radiation",4,0.4,,,,,,,,
BCSB0017,,,162.6,77.1,29.2,No,,,,Yes,,Ductal carcinoma in situ,6/2/2014,,6/2/2014,Invasive ductal carcinoma,,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage IIb,,X,,X,Ductal,,3,30,High," ER+, PR+, HER2-",90,2,70,2,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0017,,,162.6,77.1,29.2,No,,,,Yes,,Ductal carcinoma in situ,6/2/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.7,,,,,,,,,,,,,,,,
BCSB0017,,,162.6,77.1,29.2,No,,,,Yes,,Ductal carcinoma in situ,6/2/2014,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.6,1.6,"after surgical intervention, but before chemo or radiation",4.8,0.1,,,,,,,,
BCSB0020,,,165.1,81.6,29.9,No,,,,No,,,,,11/19/2020,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,N0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,X,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,0,Non-amplified,ER- PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0020,,,165.1,81.6,29.9,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Local,,,,,,,,,,,,,,,,,,,,,,
BCSB0020,,,165.1,81.6,29.9,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,,,,,,,,,,,,,,,,
BCSB0020,,,165.1,81.6,29.9,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.5,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0022,,,162.6,68,25.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0022,,,162.6,68,25.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Distant,,Bone,"Chemo started on 2/18/25
reported on 3/21/25, 30 month follow up",,,,,,,,,,,,,,,,,,,
BCSB0023,,,157.5,65.8,26.5,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/26/2021,,8/26/2021,Invasive lobular carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,,,X,,X,Lobular,,2,1,Low," ER+, PR+, HER2-",80,3,90,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0023,,,157.5,65.8,26.5,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/26/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.2,,,,,,,,,,,,,,,,
BCSB0023,,,157.5,65.8,26.5,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/26/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.1,"after surgical intervention, but before chemo or radiation",1.3,0.4,,,,,,,,
BCSB0024,,,170.2,63.5,21.9,Unknown,,,,Yes,,Ductal carcinoma in situ,2/21/2018,Right,1/9/2018,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Other,Favorable: mucinous,2,8,Low," ER+, PR+, HER2-",95,3,68,2,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,31,,,,,,
BCSB0024,,,170.2,63.5,21.9,Unknown,,,,Yes,,Ductal carcinoma in situ,2/21/2018,Right,3/2/2010,Mucinous (colloid) carcinoma,,,,,,,Stage IIb,X,,,,Other,Favorable: mucinous,2,,," ER+, PR+, HER2-",,,,,,Unknown,"ER+ PR+ HER2-, in Hong Kong",,,,,,,,,,,,,,,,,31,,,,,,
BCSB0024,,,170.2,63.5,21.9,Unknown,,,,Yes,,Ductal carcinoma in situ,2/21/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.6,Right 2018,,,,,,,,,31,,,,,,
BCSB0024,,,170.2,63.5,21.9,Unknown,,,,Yes,,Ductal carcinoma in situ,2/21/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.6,"after surgical intervention, but before chemo or radiation",0.7,0.5,Right 2018,31,,,,,,
BCSB0024,,,170.2,63.5,21.9,Unknown,,,,Yes,,Ductal carcinoma in situ,2/21/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",2.6,0,"Left 2010, in Hong Kong",31,,,,,,
BCSB0025,,,161.3,78,30,No,,,,Yes,,Ductal carcinoma in situ,4/4/2017,"Right Breast 1.0 cm, Residual grade 3",8/30/2016,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage IIa,,X,,,Ductal,,3,80,High," ER-, PR-, HER2-",0,0,0,0,1,Amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0025,,,161.3,78,30,No,,,,Yes,,Ductal carcinoma in situ,4/4/2017,"Right Breast 1.0 cm, Residual grade 3",8/30/2016,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,,T1c:>1.0 cm but <=2.0 cm,pN1: movable ipsilateral axillary LN(s),,Stage IIa,X,,,,Ductal,,2,10,Low," ER+, PR+, HER2-",95,,95,,,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0025,,,161.3,78,30,No,,,,Yes,,Ductal carcinoma in situ,4/4/2017,"Right Breast 1.0 cm, Residual grade 3",,,,,,,,,,,,,,,,,,,,,,,,,,,Local,,,,,,,,,,,,,,,,,,,,,,
BCSB0025,,,161.3,78,30,No,,,,Yes,,Ductal carcinoma in situ,4/4/2017,"Right Breast 1.0 cm, Residual grade 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.9,Right Breast,,,,,,,,,,,,,,,
BCSB0025,,,161.3,78,30,No,,,,Yes,,Ductal carcinoma in situ,4/4/2017,"Right Breast 1.0 cm, Residual grade 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,,1.6,Left Breast,,,,,,,,,,,,,,,
BCSB0025,,,161.3,78,30,No,,,,Yes,,Ductal carcinoma in situ,4/4/2017,"Right Breast 1.0 cm, Residual grade 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.9,2.9,"after surgical intervention, after neoadjuvant treatment",1.8,0,Right Breast,,,,,,,
BCSB0025,,,161.3,78,30,No,,,,Yes,,Ductal carcinoma in situ,4/4/2017,"Right Breast 1.0 cm, Residual grade 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,1.6,1.6,"after surgical intervention, after neoadjuvant treatment",1.8,,Left Breast.,,,,,,,
BCSB0026,,Kaiser HMO,160,65.3,25.5,No,,,,Yes,,Ductal carcinoma in situ,3/8/2018,"03/08/2018 Left Breast, 0.5 cm Grade 2
04/17/2018 Right Breast 3.5cm",3/8/2018,Mixed IDC+ILC (50 -90% each component),,,,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,,Stage IIa,,X,,,,,2,,," ER+, PR+, HER2-",95,3,40,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0026,,Kaiser HMO,160,65.3,25.5,No,,,,Yes,,Ductal carcinoma in situ,3/8/2018,"03/08/2018 Left Breast, 0.5 cm Grade 2
04/17/2018 Right Breast 3.5cm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.6,,,,,,,,,,,,,,,,
BCSB0026,,Kaiser HMO,160,65.3,25.5,No,,,,Yes,,Ductal carcinoma in situ,3/8/2018,"03/08/2018 Left Breast, 0.5 cm Grade 2
04/17/2018 Right Breast 3.5cm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.5,"after surgical intervention, but before chemo or radiation",2.2,1,,,,,,,,
BCSB0027,,Kaiser,165.1,104.3,38.3,No,,,,Yes,,Ductal carcinoma in situ,6/22/2021,,5/6/2021,Invasive ductal carcinoma,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,,X,,,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,1,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0027,,Kaiser,165.1,104.3,38.3,No,,,,Yes,,Ductal carcinoma in situ,6/22/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.4,,,,,,,,,,,,,,,,
BCSB0027,,Kaiser,165.1,104.3,38.3,No,,,,Yes,,Ductal carcinoma in situ,6/22/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.5,"after surgical intervention, but before chemo or radiation",0.6,0.1,,,,,,,,
BCSB0029,,Kaiser,165.1,52.2,19.2,No,,,,Yes,,Ductal carcinoma in situ,9/30/2019,Right Breast,9/9/2019,Invasive ductal carcinoma,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,,X,,,Ductal,,,,," ER+, PR+, HER2-",95,,90,,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,8,,,,,,
BCSB0029,,Kaiser,165.1,52.2,19.2,No,,,,Yes,,Ductal carcinoma in situ,9/30/2019,Right Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.9,,,,,,,,,,8,,,,,,
BCSB0029,,Kaiser,165.1,52.2,19.2,No,,,,Yes,,Ductal carcinoma in situ,9/30/2019,Right Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,0.9,"after surgical intervention, but before chemo or radiation",1.3,0.4,,8,,,,,,
BCSB0030,,,167.6,90.3,32.1,Unknown,,,,Yes,,Ductal carcinoma in situ,6/1/2007,Right Breast,10/24/2018,Invasive ductal carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,,Other,Favorable: mucinous,2,,," ER+, PR+, HER2-",100,3,100,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,5,,,,,,
BCSB0030,,,167.6,90.3,32.1,Unknown,,,,Yes,,Ductal carcinoma in situ,6/1/2007,Right Breast,1/28/2019,Invasive ductal carcinoma,,,,T1mic:Microinvasion <=0.1 cm,N0: No regional LNs metastasis,,,,X,,,Ductal,,1,,," ER+, PR+, HER2-",100,,14,,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,5,,,,,,
BCSB0030,,,167.6,90.3,32.1,Unknown,,,,Yes,,Ductal carcinoma in situ,6/1/2007,Right Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.9,Left Breast,,,,,,,,,5,,,,,,
BCSB0030,,,167.6,90.3,32.1,Unknown,,,,Yes,,Ductal carcinoma in situ,6/1/2007,Right Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,,,,"after surgical intervention, but before chemo or radiation",0.95,,Right Breast,5,,,,,,
BCSB0030,,,167.6,90.3,32.1,Unknown,,,,Yes,,Ductal carcinoma in situ,6/1/2007,Right Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,0.8,during adjuvant endocrine therapy,1.1,,Left Breast,5,,,,,,
BCSB0031,,Kaiser,165.1,62.6,23,Unknown,,,,Yes,,Ductal carcinoma in situ,10/22/2021,Right Breast,4/16/2021,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage IIIa,,X,,X,Other,Favorable: mucinous,2,15,Low," ER+, PR-, HER2-",100,3,0,0,0,Unknown,ER+ PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0031,,Kaiser,165.1,62.6,23,Unknown,,,,Yes,,Ductal carcinoma in situ,10/22/2021,Right Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,10,,,,,,,,,,,,,,,,
BCSB0031,,Kaiser,165.1,62.6,23,Unknown,,,,Yes,,Ductal carcinoma in situ,10/22/2021,Right Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,10,"after surgical intervention, after neoadjuvant treatment",0.2,1.5,,,,,,,,
BCSB0032,,,157.5,73.5,29.6,Unknown,,,,Yes,,Ductal carcinoma in situ,9/3/2021,Grade 2-3,9/3/2021,Invasive ductal carcinoma,,,,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,,Stage Ia,,X,,,Ductal,,2,10,Low," ER+, PR+, HER2-",95,3,85,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0032,,,157.5,73.5,29.6,Unknown,,,,Yes,,Ductal carcinoma in situ,9/3/2021,Grade 2-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.8,,,,,,,,,,,,,,,,
BCSB0032,,,157.5,73.5,29.6,Unknown,,,,Yes,,Ductal carcinoma in situ,9/3/2021,Grade 2-3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,0.8,"after surgical intervention, but before chemo or radiation",0.8,,,,,,,,,
BCSB0034,,Kaiser,162.6,79.4,30,No,,,,No,,,,,10/26/2020,Invasive ductal carcinoma,,,MX: cannot be assessed,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,,X,,,Ductal,,3,40,High," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0034,,Kaiser,162.6,79.4,30,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1.5,,,,,,,,,,,,,,,,
BCSB0034,,Kaiser,162.6,79.4,30,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.5,"after surgical intervention, but before chemo or radiation",1,1.5,,,,,,,,
BCSB0035,,,174,76.2,25.2,Yes,Central Intraductal Papilloma,2/2/2022,Left Breast,Yes,,Ductal carcinoma in situ,1/19/2022,Left Breast,3/21/2022,Invasive ductal carcinoma,,,MX: cannot be assessed,T1a:>0.1 but <=0.5 cm,pN1: movable ipsilateral axillary LN(s),MX: cannot be assessed,Stage Ia,X,,,,Ductal,,1,5,Low," ER+, PR+, HER2-",100,3,100,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0035,,,174,76.2,25.2,Yes,Central Intraductal Papilloma,2/2/2022,Left Breast,Yes,,Ductal carcinoma in situ,1/19/2022,Left Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,,,,,,,,,,,,,,,,,
BCSB0035,,,174,76.2,25.2,Yes,Central Intraductal Papilloma,2/2/2022,Left Breast,Yes,,Ductal carcinoma in situ,1/19/2022,Left Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,"after surgical intervention, but before chemo or radiation",0.4,0.6,,,,,,,,
BCSB0036,,Kaiser,172.7,74.8,25.1,Yes,Atypical Lobular Hyperplasia,12/9/2021,And ATYPICAL DUCTAL HYPERPLASIA in Left Breast,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/17/2022,Left Breast,12/9/2021,Invasive lobular carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,,X,,,,Lobular,,1,,," ER+, PR+, HER2-",70,3,70,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,16,,,,,,
BCSB0036,,Kaiser,172.7,74.8,25.1,Yes,Atypical Lobular Hyperplasia,12/9/2021,And ATYPICAL DUCTAL HYPERPLASIA in Left Breast,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/17/2022,Left Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,Left,,,,,,,,,16,,,,,,
BCSB0036,,Kaiser,172.7,74.8,25.1,Yes,Atypical Lobular Hyperplasia,12/9/2021,And ATYPICAL DUCTAL HYPERPLASIA in Left Breast,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/17/2022,Left Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.5,"after surgical intervention, but before chemo or radiation",1.5,,,16,,,,,,
BCSB0037,,,162.6,57.2,21.6,No,,,,Yes,,Ductal carcinoma in situ,6/17/2015,,6/17/2015,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,X,,,,Ductal,,2,17,Low," ER+, PR+, HER2-",100,3,98,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,13,,,,,,
BCSB0037,,,162.6,57.2,21.6,No,,,,Yes,,Ductal carcinoma in situ,6/17/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2,,,,,,,,,,13,,,,,,
BCSB0037,,,162.6,57.2,21.6,No,,,,Yes,,Ductal carcinoma in situ,6/17/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,1.2,"after surgical intervention, but before chemo or radiation",2.1,0.6,,13,,,,,,
BCSB0039,,,170.2,80.7,27.9,Unknown,,,,Yes,,Ductal carcinoma in situ,9/21/2016,,9/21/2016,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,,X,,,,Ductal,,3,90,High," ER+, PR+, HER2+",80,2,70,2,3+,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0039,,,170.2,80.7,27.9,Unknown,,,,Yes,,Ductal carcinoma in situ,9/21/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.5,,,,,,,,,,,,,,,,
BCSB0039,,,170.2,80.7,27.9,Unknown,,,,Yes,,Ductal carcinoma in situ,9/21/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.4,2.6,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0041,,,172.7,69.4,23.3,Unknown,,,,Yes,,Ductal carcinoma in situ,8/25/2015,"Right, Grade 1",8/25/2015,Mucinous (colloid) carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Other,Favorable: mucinous,1,5,Low," ER+, PR+, HER2-",90,3,90,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0041,,,172.7,69.4,23.3,Unknown,,,,Yes,,Ductal carcinoma in situ,8/25/2015,"Right, Grade 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.7,,,,,,,,,,,,,,,,
BCSB0041,,,172.7,69.4,23.3,Unknown,,,,Yes,,Ductal carcinoma in situ,8/25/2015,"Right, Grade 1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,0.7,"after surgical intervention, but before chemo or radiation",0.6,,,,,,,,,
BCSB0043,,,157.5,51.7,20.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0046,,,170.2,117.5,40.6,Yes,Calcifications,3/4/2009,Left,Yes,,Ductal carcinoma in situ,1/19/2018,Left,3/29/2017,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),MX: cannot be assessed,T1b:>0.5 cm but <=1.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage IIa,X,,,,Ductal,,3,34,High," PR+, HER2+, ER-",0.1,1,2.5,1,3+,Amplified,ER- PR+ HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0046,,,170.2,117.5,40.6,Yes,Calcifications,3/4/2009,Left,Yes,,Ductal carcinoma in situ,1/19/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.2,,,,,,,,,,,,,,,,
BCSB0046,,,170.2,117.5,40.6,Yes,Calcifications,3/4/2009,Left,Yes,,Ductal carcinoma in situ,1/19/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.3,"after surgical intervention, but before chemo or radiation",0.6,0.5,,,,,,,,
BCSB0048,,,172.7,64,21.5,Yes,Fibrocystic Breast Changes,8/9/2019,Right Breast,Yes,,Ductal carcinoma in situ,8/9/2019,,8/9/2019,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN0: No regional LNs metastasis,,Stage Ib,X,,,,Ductal,,2,,," ER+, PR+, HER2+",95,3,95,3,3+,Amplified,Triple positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0048,,,172.7,64,21.5,Yes,Fibrocystic Breast Changes,8/9/2019,Right Breast,Yes,,Ductal carcinoma in situ,8/9/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.5,,,,,,,,,,,,,,,,
BCSB0048,,,172.7,64,21.5,Yes,Fibrocystic Breast Changes,8/9/2019,Right Breast,Yes,,Ductal carcinoma in situ,8/9/2019,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,2.5,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0049,,,165.1,81.6,29.9,Unknown,,,,Yes,,Ductal carcinoma in situ,10/14/2021,,9/30/2021,Invasive ductal carcinoma,,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,NX: Regional LNs cannot be assessed,MX: cannot be assessed,,,X,,,Ductal,,3,30,High," ER+, PR+, HER2-",95,3,50,3,1,Non-amplified,"ER+ PR+ HER2-
Stage 1 (it was not specified in the medical records if the tumor was stage 1a or 1b)",,,,,,,,,,,,,,,,,17,,,,,,
BCSB0049,,,165.1,81.6,29.9,Unknown,,,,Yes,,Ductal carcinoma in situ,10/14/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,Local,12/1/1982,,"Right Breast, Stage 1 T2N0M0, Lumpectomy and radiation",,,,,,,,,,,,,17,,,,,,
BCSB0049,,,165.1,81.6,29.9,Unknown,,,,Yes,,Ductal carcinoma in situ,10/14/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,Local,5/1/1986,,"Left Breast, T2N1M0,  2.5-3CM, Mastectomy and CMF Chemo (6/12/86-11/24/86)",,,,,,,,,,,,,17,,,,,,
BCSB0049,,,165.1,81.6,29.9,Unknown,,,,Yes,,Ductal carcinoma in situ,10/14/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.4,,,,,,,,,,17,,,,,,
BCSB0049,,,165.1,81.6,29.9,Unknown,,,,Yes,,Ductal carcinoma in situ,10/14/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,2.4,"after surgical intervention, but before chemo or radiation",3.2,0,,17,,,,,,
BCSB0051,,,167.6,104.3,37.1,Yes,Calcifications,7/10/2014,Left Breast,Yes,,Ductal carcinoma in situ,9/30/2013,"Right, Grade 3",9/30/2013,Inflammatory breast cancer,,,,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,,Stage IIIa,,X,,,Other,Unfavorable: Inflammatory,2,11,Low," ER+, PR+, HER2-",70,3,30,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0051,,,167.6,104.3,37.1,Yes,Calcifications,7/10/2014,Left Breast,Yes,,Ductal carcinoma in situ,9/30/2013,"Right, Grade 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.7,,,,,,,,,,,,,,,,
BCSB0051,,,167.6,104.3,37.1,Yes,Calcifications,7/10/2014,Left Breast,Yes,,Ductal carcinoma in situ,9/30/2013,"Right, Grade 3",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.7,"after surgical intervention, after neoadjuvant treatment",1.45,1.8,,,,,,,,
BCSB0052,,,161.3,60.3,23.2,Unknown,,,,No,,,,,8/28/2015,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,,X,,,,Ductal,,2,,," ER+, PR+, HER2-",,,,,,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,28,,,,,,
BCSB0052,,,161.3,60.3,23.2,Unknown,,,,No,,,,,3/14/2017,Invasive ductal carcinoma,,,MX: cannot be assessed,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,,X,,,,Ductal,,2,,," ER+, PR+, HER2-",90,,7,,,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,28,,,,,,
BCSB0052,,,161.3,60.3,23.2,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Local,3/14/2017,,"first IDC:07/2015 , Recurrence:03/2017",,,,,,,,,,,,,28,,,,,,
BCSB0052,,,161.3,60.3,23.2,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Unknown,0.7,2017,,,,,,,,,28,,,,,,
BCSB0052,,,161.3,60.3,23.2,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",1.7,,Left 2015,28,,,,,,
BCSB0052,,,161.3,60.3,23.2,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,0.5,0.7,"after surgical intervention, but before chemo or radiation",0.6,0.3,Left 2017,28,,,,,,
BCSB0054,,,170.2,124.3,42.9,No,,,,Yes,,Ductal carcinoma in situ,8/10/2017,Left,8/10/2017,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),MX: cannot be assessed,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,MX: cannot be assessed,,X,,,,Ductal,,2,,," ER+, HER2+, PR-",20,,0,0,Unknown,Amplified,ER+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0054,,,170.2,124.3,42.9,No,,,,Yes,,Ductal carcinoma in situ,8/10/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.5,,,,,,,,,,,,,,,,
BCSB0054,,,170.2,124.3,42.9,No,,,,Yes,,Ductal carcinoma in situ,8/10/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,2.5,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0055,,,156.2,52.2,21.4,Unknown,,,,Yes,,Ductal carcinoma in situ,10/28/2018,,4/19/2018,Invasive ductal carcinoma,,,M0: No distant metastasis,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIa,X,,,,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0055,,,156.2,52.2,21.4,Unknown,,,,Yes,,Ductal carcinoma in situ,10/28/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4,,,,,,,,,,,,,,,,
BCSB0055,,,156.2,52.2,21.4,Unknown,,,,Yes,,Ductal carcinoma in situ,10/28/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,4,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0056,,,165.1,79.4,29.1,Yes,Atypical Lobular Hyperplasia,2/29/2016,Right Breast,Yes,,Ductal carcinoma in situ,2/3/2016,"Right Breast, nuclear grade III",2/22/2016,Invasive ductal carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,,Stage Ia,,X,,,Ductal,,3,38,High," PR+, HER2+, ER-",0,0,36,1,3+,Amplified,ER- PR+ HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0056,,,165.1,79.4,29.1,Yes,Atypical Lobular Hyperplasia,2/29/2016,Right Breast,Yes,,Ductal carcinoma in situ,2/3/2016,"Right Breast, nuclear grade III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,,IDC was diagnosed at the time of Lumpectomy.,,,,,,,,,,,,,,,
BCSB0056,,,165.1,79.4,29.1,Yes,Atypical Lobular Hyperplasia,2/29/2016,Right Breast,Yes,,Ductal carcinoma in situ,2/3/2016,"Right Breast, nuclear grade III",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.9,"after surgical intervention, after neoadjuvant treatment",,,,,,,,,,
BCSB0057,,,165.1,75.7,27.8,Unknown,,,,Yes,,Ductal carcinoma in situ,10/30/2015,Left Breast,10/30/2015,Invasive ductal carcinoma,,,MX: cannot be assessed,T1b:>0.5 cm but <=1.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,2,5,Low," ER+, PR+, HER2-",100,3,40,1,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0057,,,165.1,75.7,27.8,Unknown,,,,Yes,,Ductal carcinoma in situ,10/30/2015,Left Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,,,,,,,
BCSB0057,,,165.1,75.7,27.8,Unknown,,,,Yes,,Ductal carcinoma in situ,10/30/2015,Left Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,0.9,"after surgical intervention, after neoadjuvant treatment",0.9,0.3,,,,,,,,
BCSB0058,,Kaiser,154.9,54.4,22.7,Unknown,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/25/2021,Left Breast,12/25/2020,Invasive lobular carcinoma,T3:Tumor >5.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T3:Tumor >5.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage IIIa,X,,,,Lobular,,3,,," ER+, PR+, HER2-",40,3,20,3,0,Unknown,"ER+ PR+ HER2- ,",,,,,,,,,,,,,,,,,,,,,,,
BCSB0058,,Kaiser,154.9,54.4,22.7,Unknown,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/25/2021,Left Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,7.3,,,,,,,,,,,,,,,,
BCSB0058,,Kaiser,154.9,54.4,22.7,Unknown,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/25/2021,Left Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,7.3,"after surgical intervention, after neoadjuvant treatment",6.9,0.8,,,,,,,,
BCSB0059,,,170.2,108.9,37.6,Yes,Adenosis,4/18/2019,Left,Yes,,Ductal carcinoma in situ,4/18/2019,Left,4/18/2019,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,NX: Regional LNs cannot be assessed,,T2:Tumor >2.0 cm but <=5.0 cm,pN1: movable ipsilateral axillary LN(s),,Stage IIa,X,,,,Ductal,,3,,," ER+, PR+, HER2+",90,3,60,2,3+,Unknown,ER+ PR+ HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0059,,,170.2,108.9,37.6,Yes,Adenosis,4/18/2019,Left,Yes,,Ductal carcinoma in situ,4/18/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,,,,,,,
BCSB0059,,,170.2,108.9,37.6,Yes,Adenosis,4/18/2019,Left,Yes,,Ductal carcinoma in situ,4/18/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1,"after surgical intervention, but before chemo or radiation",2.5,,,,,,,,,
BCSB0061,,Kaiser,167.6,114.3,40.7,Unknown,,,,Yes,,Ductal carcinoma in situ,5/11/2017,"2.1cm , Grade 2",2/8/2017,Invasive ductal carcinoma,,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage IIa,X,,,,Ductal,,1,,," ER+, PR+, HER2-",100,3,80,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,21,,,,,,
BCSB0061,,Kaiser,167.6,114.3,40.7,Unknown,,,,Yes,,Ductal carcinoma in situ,5/11/2017,"2.1cm , Grade 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.5,,,,,,,,,,21,,,,,,
BCSB0061,,Kaiser,167.6,114.3,40.7,Unknown,,,,Yes,,Ductal carcinoma in situ,5/11/2017,"2.1cm , Grade 2",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,7.1,2.5,"after surgical intervention, but before chemo or radiation",2.5,,,21,,,,,,
BCSB0062,,,162.6,64.9,24.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0063,,,172.7,134.7,45.2,Yes,Atypical Ductal Hyperplasia,12/11/2015,,Yes,,Ductal carcinoma in situ,12/11/2015,,12/11/2015,Invasive ductal carcinoma,,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage IIa,X,,,,Ductal,,1,,," ER+, PR+, HER2-",90,3,90,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0063,,,172.7,134.7,45.2,Yes,Atypical Ductal Hyperplasia,12/11/2015,,Yes,,Ductal carcinoma in situ,12/11/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3,,,,,,,,,,,,,,,,
BCSB0063,,,172.7,134.7,45.2,Yes,Atypical Ductal Hyperplasia,12/11/2015,,Yes,,Ductal carcinoma in situ,12/11/2015,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,3,"after surgical intervention, but before chemo or radiation",2.8,0.5,,,,,,,,
BCSB0065,,,165.1,112.5,41.3,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/11/2021,,3/11/2021,Invasive lobular carcinoma,,,MX: cannot be assessed,T3:Tumor >5.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,,,X,,X,Lobular,,1,10,Low," ER+, PR+, HER2-",95,,95,,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,15,,,,,,
BCSB0065,,,165.1,112.5,41.3,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/11/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2,,,,,,,,,,15,,,,,,
BCSB0065,,,165.1,112.5,41.3,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/11/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2,"after surgical intervention, but before chemo or radiation",5.4,,,15,,,,,,
BCSB0066,,,162.6,49.9,18.9,No,,,,Yes,,Ductal carcinoma in situ,2/11/2020,Right,2/11/2020,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,,X,,,Ductal,,1,14,Low," ER+, PR+, HER2-",98,3,92,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,12,,,,,,
BCSB0066,,,162.6,49.9,18.9,No,,,,Yes,,Ductal carcinoma in situ,2/11/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.4,,,,,,,,,,12,,,,,,
BCSB0066,,,162.6,49.9,18.9,No,,,,Yes,,Ductal carcinoma in situ,2/11/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.8,1.4,"after surgical intervention, but before chemo or radiation",1.6,0.5,,12,,,,,,
BCSB0068,,Kaiser,161.3,78.9,30.3,No,,,,No,,,,,11/17/2016,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,NX: Regional LNs cannot be assessed,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN1: movable ipsilateral axillary LN(s),MX: cannot be assessed,Stage IIb,,X,,,Ductal,,2,,," ER+, PR+, HER2+",100,3,100,3,2,Amplified,Triple positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0068,,Kaiser,161.3,78.9,30.3,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3,,,,,,,,,,,,,,,,
BCSB0068,,Kaiser,161.3,78.9,30.3,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,3,"after surgical intervention, after neoadjuvant treatment",2.5,0.1,,,,,,,,
BCSB0071,,,162.6,63.5,24,Yes,Adenosis,8/15/2018,Left,No,,,,,8/15/2018,Invasive lobular carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,2,,," ER+, PR-, HER2-",100,,0,0,1,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,24,,,,,,
BCSB0071,,,162.6,63.5,24,Yes,Adenosis,8/15/2018,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.8,,,,,,,,,,24,,,,,,
BCSB0071,,,162.6,63.5,24,Yes,Adenosis,8/15/2018,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.3,1.8,"after surgical intervention, but before chemo or radiation",1.6,0.2,,24,,,,,,
BCSB0072,,,162.6,58.1,22,Yes,Breast Cysts,1/1/2010,,No,,,,,12/15/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,3,80,High," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,"ER- PR- HER2+,",,,,,,,,,,,,,,,,,,,,,,,
BCSB0072,,,162.6,58.1,22,Yes,Breast Cysts,1/1/2010,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,,,,,,,,,,,,,,,,
BCSB0072,,,162.6,58.1,22,Yes,Breast Cysts,1/1/2010,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.5,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0073,,,162.6,77.1,29.2,Unknown,,,,Unknown,,,,,5/18/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,3,25,High," ER+, HER2+, PR-",98,3,0,0,3+,Unknown,ER+ PR- HER2+ .,,,,,,,,,,,,,,,,,,,,,,,
BCSB0073,,,162.6,77.1,29.2,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,1.5,,,,,,,,,,,,,,,,
BCSB0073,,,162.6,77.1,29.2,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.4,1.5,"after surgical intervention, after neoadjuvant treatment",,,,,,,,,,
BCSB0074,,Blue Cross HMO,160,58.1,22.7,Yes,Atypical Lobular Hyperplasia,6/25/2019,Bilateral,No,,,,,4/10/2019,Mixed IDC+ILC (50 -90% each component),,,,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,,Stage IIa,X,,,,Other,,2,,," ER+, PR+, HER2-",90,3,99,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,24,,,,,,
BCSB0074,,Blue Cross HMO,160,58.1,22.7,Yes,Atypical Lobular Hyperplasia,6/25/2019,Bilateral,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,2.3,,,,,,,,,,24,,,,,,
BCSB0074,,Blue Cross HMO,160,58.1,22.7,Yes,Atypical Lobular Hyperplasia,6/25/2019,Bilateral,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,2.3,"after surgical intervention, but before chemo or radiation",2.4,0.2,,24,,,,,,
BCSB0075,,Blue Shield HMO,157.5,78.5,31.6,Unknown,,,,Yes,,Ductal carcinoma in situ,4/21/2021,Grade 2,4/12/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",90,3,90,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,10,,,,,,"OncotypeDX Score: Left Sided cancer 10,  Right Sided cancer 15"
BCSB0075,,Blue Shield HMO,157.5,78.5,31.6,Unknown,,,,Yes,,Ductal carcinoma in situ,4/21/2021,Grade 2,6/21/2021,Invasive ductal carcinoma,,,,T1b:>0.5 cm but <=1.0 cm,pNX: Regional LNs cannot be assessed,,Stage Ia,,X,,,Ductal,,1,20,High," ER+, PR+, HER2-",90,1,3,1,0,Unknown,"ER+ PR+ HER2- , 0.8cm",,,,,,,,,,,,,,,,,10,,,,,,"OncotypeDX Score: Left Sided cancer 10,  Right Sided cancer 15"
BCSB0075,,Blue Shield HMO,157.5,78.5,31.6,Unknown,,,,Yes,,Ductal carcinoma in situ,4/21/2021,Grade 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,,,,,,,,,,10,,,,,,"OncotypeDX Score: Left Sided cancer 10,  Right Sided cancer 15"
BCSB0075,,Blue Shield HMO,157.5,78.5,31.6,Unknown,,,,Yes,,Ductal carcinoma in situ,4/21/2021,Grade 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.5,"after surgical intervention, but before chemo or radiation",2.7,1.9,,10,,,,,,"OncotypeDX Score: Left Sided cancer 10,  Right Sided cancer 15"
BCSB0077,,,162.6,66.7,25.2,Yes,Fibroadenoma,2/28/2017,Right,No,,,,,8/1/2016,Papillary carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,,,X,,,,Other,Favorable: papillary,3,26,High," ER+, PR+, HER2+",100,3,23,1,3+,Amplified,ER+ PR+ HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0077,,,162.6,66.7,25.2,Yes,Fibroadenoma,2/28/2017,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.3,,,,,,,,,,,,,,,,
BCSB0077,,,162.6,66.7,25.2,Yes,Fibroadenoma,2/28/2017,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,2.3,"after surgical intervention, after neoadjuvant treatment",2,0.6,,,,,,,,
BCSB0078,,,167.6,92.1,32.8,Yes,Central Intraductal Papilloma,8/24/2016,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/19/2016,Left,8/24/2016,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,X,,,,Lobular,,2,,," ER+, PR+, HER2-",,2,,2,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,13,,,,,,
BCSB0078,,,167.6,92.1,32.8,Yes,Central Intraductal Papilloma,8/24/2016,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/19/2016,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,,,,,,,,,,13,,,,,,
BCSB0078,,,167.6,92.1,32.8,Yes,Central Intraductal Papilloma,8/24/2016,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/19/2016,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.2,"after surgical intervention, but before chemo or radiation",1.5,0.5,,13,,,,,,
BCSB0079,,,172.7,90.3,30.3,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/22/2019,Left Breast,2/22/2019,Invasive lobular carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,X,Lobular,,2,,," ER+, PR+, HER2-",90,2,40,2,0,Unknown,"ER+ PR+ HER2- ,",,,,,,,,,,,,,,,,,20,,,,,,
BCSB0079,,,172.7,90.3,30.3,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/22/2019,Left Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,,,,,,,,,,20,,,,,,
BCSB0079,,,172.7,90.3,30.3,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/22/2019,Left Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,1.3,"after surgical intervention, but before chemo or radiation",1.3,0.1,,20,,,,,,
BCSB0080,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0081,,,154.9,67.1,28,No,,,,No,,,,,10/12/2021,Invasive ductal carcinoma,,,MX: cannot be assessed,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,,X,,,Ductal,,2,21,High," ER+, PR+, HER2-",100,3,94,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0081,,,154.9,67.1,28,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,5,,,,,,,,,,,,,,,,
BCSB0081,,,154.9,67.1,28,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,5,"after surgical intervention, after neoadjuvant treatment",0.4,0.3,,,,,,,,
BCSB0082,,,170.2,97.5,33.7,Yes,Calcifications,12/22/2010,Both Breasts,No,,,,,11/13/2019,Invasive lobular carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,,X,,,,Lobular,,2,,," ER+, PR+, HER2-",90,3,15,1,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0082,,,170.2,97.5,33.7,Yes,Calcifications,12/22/2010,Both Breasts,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.4,,,,,,,,,,,,,,,,
BCSB0082,,,170.2,97.5,33.7,Yes,Calcifications,12/22/2010,Both Breasts,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.4,"after surgical intervention, but before chemo or radiation",1.4,0.5,,,,,,,,
BCSB0083,,,162.6,99.8,37.7,No,,,,No,,,,,12/31/2019,Invasive lobular carcinoma,,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN1: movable ipsilateral axillary LN(s),MX: cannot be assessed,Stage Ib,X,,,,Lobular,,2,28,High," ER+, PR+, HER2-",100,,60,,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,10,,,,,,
BCSB0083,,,162.6,99.8,37.7,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.6,,,,,,,,,,10,,,,,,
BCSB0083,,,162.6,99.8,37.7,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2,"after surgical intervention, but before chemo or radiation",2.6,0.2,,10,,,,,,
BCSB0086,,,170.2,80.7,27.9,Unknown,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/15/2016,,1/15/2016,Invasive lobular carcinoma,,,M0: No distant metastasis,T3:Tumor >5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,,X,,X,Lobular,,2,10,Low," ER+, PR+, HER2-",100,3,100,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0086,,,170.2,80.7,27.9,Unknown,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/15/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4,,,,,,,,,,,,,,,,
BCSB0086,,,170.2,80.7,27.9,Unknown,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/15/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,4,"after surgical intervention, but before chemo or radiation",6.5,1,,,,,,,,
BCSB0088,,,154.9,68,28.3,Unknown,,,,No,,,,,3/9/2021,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage IIa,X,,,,Lobular,,3,27,High," ER+, PR+, HER2-",100,3,96,3,0,Non-amplified,ER+ PR+ Her2-,,,,,,,,,,,,,,,,,19,,,,,,
BCSB0088,,,154.9,68,28.3,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,19,,,,,,
BCSB0088,,,154.9,68,28.3,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.4,1.1,"after surgical intervention, but before chemo or radiation",1.6,0.1,,19,,,,,,
BCSB0089,,,167.6,83,29.5,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/17/2020,Left,1/15/2021,Invasive lobular carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,X,Lobular,,2,,," ER+, HER2+, PR-",60,2,0,0,2,Amplified,ER+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0089,,,167.6,83,29.5,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/17/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.3,was diagnosed to be LCIS,,,,,,,,,,,,,,,
BCSB0089,,,167.6,83,29.5,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/17/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.6,"after surgical intervention, but before chemo or radiation",0.3,,,,,,,,,
BCSB0090,,,162.6,61.7,23.3,Unknown,,,,No,,,,,5/7/2021,Invasive lobular carcinoma,,,,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,,,X,,,,Lobular,,2,5,Low," ER+, PR+, HER2-",,,,,,,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,14,,,,,,
BCSB0090,,,162.6,61.7,23.3,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.9,,,,,,,,,,14,,,,,,
BCSB0090,,,162.6,61.7,23.3,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.9,"after surgical intervention, but before chemo or radiation",2.9,,,14,,,,,,
BCSB0091,,,158.8,60.8,24.1,Yes,Atypical Lobular Hyperplasia,1/3/2018,Right Breast,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",11/21/1995,Right Breast,6/8/2021,Invasive lobular carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pNX: Regional LNs cannot be assessed,MX: cannot be assessed,Stage Ia,,X,,,Lobular,,2,,," ER+, PR+, HER2-",90,3,95,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0091,,,158.8,60.8,24.1,Yes,Atypical Lobular Hyperplasia,1/3/2018,Right Breast,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",11/21/1995,Right Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.8,,,,,,,,,,,,,,,,
BCSB0091,,,158.8,60.8,24.1,Yes,Atypical Lobular Hyperplasia,1/3/2018,Right Breast,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",11/21/1995,Right Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,"after surgical intervention, but before chemo or radiation",1.1,0.1,,,,,,,,
BCSB0092,,,172.7,62.1,20.8,Yes,Fibrocystic Breast Changes,1/1/2010,,No,,,,,3/2/2020,Mixed IDC+ILC (50 -90% each component),T3:Tumor >5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage IIb,X,,,X,Lobular,Favorable: tubular,1,20,High," ER+, PR-, HER2-",100,3,0,0,1,Unknown,"ER+, PR-, HER2-",,,,,,,,,,,,,,,,,,2,,,,,
BCSB0092,,,172.7,62.1,20.8,Yes,Fibrocystic Breast Changes,1/1/2010,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,6.2,,,,,,,,,,,2,,,,,
BCSB0092,,,172.7,62.1,20.8,Yes,Fibrocystic Breast Changes,1/1/2010,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,6.2,"after surgical intervention, but before chemo or radiation",2.5,,,,2,,,,,
BCSB0094,,,162.6,86.4,32.7,Unknown,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/2/2020,Left Breast,6/3/2020,Invasive lobular carcinoma,,,,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,,Stage IIa,X,,,,Lobular,,2,12,Low," ER+, PR+, HER2-",97,3,48,2,2,Non-amplified,ER+ PR+ Her2-,,,,,,,,,,,,,,,,,13,,,,,,
BCSB0094,,,162.6,86.4,32.7,Unknown,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/2/2020,Left Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.8,,,,,,,,,,13,,,,,,
BCSB0094,,,162.6,86.4,32.7,Unknown,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/2/2020,Left Breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,"after surgical intervention, but before chemo or radiation",1.7,0.8,"after surgical intervention, but before chemo or radiation",2.4,1,,13,,,,,,
BCSB0095,,,158.8,73.5,29.1,Yes,Atypical Lobular Hyperplasia,9/28/2021,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/9/2021,Right,6/24/2021,Invasive lobular carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,,Stage IIa,X,,,,Lobular,,2,,," ER+, PR+, HER2-",70,2,90,3,0,Unknown,"ER+ PR+ HER2- , 3.2cm",,,,,,,,,,,,,,,,,13,,,,,,"Left Breast Oncotype: 9
Right Breast Oncotype: 13"
BCSB0095,,,158.8,73.5,29.1,Yes,Atypical Lobular Hyperplasia,9/28/2021,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/9/2021,Right,9/28/2021,Invasive lobular carcinoma,,,,T1b:>0.5 cm but <=1.0 cm,pN1a:Only micrometastasis <=0.2 cm,,Stage Ib,,X,,,Lobular,,2,,," ER+, PR+, HER2-",95,3,95,3,0,Unknown,"ER+ PR+ HER2- , 0.9cm, 1/21 Lymph nodes positive.",,,,,,,,,,,,,,,,,13,,,,,,"Left Breast Oncotype: 9
Right Breast Oncotype: 13"
BCSB0095,,,158.8,73.5,29.1,Yes,Atypical Lobular Hyperplasia,9/28/2021,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/9/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.5,Left Breast,,,,,,,,,13,,,,,,"Left Breast Oncotype: 9
Right Breast Oncotype: 13"
BCSB0095,,,158.8,73.5,29.1,Yes,Atypical Lobular Hyperplasia,9/28/2021,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/9/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.7,"after surgical intervention, but before chemo or radiation",3.2,0.1,Left Breast,13,,,,,,"Left Breast Oncotype: 9
Right Breast Oncotype: 13"
BCSB0095,,,158.8,73.5,29.1,Yes,Atypical Lobular Hyperplasia,9/28/2021,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/9/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,,,,"after surgical intervention, but before chemo or radiation",0.9,0.2,Right Breast,13,,,,,,"Left Breast Oncotype: 9
Right Breast Oncotype: 13"
BCSB0097,,,167.6,74.8,26.6,Yes,Atypical Lobular Hyperplasia,12/22/2021,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/4/2022,Left,12/22/2021,Invasive lobular carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,X,Lobular,,2,5,Low," ER+, PR+, HER2-",90,3,70,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,17,,,,,,
BCSB0097,,,167.6,74.8,26.6,Yes,Atypical Lobular Hyperplasia,12/22/2021,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/4/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.8,MRI,,,,,,,,,17,,,,,,
BCSB0097,,,167.6,74.8,26.6,Yes,Atypical Lobular Hyperplasia,12/22/2021,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/4/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.1,1.8,"after surgical intervention, but before chemo or radiation",3.7,0.3,,17,,,,,,
BCSB0098,,,152.4,54.9,23.6,Yes,Atypical Ductal Hyperplasia,4/29/2020,Right,Yes,,Ductal carcinoma in situ,2/25/2020,Left,2/25/2020,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,,Ductal,,2,25,High," ER+, PR+, HER2+",80,2,75,3,2,Amplified,Triple positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0098,,,152.4,54.9,23.6,Yes,Atypical Ductal Hyperplasia,4/29/2020,Right,Yes,,Ductal carcinoma in situ,2/25/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,,,,,,,
BCSB0098,,,152.4,54.9,23.6,Yes,Atypical Ductal Hyperplasia,4/29/2020,Right,Yes,,Ductal carcinoma in situ,2/25/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,1,"after surgical intervention, but before chemo or radiation",1.1,0.9,,,,,,,,
BCSB0099,,Guardian Insurance,157.5,95.3,38.4,No,,,,No,,,,,9/6/2017,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage IIIa,X,,,X,Lobular,,1,,," ER+, PR+, HER2-",90,3,95,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0099,,Guardian Insurance,157.5,95.3,38.4,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.1,,,,,,,,,,,,,,,,
BCSB0099,,Guardian Insurance,157.5,95.3,38.4,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.8,"after surgical intervention, but before chemo or radiation",2.2,1,,,,,,,,
BCSB0101,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0103,,,170.2,114.8,39.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0104,,,167.6,108.9,38.8,Yes,Fibromatosis,1/1/2005,Left,Yes,,Ductal carcinoma in situ,6/22/2021,Left,4/21/2021,Invasive lobular carcinoma,,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN0(i+),MX: cannot be assessed,Stage Ia,,X,,X,Lobular,,2,5,Low," ER+, PR+, HER2-",100,3,90,2,1,Non-amplified,ER+ PR+ Her2-,,,,,,,,,,,,,,,,,13,,,,,,
BCSB0104,,,167.6,108.9,38.8,Yes,Fibromatosis,1/1/2005,Left,Yes,,Ductal carcinoma in situ,6/22/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.3,,,,,,,,,,13,,,,,,
BCSB0104,,,167.6,108.9,38.8,Yes,Fibromatosis,1/1/2005,Left,Yes,,Ductal carcinoma in situ,6/22/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.4,4.3,"after surgical intervention, but before chemo or radiation",4.5,0,,13,,,,,,
BCSB0105,,,162.6,78.9,29.8,Yes,Fibrocystic Breast Changes,9/17/2020,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/10/2020,Left,9/10/2020,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,X,,,X,Lobular,,1,5,Low," ER+, PR+, HER2-",100,3,99,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,
BCSB0105,,,162.6,78.9,29.8,Yes,Fibrocystic Breast Changes,9/17/2020,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/10/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.8,,,,,,,,,,11,,,,,,
BCSB0105,,,162.6,78.9,29.8,Yes,Fibrocystic Breast Changes,9/17/2020,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/10/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.1,1.8,"after surgical intervention, but before chemo or radiation",3.3,1,,11,,,,,,
BCSB0107,,,154.9,59.4,24.8,Yes,Atypical Lobular Hyperplasia,10/2/2015,Left,Yes,,Ductal carcinoma in situ,10/2/2015,"Right,  also Lobular carcinoma In situ",9/3/2015,Mixed IDC+ILC (50 -90% each component),,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,,X,,X,Lobular,,2,15,Low," ER+, PR+, HER2-",100,3,100,3,0,Non-amplified,"ER+ PR+ HER2- , small focus of grade 1 IDC",,,,,,,,,,,,,,,,,,"Mammaprint high risk 1, BluePrint Luminal B",,,,1,Signatera positive for tDNA: 50.98 MTM/ml (date 09/24/2024)
BCSB0107,,,154.9,59.4,24.8,Yes,Atypical Lobular Hyperplasia,10/2/2015,Left,Yes,,Ductal carcinoma in situ,10/2/2015,"Right,  also Lobular carcinoma In situ",,,,,,,,,,,,,,,,,,,,,,,,,,,Local,8/8/2024,,"Right Breast, mpT2N1a, invasive lobular carcinoma, ER/PR positive, her2 1+, grade 3",,,,,,,,,,,,,,"Mammaprint high risk 1, BluePrint Luminal B",,,,1,Signatera positive for tDNA: 50.98 MTM/ml (date 09/24/2024)
BCSB0107,,,154.9,59.4,24.8,Yes,Atypical Lobular Hyperplasia,10/2/2015,Left,Yes,,Ductal carcinoma in situ,10/2/2015,"Right,  also Lobular carcinoma In situ",,,,,,,,,,,,,,,,,,,,,,,,,,,Distant,10/3/2024,Bone,"ER/PR positive, her2 1+",,,,,,,,,,,,,,"Mammaprint high risk 1, BluePrint Luminal B",,,,1,Signatera positive for tDNA: 50.98 MTM/ml (date 09/24/2024)
BCSB0107,,,154.9,59.4,24.8,Yes,Atypical Lobular Hyperplasia,10/2/2015,Left,Yes,,Ductal carcinoma in situ,10/2/2015,"Right,  also Lobular carcinoma In situ",,,,,,,,,,,,,,,,,,,,,,,,,,,Distant,10/3/2024,Liver,"ER/PR rich positive, her2 0, ki67 54%.",,,,,,,,,,,,,,"Mammaprint high risk 1, BluePrint Luminal B",,,,1,Signatera positive for tDNA: 50.98 MTM/ml (date 09/24/2024)
BCSB0107,,,154.9,59.4,24.8,Yes,Atypical Lobular Hyperplasia,10/2/2015,Left,Yes,,Ductal carcinoma in situ,10/2/2015,"Right,  also Lobular carcinoma In situ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.9,,,,,,,,,,,"Mammaprint high risk 1, BluePrint Luminal B",,,,1,Signatera positive for tDNA: 50.98 MTM/ml (date 09/24/2024)
BCSB0107,,,154.9,59.4,24.8,Yes,Atypical Lobular Hyperplasia,10/2/2015,Left,Yes,,Ductal carcinoma in situ,10/2/2015,"Right,  also Lobular carcinoma In situ",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.9,"after surgical intervention, but before chemo or radiation",1.8,1,,,"Mammaprint high risk 1, BluePrint Luminal B",,,,1,Signatera positive for tDNA: 50.98 MTM/ml (date 09/24/2024)
BCSB0108,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0110,,,152.4,79.4,34.2,Yes,Calcifications,4/19/2022,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/11/2022,Right,5/11/2022,Invasive lobular carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Lobular,,1,,," ER+, PR-, HER2-",100,3,0,0,0,Unknown,ER+ PR- HER2-,,,,,,,,,,,,,,,,,20,,,,,,
BCSB0110,,,152.4,79.4,34.2,Yes,Calcifications,4/19/2022,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/11/2022,Right,6/28/2022,Mixed IDC+ILC (50 -90% each component),,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,1,,," ER+, PR+, HER2-",100,3,50,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,20,,,,,,
BCSB0110,,,152.4,79.4,34.2,Yes,Calcifications,4/19/2022,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/11/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.7,Right,,,,,,,,,20,,,,,,
BCSB0110,,,152.4,79.4,34.2,Yes,Calcifications,4/19/2022,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/11/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,1.2,Left,,,,,,,,,20,,,,,,
BCSB0110,,,152.4,79.4,34.2,Yes,Calcifications,4/19/2022,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/11/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.9,1.7,"after surgical intervention, but before chemo or radiation",1.7,1,"Right,  2.5 LCIS",20,,,,,,
BCSB0110,,,152.4,79.4,34.2,Yes,Calcifications,4/19/2022,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/11/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,1.1,1,"after surgical intervention, but before chemo or radiation",1.3,0.5,Left IDC,20,,,,,,
BCSB0112,,,156.2,50.8,20.8,No,,,,Yes,,Ductal carcinoma in situ,3/4/2021,,2/23/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0(i+),M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,10,Low," ER+, PR+, HER2-",100,3,10,2,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,17,,,,,,
BCSB0112,,,156.2,50.8,20.8,No,,,,Yes,,Ductal carcinoma in situ,3/4/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,,,,,,,,,,17,,,,,,
BCSB0112,,,156.2,50.8,20.8,No,,,,Yes,,Ductal carcinoma in situ,3/4/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.5,"after surgical intervention, but before chemo or radiation",1.9,0.1,Right,17,,,,,,
BCSB0114,,Blue Cross PPO,174,73.5,24.3,Yes,Fibrocystic Breast Changes,8/29/2014,Left,Yes,,Ductal carcinoma in situ,5/11/2016,Left,5/11/2016,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIa,X,,,,Ductal,,3,,," ER+, HER2+, PR-",,,0,0,3+,Unknown,ER weakly+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0114,,Blue Cross PPO,174,73.5,24.3,Yes,Fibrocystic Breast Changes,8/29/2014,Left,Yes,,Ductal carcinoma in situ,5/11/2016,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,8,,,,,,,,,,,,,,,,
BCSB0114,,Blue Cross PPO,174,73.5,24.3,Yes,Fibrocystic Breast Changes,8/29/2014,Left,Yes,,Ductal carcinoma in situ,5/11/2016,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,8,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0115,,,160,81.6,31.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/12/2021,,3/12/2021,Invasive ductal carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",95,3,90,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,22,,,,,,
BCSB0115,,,160,81.6,31.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/12/2021,,3/12/2021,Invasive lobular carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,,Lobular,,2,,," ER+, PR+, HER2-",90,3,50,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,22,,,,,,
BCSB0115,,,160,81.6,31.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/12/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.8,Left,,,,,,,,,22,,,,,,
BCSB0115,,,160,81.6,31.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/12/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,1.3,Right,,,,,,,,,22,,,,,,
BCSB0115,,,160,81.6,31.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/12/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.8,"after surgical intervention, but before chemo or radiation",1.5,0.1,Left,22,,,,,,
BCSB0115,,,160,81.6,31.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/12/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,,1.3,"after surgical intervention, but before chemo or radiation",1.6,0,Right,22,,,,,,
BCSB0116,,,160,65.8,25.7,No,,,,No,,,,,1/5/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,,Stage IIa,,X,,,Ductal,,3,,," ER+, HER2+, PR-",95,3,0,0,3+,Unknown,ER+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0116,,,160,65.8,25.7,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.3,,,,,,,,,,,,,,,,
BCSB0116,,,160,65.8,25.7,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,3.3,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0118,,,170.2,86.2,29.8,Unknown,,,,Yes,,Ductal carcinoma in situ,6/10/2008,Left,8/3/2015,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,,,X,,,Ductal,,3,50,High," ER+, PR-, HER2-",3,2,0,0,1,Unknown,"ER+ PR- HER2-, Essentially Triple Negative,  Right 2015",,,,,,,,,,,,,,,,,,,,,,,
BCSB0118,,,170.2,86.2,29.8,Unknown,,,,Yes,,Ductal carcinoma in situ,6/10/2008,Left,4/10/2008,Invasive ductal carcinoma,,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN3: to ipsilateral internal mammary LN(s),MX: cannot be assessed,,X,,,,Ductal,,3,50,High," ER+, PR+, HER2-",30,2,5,2,1,Non-amplified,"ER+ PR+ HER2-, Left 2008",,,,,,,,,,,,,,,,,,,,,,,
BCSB0118,,,170.2,86.2,29.8,Unknown,,,,Yes,,Ductal carcinoma in situ,6/10/2008,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,Right 2015,,,,,,,,,,,,,,,
BCSB0118,,,170.2,86.2,29.8,Unknown,,,,Yes,,Ductal carcinoma in situ,6/10/2008,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,2,"Left, 2008",,,,,,,,,,,,,,,
BCSB0118,,,170.2,86.2,29.8,Unknown,,,,Yes,,Ductal carcinoma in situ,6/10/2008,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,1.1,"after surgical intervention, but before chemo or radiation",1.2,0,"Right, 2015",,,,,,,
BCSB0118,,,170.2,86.2,29.8,Unknown,,,,Yes,,Ductal carcinoma in situ,6/10/2008,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,,2,"after surgical intervention, but before chemo or radiation",2.3,0,"Left, 2008",,,,,,,
BCSB0119,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0122,,,167.6,57.6,20.5,Yes,Fibrocystic Breast Changes,1/26/2022,Left,No,,,,,6/9/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,,X,,,Ductal,,3,60,High," ER-, PR-, HER2-",0,0,0,0,1,Unknown,Triple negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0122,,,167.6,57.6,20.5,Yes,Fibrocystic Breast Changes,1/26/2022,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.2,,,,,,,,,,,,,,,,
BCSB0122,,,167.6,57.6,20.5,Yes,Fibrocystic Breast Changes,1/26/2022,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0124,,,175.3,79.4,25.8,No,,,,Yes,,Ductal carcinoma in situ,7/3/2019,Left,6/17/2019,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage IIa,X,,,,Ductal,,3,,," ER+, PR+, HER2-",85,3,85,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,38,,,,,,
BCSB0124,,,175.3,79.4,25.8,No,,,,Yes,,Ductal carcinoma in situ,7/3/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.8,,,,,,,,,,38,,,,,,
BCSB0124,,,175.3,79.4,25.8,No,,,,Yes,,Ductal carcinoma in situ,7/3/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.3,"after surgical intervention, but before chemo or radiation",2.4,0.5,,38,,,,,,
BCSB0126,,,163.8,94.8,35.3,No,,,,Yes,,Ductal carcinoma in situ,6/19/2018,Right,12/21/2017,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,,X,,,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,1,Non-amplified,ER- PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0126,,,163.8,94.8,35.3,No,,,,Yes,,Ductal carcinoma in situ,6/19/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,3.8,,,,,,,,,,,,,,,,
BCSB0126,,,163.8,94.8,35.3,No,,,,Yes,,Ductal carcinoma in situ,6/19/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,0.9,"after surgical intervention, after neoadjuvant treatment",1.5,2.7,,,,,,,,
BCSB0127,,,175.3,90.7,29.5,Yes,Fibrocystic Breast Changes,5/31/2016,Left,Yes,,Ductal carcinoma in situ,11/15/2019,Left,11/15/2019,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage Ib,X,,,X,Ductal,,2,30,High," ER+, PR+, HER2-",99,3,90,2,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0127,,,175.3,90.7,29.5,Yes,Fibrocystic Breast Changes,5/31/2016,Left,Yes,,Ductal carcinoma in situ,11/15/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.6,,,,,,,,,,,,,,,,
BCSB0127,,,175.3,90.7,29.5,Yes,Fibrocystic Breast Changes,5/31/2016,Left,Yes,,Ductal carcinoma in situ,11/15/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,4,1.6,"after surgical intervention, after neoadjuvant treatment",1.1,0.5,,,,,,,,
BCSB0128,,,167.6,82.6,29.4,Yes,Adenosis,12/5/2012,,Yes,,Ductal carcinoma in situ,9/24/2020,Bilateral,11/25/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,1,5,Low," ER+, PR+, HER2-",95,3,80,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,9,,,,,,
BCSB0128,,,167.6,82.6,29.4,Yes,Adenosis,12/5/2012,,Yes,,Ductal carcinoma in situ,9/24/2020,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.7,,,,,,,,,,9,,,,,,
BCSB0128,,,167.6,82.6,29.4,Yes,Adenosis,12/5/2012,,Yes,,Ductal carcinoma in situ,9/24/2020,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,0.7,"after surgical intervention, but before chemo or radiation",0.9,0.5,,9,,,,,,
BCSB0130,,,153.7,83.5,35.3,Unknown,,,,No,,,,,3/26/2020,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T3:Tumor >5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage IIIb,X,,,X,Other,Favorable: mucinous,3,30,High," ER+, PR+, HER2+",80,3,5,3,3+,Unknown,ER+ PR+ HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0130,,,153.7,83.5,35.3,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,6.8,"Multiple (scattered) foci of residual tumor present involving an
overall area of 80 mm (by slice method).",,,,,,,,,,,,,,,
BCSB0130,,,153.7,83.5,35.3,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,4,"after surgical intervention, after neoadjuvant treatment",8,1,"Multiple (scattered) foci of residual tumor present involving an
overall area of 80 mm (by slice method).",,,,,,,
BCSB0131,,Kaiser,170.2,69.9,24.1,Yes,Calcifications,,"Left, Benign 2009, 2011",Yes,,Ductal carcinoma in situ,1/26/2022,Right,1/26/2022,Invasive ductal carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,,,X,,,Ductal,,2,30,High," ER+, PR+, HER2-",100,3,40,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0131,,Kaiser,170.2,69.9,24.1,Yes,Calcifications,,"Left, Benign 2009, 2011",Yes,,Ductal carcinoma in situ,1/26/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,,,,,,,
BCSB0131,,Kaiser,170.2,69.9,24.1,Yes,Calcifications,,"Left, Benign 2009, 2011",Yes,,Ductal carcinoma in situ,1/26/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.2,1,"after surgical intervention, but before chemo or radiation",2,1,,,,,,,,
BCSB0132,,,165.1,59,21.6,Yes,Fibrocystic Breast Changes,11/18/2021,Right,No,,,,,11/18/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T3:Tumor >5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,3,,," ER+, PR+, HER2-",90,3,30,2,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,36,,,,,,
BCSB0132,,,165.1,59,21.6,Yes,Fibrocystic Breast Changes,11/18/2021,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.4,,,,,,,,,,36,,,,,,
BCSB0132,,,165.1,59,21.6,Yes,Fibrocystic Breast Changes,11/18/2021,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,3.4,"after surgical intervention, but before chemo or radiation",5.2,0.2,,36,,,,,,
BCSB0133,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0134,,,157.5,64.9,26.2,Unknown,,,,Yes,,Ductal carcinoma in situ,9/10/2021,Left,8/18/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,,,T3:Tumor >5.0 cm,pN1a:Only micrometastasis <=0.2 cm,,,X,,,,Ductal,,2,,," ER+, PR+, HER2+",90,3,30,1,3+,Unknown,ER+ PR+ HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0134,,,157.5,64.9,26.2,Unknown,,,,Yes,,Ductal carcinoma in situ,9/10/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.2,,,,,,,,,,,,,,,,
BCSB0134,,,157.5,64.9,26.2,Unknown,,,,Yes,,Ductal carcinoma in situ,9/10/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,1.2,"after surgical intervention, but before chemo or radiation",6,0.5,,,,,,,,
BCSB0137,,,154.9,95.3,39.7,Yes,Fibrocystic Breast Changes,1/11/2018,Right,Unknown,,,,,11/16/2017,Mucinous (colloid) carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,,X,,,,Other,Favorable: mucinous,1,10,Low," ER+, PR+, HER2-",90,3,90,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0137,,,154.9,95.3,39.7,Yes,Fibrocystic Breast Changes,1/11/2018,Right,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.7,,,,,,,,,,,,,,,,
BCSB0137,,,154.9,95.3,39.7,Yes,Fibrocystic Breast Changes,1/11/2018,Right,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.7,"after surgical intervention, but before chemo or radiation",1.6,0,,,,,,,,
BCSB0139,,,157.5,53.5,21.6,No,,,,Yes,,Ductal carcinoma in situ,11/10/2020,Right,11/10/2020,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,34,High," ER+, PR+, HER2-",92,3,86,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,15,,,,,,
BCSB0139,,,157.5,53.5,21.6,No,,,,Yes,,Ductal carcinoma in situ,11/10/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.8,,,,,,,,,,15,,,,,,
BCSB0139,,,157.5,53.5,21.6,No,,,,Yes,,Ductal carcinoma in situ,11/10/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,0.8,"after surgical intervention, but before chemo or radiation",0.9,0.2,,15,,,,,,
BCSB0141,,,160,58.1,22.7,Unknown,,,,Yes,,Ductal carcinoma in situ,3/22/2016,,2/18/2016,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,3,10,Low," ER+, PR+, HER2-",95,3,10,3,2,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,26,,,,,,
BCSB0141,,,160,58.1,22.7,Unknown,,,,Yes,,Ductal carcinoma in situ,3/22/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,26,,,,,,
BCSB0141,,,160,58.1,22.7,Unknown,,,,Yes,,Ductal carcinoma in situ,3/22/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1,"after surgical intervention, but before chemo or radiation",1.1,0.2,,26,,,,,,
BCSB0143,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0144,,,157.5,92.5,37.3,No,,,,Yes,,Ductal carcinoma in situ,12/18/2018,,12/18/2018,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage IIIb,,X,,,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,1,Unknown,Triple negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0144,,,157.5,92.5,37.3,No,,,,Yes,,Ductal carcinoma in situ,12/18/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.8,,,,,,,,,,,,,,,,
BCSB0144,,,157.5,92.5,37.3,No,,,,Yes,,Ductal carcinoma in situ,12/18/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,2.8,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0147,,,165.1,60.3,22.1,Yes,Adenosis,4/5/2021,Right,Yes,,Ductal carcinoma in situ,3/11/2021,Left,3/11/2021,Invasive ductal carcinoma,,,MX: cannot be assessed,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,X,Ductal,,2,40,High," HER2+, ER-, PR-",10,1,0,0,3+,Amplified,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0147,,,165.1,60.3,22.1,Yes,Adenosis,4/5/2021,Right,Yes,,Ductal carcinoma in situ,3/11/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.9,,,,,,,,,,,,,,,,
BCSB0147,,,165.1,60.3,22.1,Yes,Adenosis,4/5/2021,Right,Yes,,Ductal carcinoma in situ,3/11/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.4,"after surgical intervention, but before chemo or radiation",0.9,0.7,,,,,,,,
BCSB0146,,,170.2,45.4,15.7,Unknown,,,,Unknown,,,,,2/22/2022,Invasive ductal carcinoma,,,,T0:No evidence of primary tumor,N0: No regional LNs metastasis,,Stage IIa,,X,,X,Ductal,,3,60,High," ER+, PR+, HER2+",,,,,3+,Unknown,Triple positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0146,,,170.2,45.4,15.7,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.6,,,,,,,,,,,,,,,,
BCSB0146,,,170.2,45.4,15.7,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,3,"after surgical intervention, after neoadjuvant treatment",0.4,,,,,,,,,
BCSB0148,,,157.5,70.3,28.3,No,,,,Yes,,Ductal carcinoma in situ,3/3/2021,Left,2/8/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,15,Low," ER+, PR+, HER2-",95,3,95,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,10,,,,,,
BCSB0148,,,157.5,70.3,28.3,No,,,,Yes,,Ductal carcinoma in situ,3/3/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.6,,,,,,,,,,10,,,,,,
BCSB0148,,,157.5,70.3,28.3,No,,,,Yes,,Ductal carcinoma in situ,3/3/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.9,1.6,"after surgical intervention, but before chemo or radiation",2,0.3,,10,,,,,,
BCSB0155,,Healthcare Partners Region 5 Medicare Advantage,154.9,71.2,29.7,Yes,Fibroadenoma,12/21/2022,Right,Yes,,Ductal carcinoma in situ,10/26/2022,Right,10/26/2022,Invasive ductal carcinoma,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,20,High," ER+, PR+, HER2-",100,3,95,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,0,,,,,,
BCSB0155,,Healthcare Partners Region 5 Medicare Advantage,154.9,71.2,29.7,Yes,Fibroadenoma,12/21/2022,Right,Yes,,Ductal carcinoma in situ,10/26/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.5,,,,,,,,,,0,,,,,,
BCSB0155,,Healthcare Partners Region 5 Medicare Advantage,154.9,71.2,29.7,Yes,Fibroadenoma,12/21/2022,Right,Yes,,Ductal carcinoma in situ,10/26/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.5,"after surgical intervention, but before chemo or radiation",0.8,0.4,,0,,,,,,
BCSB0151,,,149.9,70.8,31.5,Unknown,,,,Yes,,Ductal carcinoma in situ,10/5/2020,Left,9/9/2019,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),,T1c:>1.0 cm but <=2.0 cm,pN1: movable ipsilateral axillary LN(s),,Stage Ib,,X,,X,Ductal,,3,,High," ER+, PR+, HER2-",95,3,95,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0151,,,149.9,70.8,31.5,Unknown,,,,Yes,,Ductal carcinoma in situ,10/5/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.4,,,,,,,,,,,,,,,,
BCSB0151,,,149.9,70.8,31.5,Unknown,,,,Yes,,Ductal carcinoma in situ,10/5/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.3,"after surgical intervention, after neoadjuvant treatment",1.5,,,,,,,,,
BCSB0152,,LA Care Medical,172.7,66.7,22.4,,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/10/2018,,4/24/2018,Invasive lobular carcinoma,,,M0: No distant metastasis,T3:Tumor >5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,X,Lobular,,2,3,Low," ER+, PR+, HER2-",85,3,4,1,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,18,LOW RISK,,,,,
BCSB0152,,LA Care Medical,172.7,66.7,22.4,,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/10/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,3.7,,,,,,,,,,18,LOW RISK,,,,,
BCSB0152,,LA Care Medical,172.7,66.7,22.4,,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/10/2018,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",7.7,0.1,5.5cm & 2.2cm,18,LOW RISK,,,,,
BCSB0154,,Medicare A and B,160,64.9,25.4,Yes,Atypical Lobular Hyperplasia,6/30/2021,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/21/2021,Right,4/21/2021,Invasive lobular carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T3:Tumor >5.0 cm,pN0(i+),M0: No distant metastasis,,,X,,,Lobular,,2,5,Low," ER+, PR+, HER2-",100,3,50,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,22,,,,,,
BCSB0154,,Medicare A and B,160,64.9,25.4,Yes,Atypical Lobular Hyperplasia,6/30/2021,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/21/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3,,,,,,,,,,22,,,,,,
BCSB0154,,Medicare A and B,160,64.9,25.4,Yes,Atypical Lobular Hyperplasia,6/30/2021,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/21/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,3,"after surgical intervention, but before chemo or radiation",9.4,0.1,5cm + 4.4cm,22,,,,,,
BCSB0158,,,167.6,79.4,28.3,Unknown,,,,Yes,,Ductal carcinoma in situ,9/22/2020,Right,2/6/2020,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),MX: cannot be assessed,T3:Tumor >5.0 cm,pN3: to ipsilateral internal mammary LN(s),MX: cannot be assessed,Stage IIIc,,X,,X,Ductal,,3,,," ER+, PR+, HER2-",100,3,100,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0158,,,167.6,79.4,28.3,Unknown,,,,Yes,,Ductal carcinoma in situ,9/22/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,7.8,,,,,,,,,,,,,,,,
BCSB0158,,,167.6,79.4,28.3,Unknown,,,,Yes,,Ductal carcinoma in situ,9/22/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,5.2,"after surgical intervention, after neoadjuvant treatment",6.8,0.2,,,,,,,,
BCSB0159,,,160,78.9,30.8,No,,,,No,,,,,2/2/2018,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,,Stage IIa,,X,,,Ductal,,2,,," ER-, PR-, HER2-",3,,1,,1,Unknown,ER- PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0159,,,160,78.9,30.8,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,4.3,,,,,,,,,,,,,,,,
BCSB0159,,,160,78.9,30.8,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,4.3,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0160,,,165.1,55.3,20.3,Unknown,,,,No,,,,,6/9/2022,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,,Stage Ia,X,,,,Ductal,,2,,," ER+, HER2+, PR-",,,0,,,Unknown,ER+ PR- Her2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0160,,,165.1,55.3,20.3,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,,,,,,,
BCSB0160,,,165.1,55.3,20.3,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.9,"after surgical intervention, after neoadjuvant treatment",0,,,,,,,,,
BCSB0162,,,175.3,104.3,33.9,No,,,,Yes,,Ductal carcinoma in situ,4/6/2022,Right,4/6/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0162,,,175.3,104.3,33.9,No,,,,Yes,,Ductal carcinoma in situ,4/6/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.8,,,,,,,,,,,,,,,,
BCSB0162,,,175.3,104.3,33.9,No,,,,Yes,,Ductal carcinoma in situ,4/6/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,2.8,"after surgical intervention, but before chemo or radiation",2.7,1,,,,,,,,
BCSB0163,,,162.6,76.7,29,Yes,Breast Cysts,6/1/2022,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/5/2022,Left,7/5/2022,Invasive lobular carcinoma,,,,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,,,X,,,X,Lobular,,2,15,Low," ER+, PR+, HER2-",95,3,95,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,6,,,,,,
BCSB0163,,,162.6,76.7,29,Yes,Breast Cysts,6/1/2022,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/5/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,6,,,,,,
BCSB0163,,,162.6,76.7,29,Yes,Breast Cysts,6/1/2022,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/5/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,1,"after surgical intervention, but before chemo or radiation",2.2,0.1,"Multifocal: 2.2cm, 0.5cm, 0.3cm",6,,,,,,
BCSB0164,,,157.5,98.4,39.7,Yes,Calcifications,5/1/2022,Left,Yes,,Ductal carcinoma in situ,5/4/2022,Left,6/27/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,,X,,,X,Ductal,,2,29,High," HER2+, ER-, PR-",0,0,0,0,2,Amplified,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0164,,,157.5,98.4,39.7,Yes,Calcifications,5/1/2022,Left,Yes,,Ductal carcinoma in situ,5/4/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,,,,,,,,,,,,,,,,,
BCSB0164,,,157.5,98.4,39.7,Yes,Calcifications,5/1/2022,Left,Yes,,Ductal carcinoma in situ,5/4/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",0.4,0.7,"and 0.2cm, 01cm",,,,,,,
BCSB0165,,,172.7,152.9,51.3,Yes,Atypical Ductal Hyperplasia,10/8/2010,Right,No,,,,,10/8/2010,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,0,Non-amplified,Triple negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0165,,,172.7,152.9,51.3,Yes,Atypical Ductal Hyperplasia,10/8/2010,Right,No,,,,,4/8/2020,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pNX: Regional LNs cannot be assessed,M0: No distant metastasis,Stage Ib,,X,,X,Ductal,,2,15,Low," ER+, PR+, HER2-",95,,95,,2,Non-amplified,ER+ PR+ Her2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0165,,,172.7,152.9,51.3,Yes,Atypical Ductal Hyperplasia,10/8/2010,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3,2020,,,,,,,,,,,,,,,
BCSB0165,,,172.7,152.9,51.3,Yes,Atypical Ductal Hyperplasia,10/8/2010,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.8,"after surgical intervention, but before chemo or radiation",2.8,0,2010 Right,,,,,,,
BCSB0165,,,172.7,152.9,51.3,Yes,Atypical Ductal Hyperplasia,10/8/2010,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,,3,"after surgical intervention, after neoadjuvant treatment",2.5,2,2020 Right,,,,,,,
BCSB0166,,,167.6,66.2,23.6,No,,,,No,,,,,10/19/2021,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,,X,,,Ductal,,3,,," ER+, PR+, HER2+",70,1,5,1,1,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0166,,,167.6,66.2,23.6,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,11.8,,,,,,,,,,,,,,,,
BCSB0166,,,167.6,66.2,23.6,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,11.8,"after surgical intervention, after neoadjuvant treatment",2.5,0.3,,,,,,,,
BCSB0167,,,154.9,65.8,27.4,No,,,,Yes,,Ductal carcinoma in situ,10/23/2021,,10/23/2021,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N0: No regional LNs metastasis,,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,,Stage IIa,X,,,,Ductal,,2,,," ER+, HER2+, PR-",10,2,0,0,3+,Unknown,ER+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0167,,,154.9,65.8,27.4,No,,,,Yes,,Ductal carcinoma in situ,10/23/2021,,2/2/2022,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,,Stage Ia,,X,,,Ductal,,2,,," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0167,,,154.9,65.8,27.4,No,,,,Yes,,Ductal carcinoma in situ,10/23/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,6,Left,,,,,,,,,,,,,,,
BCSB0167,,,154.9,65.8,27.4,No,,,,Yes,,Ductal carcinoma in situ,10/23/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,0.6,Right,,,,,,,,,,,,,,,
BCSB0167,,,154.9,65.8,27.4,No,,,,Yes,,Ductal carcinoma in situ,10/23/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,6,"after surgical intervention, after neoadjuvant treatment",0,,Left,,,,,,,
BCSB0167,,,154.9,65.8,27.4,No,,,,Yes,,Ductal carcinoma in situ,10/23/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,,0.6,"after surgical intervention, after neoadjuvant treatment",0,,Right,,,,,,,
BCSB0174,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0171,,,170.2,59,20.4,Yes,Breast Cysts,3/1/2018,,Yes,,Ductal carcinoma in situ,7/22/2021,,7/22/2021,Invasive ductal carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN1: movable ipsilateral axillary LN(s),,Stage Ia,,X,,X,Ductal,,2,,," ER+, PR+, HER2-",93,3,37,1,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,22,,,,,,
BCSB0171,,,170.2,59,20.4,Yes,Breast Cysts,3/1/2018,,Yes,,Ductal carcinoma in situ,7/22/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.8,,,,,,,,,,22,,,,,,
BCSB0171,,,170.2,59,20.4,Yes,Breast Cysts,3/1/2018,,Yes,,Ductal carcinoma in situ,7/22/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.4,1.8,"after surgical intervention, but before chemo or radiation",1.8,0.5,,22,,,,,,
BCSB0172,,,165.1,77.1,28.3,No,,,,Yes,,Ductal carcinoma in situ,2/7/2020,,7/18/2019,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,,Stage IIa,,X,,X,Ductal,,3,,," ER+, PR+, HER2+",70,3,5,3,3+,Unknown,Triple positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0172,,,165.1,77.1,28.3,No,,,,Yes,,Ductal carcinoma in situ,2/7/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.4,,,,,,,,,,,,,,,,
BCSB0172,,,165.1,77.1,28.3,No,,,,Yes,,Ductal carcinoma in situ,2/7/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,2.4,"after surgical intervention, after neoadjuvant treatment",1.1,0.2,,,,,,,,
BCSB0175,,,152.4,54.4,23.4,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/28/2018,Left,9/23/2017,Invasive lobular carcinoma,T4a:Any size with direct extension to chest wall,N3: Ipsilateral internal mammary LN(s),M0: No distant metastasis,T3:Tumor >5.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage IIIc,X,,,X,Lobular,,2,40,High," ER+, PR-, HER2-",95,3,0,0,2,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0175,,,152.4,54.4,23.4,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/28/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,11.3,5.9 + 5.4,,,,,,,,,,,,,,,
BCSB0175,,,152.4,54.4,23.4,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/28/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,11.3,"after surgical intervention, after neoadjuvant treatment",5.6,0.1,,,,,,,,
BCSB0180,,,154.9,62.6,26.1,No,,,,Yes,,Ductal carcinoma in situ,3/19/2020,Left,3/31/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,X,,,X,Ductal,,3,,," ER+, PR+, HER2-",13,2,2,2,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,56,,,,,,
BCSB0180,,,154.9,62.6,26.1,No,,,,Yes,,Ductal carcinoma in situ,3/19/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.3,,,,,,,,,,56,,,,,,
BCSB0180,,,154.9,62.6,26.1,No,,,,Yes,,Ductal carcinoma in situ,3/19/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.3,"after surgical intervention, but before chemo or radiation",2.4,4,,56,,,,,,
BCSB0177,,,171.4,99.8,34,Yes,Peripheral Intraductal Papillomas,11/25/2009,Left,Yes,,Ductal carcinoma in situ,9/16/2020,Left,1/14/2015,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,,Ductal,,1,12,Low," ER+, PR+, HER2-",100,3,100,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0177,,,171.4,99.8,34,Yes,Peripheral Intraductal Papillomas,11/25/2009,Left,Yes,,Ductal carcinoma in situ,9/16/2020,Left,8/14/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,,Other,Unfavorable: metaplastic,2,31,High," ER-, PR-, HER2-",1.4,2,0,0,2,Non-amplified,Triple negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0177,,,171.4,99.8,34,Yes,Peripheral Intraductal Papillomas,11/25/2009,Left,Yes,,Ductal carcinoma in situ,9/16/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.5,2015,,,,,,,,,,,,,,,
BCSB0177,,,171.4,99.8,34,Yes,Peripheral Intraductal Papillomas,11/25/2009,Left,Yes,,Ductal carcinoma in situ,9/16/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,1,2020,,,,,,,,,,,,,,,
BCSB0177,,,171.4,99.8,34,Yes,Peripheral Intraductal Papillomas,11/25/2009,Left,Yes,,Ductal carcinoma in situ,9/16/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.5,"after surgical intervention, but before chemo or radiation",0.5,,2015,,,,,,,
BCSB0177,,,171.4,99.8,34,Yes,Peripheral Intraductal Papillomas,11/25/2009,Left,Yes,,Ductal carcinoma in situ,9/16/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,0.9,1,"after surgical intervention, but before chemo or radiation",1,1,2020,,,,,,,
BCSB0182,,,170.2,109.8,37.9,No,,,,No,,,,,12/13/2022,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,15,Low," ER+, PR+, HER2-",90,3,90,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,16,,,,,,
BCSB0182,,,170.2,109.8,37.9,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,0.6,,,,,,,,,,16,,,,,,
BCSB0182,,,170.2,109.8,37.9,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,0.6,"after surgical intervention, but before chemo or radiation",0.5,0.5,,16,,,,,,
BCSB0186,,,162.6,68,25.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0179,,,157.5,90.7,36.6,No,,,,Yes,,Ductal carcinoma in situ,8/30/2021,,2/9/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,X,,,,Ductal,,3,,," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,ER- PR- HER+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0179,,,157.5,90.7,36.6,No,,,,Yes,,Ductal carcinoma in situ,8/30/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.7,,,,,,,,,,,,,,,,
BCSB0179,,,157.5,90.7,36.6,No,,,,Yes,,Ductal carcinoma in situ,8/30/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,3.7,"after surgical intervention, after neoadjuvant treatment",0.3,0,,,,,,,,
BCSB0195,,,175.3,98.9,32.2,Yes,Central Intraductal Papilloma,1/23/2020,Right,Yes,,Ductal carcinoma in situ,6/9/2020,Left,1/23/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage IIa,X,,,X,Ductal,,1,,," ER+, PR+, HER2-",91,3,91,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0195,,,175.3,98.9,32.2,Yes,Central Intraductal Papilloma,1/23/2020,Right,Yes,,Ductal carcinoma in situ,6/9/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,,,,,,,,,,,,,,,,,
BCSB0195,,,175.3,98.9,32.2,Yes,Central Intraductal Papilloma,1/23/2020,Right,Yes,,Ductal carcinoma in situ,6/9/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",1.5,0,,,,,,,,
BCSB0196,,,174,108.9,36,No,,,,No,,,,,11/30/2021,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,X,Ductal,,1,12,Low," ER+, PR+, HER2-",63.8,3,94,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0196,,,174,108.9,36,No,,,,No,,,,,12/22/2021,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,X,Ductal,,1,2.6,Low," ER+, PR+, HER2-",89,3,42,2,2,Non-amplified,"ER+ PR+ HER2- , smaller foci",,,,,,,,,,,,,,,,,,,,,,,
BCSB0196,,,174,108.9,36,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.6,larger foci,,,,,,,,,,,,,,,
BCSB0196,,,174,108.9,36,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,No,0.4,smaller foci,,,,,,,,,,,,,,,
BCSB0196,,,174,108.9,36,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.7,0.6,"after surgical intervention, but before chemo or radiation",1.5,0.7,Larger foci,,,,,,,
BCSB0196,,,174,108.9,36,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,2.3,0.4,"after surgical intervention, but before chemo or radiation",0.4,0.7,Smaller foci,,,,,,,
BCSB0161,,,154.9,90.3,37.6,Yes,Atypical Lobular Hyperplasia,7/14/2021,Right,Yes,,Ductal carcinoma in situ,8/6/2021,Right,7/14/2021,Invasive ductal carcinoma,,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,,,X,,,Ductal,,,,," ER+, PR+, HER2-",95,3,80,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,26,,,,,,
BCSB0161,,,154.9,90.3,37.6,Yes,Atypical Lobular Hyperplasia,7/14/2021,Right,Yes,,Ductal carcinoma in situ,8/6/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.2,,,,,,,,,,26,,,,,,
BCSB0161,,,154.9,90.3,37.6,Yes,Atypical Lobular Hyperplasia,7/14/2021,Right,Yes,,Ductal carcinoma in situ,8/6/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,4.2,"after surgical intervention, but before chemo or radiation",4.1,0,,26,,,,,,
BCSB0185,,,162.6,77.1,29.2,Unknown,,,,Yes,,Ductal carcinoma in situ,10/13/2021,Right,10/13/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,3,30,High," ER+, HER2+, PR-",6,3,0,0,3+,Unknown,ER+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0185,,,162.6,77.1,29.2,Unknown,,,,Yes,,Ductal carcinoma in situ,10/13/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,,,,,,,,,,,,,,,,
BCSB0185,,,162.6,77.1,29.2,Unknown,,,,Yes,,Ductal carcinoma in situ,10/13/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.4,1,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0187,,,172.7,131.5,44.1,Yes,Flat Epithelial Atypia,9/22/2020,,No,,,,,9/22/2020,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,,Ductal,,2,25,High," ER-, PR-, HER2-",0,0,0,0,1,Unknown,Triple negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0187,,,172.7,131.5,44.1,Yes,Flat Epithelial Atypia,9/22/2020,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.2,,,,,,,,,,,,,,,,
BCSB0187,,,172.7,131.5,44.1,Yes,Flat Epithelial Atypia,9/22/2020,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.9,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0194,,,157.5,61.2,24.7,Yes,Calcifications,6/4/2021,Left,Yes,,Ductal carcinoma in situ,6/9/2021,Left,6/9/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,,Stage IIa,X,,,,Ductal,,3,85,High," ER+, HER2+, PR-",2,2,0,0,3+,Amplified,ER low+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0194,,,157.5,61.2,24.7,Yes,Calcifications,6/4/2021,Left,Yes,,Ductal carcinoma in situ,6/9/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.2,,,,,,,,,,,,,,,,
BCSB0194,,,157.5,61.2,24.7,Yes,Calcifications,6/4/2021,Left,Yes,,Ductal carcinoma in situ,6/9/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.2,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0204,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0203,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0208,,,172.7,104.3,35,No,,,,No,,,,,2/4/2021,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,,X,,,X,Ductal,,3,84,High," ER-, PR-, HER2-",0,0,0,0,1,Non-amplified,Triple negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0208,,,172.7,104.3,35,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.5,,,,,,,,,,,,,,,,
BCSB0208,,,172.7,104.3,35,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.8,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0210,,,161.6,60.5,23.2,Yes,Atypical Ductal Hyperplasia,6/20/2019,Left,Yes,,Ductal carcinoma in situ,4/25/2019,Left,4/25/2019,Mixed IDC+ILC (50 -90% each component),,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,X,,,X,,,2,,," ER+, PR+, HER2-",100,3,98,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,13,,,,,,
BCSB0210,,,161.6,60.5,23.2,Yes,Atypical Ductal Hyperplasia,6/20/2019,Left,Yes,,Ductal carcinoma in situ,4/25/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.9,,,,,,,,,,13,,,,,,
BCSB0210,,,161.6,60.5,23.2,Yes,Atypical Ductal Hyperplasia,6/20/2019,Left,Yes,,Ductal carcinoma in situ,4/25/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,0.7,"after surgical intervention, but before chemo or radiation",1.1,0.1,and 0.17cm,13,,,,,,
BCSB0211,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0212,,,167.6,84.3,30,Unknown,,,,No,,,,,4/15/2020,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,X,,,,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,1,Non-amplified,ER- PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0212,,,167.6,84.3,30,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.8,,,,,,,,,,,,,,,,
BCSB0212,,,167.6,84.3,30,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,0.8,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0214,,,160,82,32,Yes,Breast Cysts,8/29/2016,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/13/2017,Right,6/13/2017,Invasive ductal carcinoma,T4d:Inflammatory carcinoma,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage IIIb,,X,,X,Ductal,,2,14,Low," ER+, HER2+, PR-",2,1,0,0,3+,Amplified,ER+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0214,,,160,82,32,Yes,Breast Cysts,8/29/2016,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/13/2017,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.6,,,,,,,,,,,,,,,,
BCSB0214,,,160,82,32,Yes,Breast Cysts,8/29/2016,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/13/2017,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.8,1.6,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0216,,,160,59.6,23.3,Yes,Flat Epithelial Atypia,8/17/2020,Right,Yes,,Ductal carcinoma in situ,3/17/2020,,3/26/2020,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ib,,X,,X,Ductal,,1,,," ER+, PR+, HER2+",90,3,60,2,2,Amplified,Triple positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0216,,,160,59.6,23.3,Yes,Flat Epithelial Atypia,8/17/2020,Right,Yes,,Ductal carcinoma in situ,3/17/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,,,,,,,
BCSB0216,,,160,59.6,23.3,Yes,Flat Epithelial Atypia,8/17/2020,Right,Yes,,Ductal carcinoma in situ,3/17/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,0.6,"after surgical intervention, after neoadjuvant treatment",0.3,0.2,,,,,,,,
BCSB0206,,,163,89.9,33.8,Yes,Fibroadenoma,1/29/2019,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/17/2019,Left LCIS and DCIS present,3/1/2019,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,X,,,,Ductal,,3,20,High," ER-, PR-, HER2-",0,0,0,0,2,Non-amplified,ER- PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0206,,,163,89.9,33.8,Yes,Fibroadenoma,1/29/2019,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/17/2019,Left LCIS and DCIS present,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.1,,,,,,,,,,,,,,,,
BCSB0206,,,163,89.9,33.8,Yes,Fibroadenoma,1/29/2019,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/17/2019,Left LCIS and DCIS present,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.1,"after surgical intervention, after neoadjuvant treatment",2.3,0.4,,,,,,,,
BCSB0215,,,167.6,56.4,20.1,Yes,Calcifications,6/2/2021,Right,Yes,,Ductal carcinoma in situ,7/20/2021,Right,7/20/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,,,," ER+, PR-, HER2-",90,3,0,0,2,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,17,,,,,,
BCSB0215,,,167.6,56.4,20.1,Yes,Calcifications,6/2/2021,Right,Yes,,Ductal carcinoma in situ,7/20/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,,,,,,,,,,,17,,,,,,
BCSB0215,,,167.6,56.4,20.1,Yes,Calcifications,6/2/2021,Right,Yes,,Ductal carcinoma in situ,7/20/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,,"after surgical intervention, but before chemo or radiation",1.4,0,,17,,,,,,
BCSB0205,,,154.8,84.7,35.3,Yes,Atypical Ductal Hyperplasia,9/11/2015,Left,Yes,,Ductal carcinoma in situ,8/17/2015,Right,8/17/2015,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T3:Tumor >5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage IIIb,,X,,,Ductal,,3,70,High," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0205,,,154.8,84.7,35.3,Yes,Atypical Ductal Hyperplasia,9/11/2015,Left,Yes,,Ductal carcinoma in situ,8/17/2015,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,7.4,,,,,,,,,,,,,,,,
BCSB0205,,,154.8,84.7,35.3,Yes,Atypical Ductal Hyperplasia,9/11/2015,Left,Yes,,Ductal carcinoma in situ,8/17/2015,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,7.4,"after surgical intervention, but before chemo or radiation",8.5,0.4,,,,,,,,
BCSB0213,,,170.1,84.7,29.3,Yes,Calcifications,12/3/2021,Right,Yes,,Ductal carcinoma in situ,5/17/2022,"Left, And LCIS",12/21/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,2,15,Low," ER+, HER2+, PR-",100,3,0,0,3+,Non-amplified,ER+ PR- HER2+,,,,,,,,,,,,,,,,,15,,,,,,
BCSB0213,,,170.1,84.7,29.3,Yes,Calcifications,12/3/2021,Right,Yes,,Ductal carcinoma in situ,5/17/2022,"Left, And LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.7,,,,,,,,,,15,,,,,,
BCSB0213,,,170.1,84.7,29.3,Yes,Calcifications,12/3/2021,Right,Yes,,Ductal carcinoma in situ,5/17/2022,"Left, And LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.1,0.9,"after surgical intervention, after neoadjuvant treatment",2,0.1,,15,,,,,,
BCSB0217,,,167.6,77.6,27.6,No,,,,Yes,,Ductal carcinoma in situ,4/24/2018,Right,3/12/2018,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,,," ER+, PR+, HER2-",95,3,12,2,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,26,,,,,,
BCSB0217,,,167.6,77.6,27.6,No,,,,Yes,,Ductal carcinoma in situ,4/24/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1.2,,,,,,,,,,26,,,,,,
BCSB0217,,,167.6,77.6,27.6,No,,,,Yes,,Ductal carcinoma in situ,4/24/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3.7,1.2,"after surgical intervention, but before chemo or radiation",1.3,4.7,,26,,,,,,
BCSB0219,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0224,,,160,93.8,36.6,No,,,,Yes,,Ductal carcinoma in situ,8/24/2022,Right,7/8/2022,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,2,30,Low," ER+, PR+, HER2-",95,3,70,2,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,33,,,,,,
BCSB0224,,,160,93.8,36.6,No,,,,Yes,,Ductal carcinoma in situ,8/24/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.6,,,,,,,,,,33,,,,,,
BCSB0224,,,160,93.8,36.6,No,,,,Yes,,Ductal carcinoma in situ,8/24/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,0.6,"after surgical intervention, but before chemo or radiation",2.4,0.5,,33,,,,,,
BCSB0227,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0234,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0237,,,162.4,82.3,31.2,Yes,Calcifications,2/22/2022,Right,Yes,,Ductal carcinoma in situ,3/11/2022,Right,3/30/2022,Invasive ductal carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,,Stage IIa,,X,,X,Ductal,,2,85,High," HER2+, ER-, PR-",0,0,0,0,3+,Amplified,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0237,,,162.4,82.3,31.2,Yes,Calcifications,2/22/2022,Right,Yes,,Ductal carcinoma in situ,3/11/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.8,,,,,,,,,,,,,,,,
BCSB0237,,,162.4,82.3,31.2,Yes,Calcifications,2/22/2022,Right,Yes,,Ductal carcinoma in situ,3/11/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.9,0.3,"after surgical intervention, but before chemo or radiation",1.5,0.9,,,,,,,,
BCSB0245,,,177.8,72.6,23,Yes,Calcifications,7/17/2020,Left,Yes,,Ductal carcinoma in situ,7/17/2020,Left,7/17/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage Ib,X,,,,Ductal,,1,,," ER+, PR+, HER2+",95,3,95,3,2,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0245,,,177.8,72.6,23,Yes,Calcifications,7/17/2020,Left,Yes,,Ductal carcinoma in situ,7/17/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.1,,,,,,,,,,,,,,,,
BCSB0245,,,177.8,72.6,23,Yes,Calcifications,7/17/2020,Left,Yes,,Ductal carcinoma in situ,7/17/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.1,"after surgical intervention, after neoadjuvant treatment",1.6,0.2,,,,,,,,
BCSB0192,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0220,,,160,99.7,38.9,No,,,,No,,,,,3/5/2020,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,3,,," ER+, HER2+, PR-",98,3,0,0,3+,Amplified,ER+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0220,,,160,99.7,38.9,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,3.8,,,,,,,,,,,,,,,,
BCSB0220,,,160,99.7,38.9,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,3.8,"after surgical intervention, after neoadjuvant treatment",0,-1,,,,,,,,
BCSB0242,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0244,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0248,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0199,,,162.6,63,23.8,Yes,Fibroadenoma,1/1/1991,Left,Yes,,Ductal carcinoma in situ,8/1/2018,Right,8/1/2018,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN1: movable ipsilateral axillary LN(s),,Stage IIb,,X,,X,Ductal,,3,40,High," ER+, PR+, HER2+",96,3,90,3,3+,Unknown,ER+ PR+ HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0199,,,162.6,63,23.8,Yes,Fibroadenoma,1/1/1991,Left,Yes,,Ductal carcinoma in situ,8/1/2018,Right,1/28/2019,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",96,3,92,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0199,,,162.6,63,23.8,Yes,Fibroadenoma,1/1/1991,Left,Yes,,Ductal carcinoma in situ,8/1/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,5.7,Right,,,,,,,,,,,,,,,
BCSB0199,,,162.6,63,23.8,Yes,Fibroadenoma,1/1/1991,Left,Yes,,Ductal carcinoma in situ,8/1/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,2.1,Left,,,,,,,,,,,,,,,
BCSB0199,,,162.6,63,23.8,Yes,Fibroadenoma,1/1/1991,Left,Yes,,Ductal carcinoma in situ,8/1/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3,,"after surgical intervention, after neoadjuvant treatment",0,0,Right,,,,,,,
BCSB0199,,,162.6,63,23.8,Yes,Fibroadenoma,1/1/1991,Left,Yes,,Ductal carcinoma in situ,8/1/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,,,,"after surgical intervention, after neoadjuvant treatment",1.6,0,Left,,,,,,,
BCSB0229,,,172.7,87.7,29.4,Yes,Fibrocystic Breast Changes,1/25/2022,Left,Yes,,Ductal carcinoma in situ,1/25/2022,Right,9/28/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ib,,X,,,Ductal,,3,30,High," ER+, PR+, HER2+",95,3,70,3,3+,Unknown,Triple positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0229,,,172.7,87.7,29.4,Yes,Fibrocystic Breast Changes,1/25/2022,Left,Yes,,Ductal carcinoma in situ,1/25/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3,,,,,,,,,,,,,,,,
BCSB0229,,,172.7,87.7,29.4,Yes,Fibrocystic Breast Changes,1/25/2022,Left,Yes,,Ductal carcinoma in situ,1/25/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.2,"after surgical intervention, after neoadjuvant treatment",1.5,0,,,,,,,,
BCSB0246,,,163.5,71.2,26.6,Yes,Fibroadenoma,5/9/2022,Left,Yes,,Ductal carcinoma in situ,9/28/2021,Right,9/28/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,X,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,2,Non-amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0246,,,163.5,71.2,26.6,Yes,Fibroadenoma,5/9/2022,Left,Yes,,Ductal carcinoma in situ,9/28/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.4,,,,,,,,,,,,,,,,
BCSB0246,,,163.5,71.2,26.6,Yes,Fibroadenoma,5/9/2022,Left,Yes,,Ductal carcinoma in situ,9/28/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.4,"after surgical intervention, after neoadjuvant treatment",0.3,0.2,,,,,,,,
BCSB0201,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0233,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0239,,,152.4,108.5,46.7,Yes,Calcifications,2/11/2022,Right,Unknown,,,,,2/11/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage IIb,,X,,,Ductal,,2,40,High," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,1,Signatera result: Negative
BCSB0239,,,152.4,108.5,46.7,Yes,Calcifications,2/11/2022,Right,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2,,,,,,,,,,,,,,,1,Signatera result: Negative
BCSB0239,,,152.4,108.5,46.7,Yes,Calcifications,2/11/2022,Right,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2,"after surgical intervention, after neoadjuvant treatment",0.6,,,,,,,,1,Signatera result: Negative
BCSB0240,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0251,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0253,,,165,122.3,44.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/8/2020,,10/11/2019,Invasive lobular carcinoma,T3:Tumor >5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0(i+),M0: No distant metastasis,Stage Ia,X,,,X,Lobular,,1,,," ER+, PR+, HER2-",100,3,100,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0253,,,165,122.3,44.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/8/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,8,,,,,,,,,,,,,,,,
BCSB0253,,,165,122.3,44.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/8/2020,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,3,"after surgical intervention, but before chemo or radiation",2.3,0.8,,,,,,,,
BCSB0254,,,165.1,106.5,39.1,Unknown,,,,Yes,,Ductal carcinoma in situ,12/9/2022,Right,10/13/2022,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,X,Ductal,,1,8,Low," ER+, PR+, HER2+",95,,80,,3+,,ER+ PR+ HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0254,,,165.1,106.5,39.1,Unknown,,,,Yes,,Ductal carcinoma in situ,12/9/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,,,,,,,,,,,,,,,,
BCSB0254,,,165.1,106.5,39.1,Unknown,,,,Yes,,Ductal carcinoma in situ,12/9/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.3,"after surgical intervention, but before chemo or radiation",0.5,0,,,,,,,,
BCSB0256,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0257,,,172.7,88.6,29.7,Yes,Atypical Lobular Hyperplasia,11/19/2018,Bilateral,Yes,,Ductal carcinoma in situ,11/19/2018,Bilateral,10/18/2018,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,X,Ductal,,3,12,Low," ER+, PR+, HER2-",95,3,90,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,9,,,,,,
BCSB0257,,,172.7,88.6,29.7,Yes,Atypical Lobular Hyperplasia,11/19/2018,Bilateral,Yes,,Ductal carcinoma in situ,11/19/2018,Bilateral,10/18/2018,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,X,Ductal,,1,6,Low," ER+, PR+, HER2-",95,3,95,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,9,,,,,,
BCSB0257,,,172.7,88.6,29.7,Yes,Atypical Lobular Hyperplasia,11/19/2018,Bilateral,Yes,,Ductal carcinoma in situ,11/19/2018,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,Left,,,,,,,,,9,,,,,,
BCSB0257,,,172.7,88.6,29.7,Yes,Atypical Lobular Hyperplasia,11/19/2018,Bilateral,Yes,,Ductal carcinoma in situ,11/19/2018,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,,0.7,Right,,,,,,,,,9,,,,,,
BCSB0257,,,172.7,88.6,29.7,Yes,Atypical Lobular Hyperplasia,11/19/2018,Bilateral,Yes,,Ductal carcinoma in situ,11/19/2018,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.1,"after surgical intervention, but before chemo or radiation",2.9,0.1,Left,9,,,,,,
BCSB0257,,,172.7,88.6,29.7,Yes,Atypical Lobular Hyperplasia,11/19/2018,Bilateral,Yes,,Ductal carcinoma in situ,11/19/2018,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,,0.4,"after surgical intervention, but before chemo or radiation",1.2,0.1,Right,9,,,,,,
BCSB0259,,,167.6,69,24.6,No,,,,No,,,,,1/6/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,5,Low," ER+, PR+, HER2-",95,3,95,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0259,,,167.6,69,24.6,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.7,,,,,,,,,,,,,,,,
BCSB0259,,,167.6,69,24.6,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,4.8,0.7,"after surgical intervention, but before chemo or radiation",0.3,0,,,,,,,,
BCSB0263,,,163.8,105.7,39.4,Yes,Atypical Ductal Hyperplasia,8/30/2021,Right,Yes,,Ductal carcinoma in situ,8/30/2021,Right,8/30/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,,X,,X,Ductal,,2,,," ER-, PR-, HER2-",0,0,0,0,1,Non-amplified,ER- PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0263,,,163.8,105.7,39.4,Yes,Atypical Ductal Hyperplasia,8/30/2021,Right,Yes,,Ductal carcinoma in situ,8/30/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.6,,,,,,,,,,,,,,,,
BCSB0263,,,163.8,105.7,39.4,Yes,Atypical Ductal Hyperplasia,8/30/2021,Right,Yes,,Ductal carcinoma in situ,8/30/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.6,"after surgical intervention, but before chemo or radiation",1.1,0.3,,,,,,,,
BCSB0264,,,160,85.3,33.3,No,,,,Yes,,Ductal carcinoma in situ,11/8/2021,Left,11/8/2021,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,,," ER+, PR+, HER2-",95,3,90,2,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0264,,,160,85.3,33.3,No,,,,Yes,,Ductal carcinoma in situ,11/8/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.3,,,,,,,,,,,,,,,,
BCSB0264,,,160,85.3,33.3,No,,,,Yes,,Ductal carcinoma in situ,11/8/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,1,"after surgical intervention, but before chemo or radiation",0.8,0.5,,,,,,,,
BCSB0247,,,162.6,67.6,25.6,Yes,Atypical Lobular Hyperplasia,1/17/2023,Right,No,,,,,1/17/2023,Invasive lobular carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage Ia,,X,,,Lobular,,2,,," ER+, PR+, HER2-",95,3,95,2,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,20,,,,,,
BCSB0247,,,162.6,67.6,25.6,Yes,Atypical Lobular Hyperplasia,1/17/2023,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.5,,,,,,,,,,20,,,,,,
BCSB0247,,,162.6,67.6,25.6,Yes,Atypical Lobular Hyperplasia,1/17/2023,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.4,0.5,"after surgical intervention, but before chemo or radiation",1.4,0.8,,20,,,,,,
BCSB0260,,,170.1,77.1,26.6,Unknown,,,,Unknown,,,,,1/6/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,60,High," ER+, PR+, HER2-",100,3,90,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,Low risk,,,,,
BCSB0260,,,170.1,77.1,26.6,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,,Low risk,,,,,
BCSB0260,,,170.1,77.1,26.6,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.1,"after surgical intervention, but before chemo or radiation",1.1,0.6,,,Low risk,,,,,
BCSB0262,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0265,,,165.1,64.4,23.6,Unknown,,,,Unknown,,,,,12/29/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,,X,,,,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,Positive >10%,,,,
BCSB0265,,,165.1,64.4,23.6,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1.3,,,,,,,,,,,,Positive >10%,,,,
BCSB0265,,,165.1,64.4,23.6,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,1.3,"after surgical intervention, after neoadjuvant treatment",0,0,,,,Positive >10%,,,,
BCSB0268,,,154.9,52.7,22,Yes,Peripheral Intraductal Papillomas,10/3/2022,Left,Yes,,Ductal carcinoma in situ,10/3/2022,Left,10/3/2022,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,,X,,,,Ductal,,2,10,Low," ER+, PR+, HER2+",95,3,28,2,2,Unknown,Triple positive,,,,,,,,,,,,,,,,,,"low risk, MarnmaPrint lndex (MPI): +0.026",,,,,
BCSB0268,,,154.9,52.7,22,Yes,Peripheral Intraductal Papillomas,10/3/2022,Left,Yes,,Ductal carcinoma in situ,10/3/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,,,,,,,,,,,"low risk, MarnmaPrint lndex (MPI): +0.026",,,,,
BCSB0268,,,154.9,52.7,22,Yes,Peripheral Intraductal Papillomas,10/3/2022,Left,Yes,,Ductal carcinoma in situ,10/3/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.2,0.9,"after surgical intervention, after neoadjuvant treatment",1.2,0.5,,,"low risk, MarnmaPrint lndex (MPI): +0.026",,,,,
BCSB0200,,,172.7,83.9,28.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0273,,,165.1,73.5,27,Yes,Atypical Lobular Hyperplasia,11/5/2019,Right,Yes,,Ductal carcinoma in situ,10/11/2019,Left,10/11/2019,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage Ib,X,,,X,Ductal,,2,13,Low," ER+, PR+, HER2-",97,3,97,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,Low Risk,,,,,
BCSB0273,,,165.1,73.5,27,Yes,Atypical Lobular Hyperplasia,11/5/2019,Right,Yes,,Ductal carcinoma in situ,10/11/2019,Left,10/11/2019,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage Ib,X,,,X,Ductal,,2,8,Low," ER+, PR+, HER2-",92,3,71,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,Low Risk,,,,,
BCSB0273,,,165.1,73.5,27,Yes,Atypical Lobular Hyperplasia,11/5/2019,Right,Yes,,Ductal carcinoma in situ,10/11/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.2,,,,,,,,,,,Low Risk,,,,,
BCSB0273,,,165.1,73.5,27,Yes,Atypical Lobular Hyperplasia,11/5/2019,Right,Yes,,Ductal carcinoma in situ,10/11/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.9,"after surgical intervention, but before chemo or radiation",2.5,,2.5cm and 1.0cm,,Low Risk,,,,,
BCSB0266,,,160,102.5,40,Unknown,,,,Unknown,,,,,11/5/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1mic:Microinvasion <=0.1 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,,Ductal,,2,,," ER+, PR+, HER2+",75,,60,,2,Amplified,ER+ PR+ HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0266,,,160,102.5,40,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,4.8,,,,,,,,,,,,,,,,
BCSB0266,,,160,102.5,40,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,4.8,"after surgical intervention, after neoadjuvant treatment",0.1,1.2,,,,,,,,
BCSB0189,,,167.6,61.2,21.8,Yes,Breast Cysts,3/30/2017,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/18/2017,"Right , Both DCIS & LCIS",3/30/2017,Invasive lobular carcinoma,,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage IIa,,X,,,Lobular,,2,,," ER+, PR+, HER2-",90,3,30,2,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,22,,,,,,
BCSB0189,,,167.6,61.2,21.8,Yes,Breast Cysts,3/30/2017,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/18/2017,"Right , Both DCIS & LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,22,,,,,,
BCSB0189,,,167.6,61.2,21.8,Yes,Breast Cysts,3/30/2017,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/18/2017,"Right , Both DCIS & LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.1,"after surgical intervention, but before chemo or radiation",2.7,0.5,,22,,,,,,
BCSB0255,,,165.1,55.2,20.3,No,,,,Yes,,Ductal carcinoma in situ,1/25/2022,Left,1/25/2022,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,3,60,High," ER+, PR+, HER2+",80,2,90,3,3+,Amplified,"Triple positive, 1.3cm",,,,,,,,,,,,,,,,,,,,,,,
BCSB0255,,,165.1,55.2,20.3,No,,,,Yes,,Ductal carcinoma in situ,1/25/2022,Left,1/25/2022,Invasive ductal carcinoma,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,3,40,High," HER2+, ER-, PR-",0,0,0,0,3+,Amplified,"ER- PR- HER2+, 0.2cm",,,,,,,,,,,,,,,,,,,,,,,
BCSB0255,,,165.1,55.2,20.3,No,,,,Yes,,Ductal carcinoma in situ,1/25/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,,,,,,,,,,,,,,,,
BCSB0255,,,165.1,55.2,20.3,No,,,,Yes,,Ductal carcinoma in situ,1/25/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,0.2,,,,,,,,,,,,,,,,
BCSB0255,,,165.1,55.2,20.3,No,,,,Yes,,Ductal carcinoma in situ,1/25/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,1.3,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0255,,,165.1,55.2,20.3,No,,,,Yes,,Ductal carcinoma in situ,1/25/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,2.1,0.2,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0261,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0250,,,175.5,62,20.1,Yes,Fibrocystic Breast Changes,9/28/2021,Left,Yes,,Ductal carcinoma in situ,9/28/2021,Right,8/5/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,3,60,High," ER+, PR-, HER2-",9,2,0,0,2,Non-amplified,"ER+ PR- HER2- (Low ER, Triple Negative like Carcinoma)",,,,,,,,,,,,,,,,,52,,,,,,
BCSB0250,,,175.5,62,20.1,Yes,Fibrocystic Breast Changes,9/28/2021,Left,Yes,,Ductal carcinoma in situ,9/28/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.8,,,,,,,,,,52,,,,,,
BCSB0250,,,175.5,62,20.1,Yes,Fibrocystic Breast Changes,9/28/2021,Left,Yes,,Ductal carcinoma in situ,9/28/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.7,"after surgical intervention, but before chemo or radiation",3,0.4,,52,,,,,,
BCSB0277,,,157.4,53.3,21.5,Yes,Breast Cysts,1/1/2012,,Yes,,Ductal carcinoma in situ,1/6/2021,Right,1/6/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N2: Ipsilateral axillary LN(s) fixed,,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN1: movable ipsilateral axillary LN(s),,,,X,,,Ductal,,,,," ER+, PR+, HER2-",95,3,19,1,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0277,,,157.4,53.3,21.5,Yes,Breast Cysts,1/1/2012,,Yes,,Ductal carcinoma in situ,1/6/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.6,,,,,,,,,,,,,,,,
BCSB0277,,,157.4,53.3,21.5,Yes,Breast Cysts,1/1/2012,,Yes,,Ductal carcinoma in situ,1/6/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.6,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0279,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0231,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0243,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0228,,,176,87.3,28.2,No,,,,No,,,,,1/15/2019,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,X,,,X,Ductal,,3,90,High," ER+, PR+, HER2+",95,,50,,2,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0228,,,176,87.3,28.2,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,4.8,,,,,,,,,,,,,,,,
BCSB0228,,,176,87.3,28.2,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,4.1,"after surgical intervention, after neoadjuvant treatment",1.5,,,,,,,,,
BCSB0275,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0276,,,162.6,62.6,23.7,Yes,Atypical Ductal Hyperplasia,4/11/2019,Right,Yes,,Ductal carcinoma in situ,3/14/2019,Left,3/14/2019,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,,Other,Favorable: tubular,1,5,Low," ER+, PR+, HER2-",87,3,83,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,13,,,,,,
BCSB0276,,,162.6,62.6,23.7,Yes,Atypical Ductal Hyperplasia,4/11/2019,Right,Yes,,Ductal carcinoma in situ,3/14/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,13,,,,,,
BCSB0276,,,162.6,62.6,23.7,Yes,Atypical Ductal Hyperplasia,4/11/2019,Right,Yes,,Ductal carcinoma in situ,3/14/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,1,"after surgical intervention, but before chemo or radiation",2.2,1.3,,13,,,,,,
BCSB0282,,,164.6,131.5,48.5,Yes,Papillary Apocrine Change,3/24/2021,Left,No,,,,,3/24/2021,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIa,X,,,,Ductal,,2,70,High," ER-, PR-, HER2-",0,0,0,0,0,Non-amplified,"ER- PR- HER2-
Invasive mammary carcinoma, no special type with medullary pattem features",,,,,,,,,,,,,,,,,,High Risk,,,,,
BCSB0282,,,164.6,131.5,48.5,Yes,Papillary Apocrine Change,3/24/2021,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,6,,,,,,,,,,,High Risk,,,,,
BCSB0282,,,164.6,131.5,48.5,Yes,Papillary Apocrine Change,3/24/2021,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,6,"after surgical intervention, after neoadjuvant treatment",0.4,1,,,High Risk,,,,,
BCSB0287,,,165.1,99.8,36.6,Yes,Atypical Ductal Hyperplasia,10/26/2020,Left,Yes,,Ductal carcinoma in situ,10/26/2020,Left,9/10/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,,," ER+, PR+, HER2-",91,3,81,2,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,13,,,,,,
BCSB0287,,,165.1,99.8,36.6,Yes,Atypical Ductal Hyperplasia,10/26/2020,Left,Yes,,Ductal carcinoma in situ,10/26/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.5,,,,,,,,,,13,,,,,,
BCSB0287,,,165.1,99.8,36.6,Yes,Atypical Ductal Hyperplasia,10/26/2020,Left,Yes,,Ductal carcinoma in situ,10/26/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,0.5,"after surgical intervention, but before chemo or radiation",0.9,0.5,,13,,,,,,
BCSB0288,,,162.5,93.5,35.4,No,,,,No,,,,,3/15/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,,X,,,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,1,,ER- PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0288,,,162.5,93.5,35.4,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.4,,,,,,,,,,,,,,,,
BCSB0288,,,162.5,93.5,35.4,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.7,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0290,,Kaiser,165.1,68.4,25.1,Yes,Breast Cysts,1/1/1980,Left,No,,,,,1/28/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2+",90,3,30,3,3+,Unknown,ER+ PR+ HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0290,,Kaiser,165.1,68.4,25.1,Yes,Breast Cysts,1/1/1980,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.5,,,,,,,,,,,,,,,,
BCSB0290,,Kaiser,165.1,68.4,25.1,Yes,Breast Cysts,1/1/1980,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.7,1.5,"after surgical intervention, but before chemo or radiation",1.5,1,,,,,,,,
BCSB0291,,,170.1,92.9,32.1,Unknown,,,,Yes,,Ductal carcinoma in situ,4/14/2021,Left,4/14/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,3,,," ER+, PR+, HER2-",98,3,98,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,0,,,,,,
BCSB0291,,,170.1,92.9,32.1,Unknown,,,,Yes,,Ductal carcinoma in situ,4/14/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,,,,,,,,,,0,,,,,,
BCSB0291,,,170.1,92.9,32.1,Unknown,,,,Yes,,Ductal carcinoma in situ,4/14/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,0.9,"after surgical intervention, but before chemo or radiation",0.9,1,,0,,,,,,
BCSB0181,,,154.9,66.2,27.6,Yes,Atypical Lobular Hyperplasia,3/28/2023,Left,Yes,,Ductal carcinoma in situ,3/28/2023,Left,9/23/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN3: to ipsilateral internal mammary LN(s),MX: cannot be assessed,Stage IIIa,X,,,X,Ductal,,2,5,Low," ER+, PR+, HER2-",95,3,5,2,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0181,,,154.9,66.2,27.6,Yes,Atypical Lobular Hyperplasia,3/28/2023,Left,Yes,,Ductal carcinoma in situ,3/28/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.5,,,,,,,,,,,,,,,,
BCSB0181,,,154.9,66.2,27.6,Yes,Atypical Lobular Hyperplasia,3/28/2023,Left,Yes,,Ductal carcinoma in situ,3/28/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2,"after surgical intervention, after neoadjuvant treatment",4.1,0.1,And 0.3cm,,,,,,,
BCSB0293,,,160,69.4,27.1,No,,,,Yes,,Ductal carcinoma in situ,10/9/2020,Right,10/9/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage Ib,,X,,,Ductal,,2,,," ER+, PR+, HER2-",100,3,90,2,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,19,,,,,,
BCSB0293,,,160,69.4,27.1,No,,,,Yes,,Ductal carcinoma in situ,10/9/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,4.2,,,,,,,,,,19,,,,,,
BCSB0293,,,160,69.4,27.1,No,,,,Yes,,Ductal carcinoma in situ,10/9/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,4.2,"after surgical intervention, but before chemo or radiation",5,,,19,,,,,,
BCSB0294,,,172.7,87.1,29.2,Unknown,,,,Yes,,Ductal carcinoma in situ,6/1/2021,Right,6/1/2021,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIc,,X,,,Ductal,,3,60,High," ER-, PR-, HER2-",0,0,0,0,1,Unknown,ER- PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0294,,,172.7,87.1,29.2,Unknown,,,,Yes,,Ductal carcinoma in situ,6/1/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,5.9,,,,,,,,,,,,,,,,
BCSB0294,,,172.7,87.1,29.2,Unknown,,,,Yes,,Ductal carcinoma in situ,6/1/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.9,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0297,,,,,40,Yes,Fibrocystic Breast Changes,3/29/2023,Right,Yes,,Ductal carcinoma in situ,3/29/2023,Right,3/29/2023,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,,,X,,,Ductal,,1,,," ER+, PR+, HER2-",99,3,99,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0297,,,,,40,Yes,Fibrocystic Breast Changes,3/29/2023,Right,Yes,,Ductal carcinoma in situ,3/29/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.4,,,,,,,,,,,,,,,,
BCSB0297,,,,,40,Yes,Fibrocystic Breast Changes,3/29/2023,Right,Yes,,Ductal carcinoma in situ,3/29/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.8,"after surgical intervention, but before chemo or radiation",1.2,0.9,,,,,,,,
BCSB0300,,,162,89.4,34.1,No,,,,Yes,,Ductal carcinoma in situ,8/15/2017,Right,8/15/2017,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,,X,,,Ductal,,2,,," ER+, HER2+, PR-",5,1,0,0,3+,Unknown,ER+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0300,,,162,89.4,34.1,No,,,,Yes,,Ductal carcinoma in situ,8/15/2017,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.2,,,,,,,,,,,,,,,,
BCSB0300,,,162,89.4,34.1,No,,,,Yes,,Ductal carcinoma in situ,8/15/2017,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.1,"after surgical intervention, but before chemo or radiation",1.4,1,,,,,,,,
BCSB0304,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0303,,,168,65,23,Yes,Atypical Lobular Hyperplasia,4/22/2021,Left,Yes,,Ductal carcinoma in situ,4/22/2021,Right,4/22/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),MX: cannot be assessed,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage IIa,,X,,,Ductal,,2,52,High," ER+, HER2+, PR-",,,0,0,3+,Unknown,ER+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0303,,,168,65,23,Yes,Atypical Lobular Hyperplasia,4/22/2021,Left,Yes,,Ductal carcinoma in situ,4/22/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,,,,,,,,,,,,,,,,
BCSB0303,,,168,65,23,Yes,Atypical Lobular Hyperplasia,4/22/2021,Left,Yes,,Ductal carcinoma in situ,4/22/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.3,"after surgical intervention, after neoadjuvant treatment",0.3,0.9,,,,,,,,
BCSB0309,,,162.5,120.9,45.8,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/4/2023,Right,11/23/2022,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Lobular,,2,,," ER+, PR+, HER2-",95,3,95,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,Low risk luminal A +0.471.,,,,,
BCSB0309,,,162.5,120.9,45.8,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/4/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.7,,,,,,,,,,,Low risk luminal A +0.471.,,,,,
BCSB0309,,,162.5,120.9,45.8,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/4/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,1.7,"after surgical intervention, but before chemo or radiation",2.5,0.2,,,Low risk luminal A +0.471.,,,,,
BCSB0299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0305,,,175.3,83.9,27.3,No,,,,Yes,,Ductal carcinoma in situ,6/9/2021,Right,6/9/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,,," ER+, PR+, HER2-",90,2,100,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,"low risk, luminal A type",,,,,
BCSB0305,,,175.3,83.9,27.3,No,,,,Yes,,Ductal carcinoma in situ,6/9/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.7,,,,,,,,,,,"low risk, luminal A type",,,,,
BCSB0305,,,175.3,83.9,27.3,No,,,,Yes,,Ductal carcinoma in situ,6/9/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.2,0.7,"after surgical intervention, but before chemo or radiation",0.9,0.3,,,"low risk, luminal A type",,,,,
BCSB0302,,,171.4,127.4,43.4,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/2/2023,Left,4/5/2023,Invasive lobular carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,2,20.5,High," ER+, PR+, HER2-",98.2,3,95.5,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0302,,,171.4,127.4,43.4,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/2/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.3,Category B dense,,,,,,,,,,,,,,,
BCSB0302,,,171.4,127.4,43.4,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/2/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.3,"after surgical intervention, but before chemo or radiation",1.5,0.1,,,,,,,,
BCSB0315,,,167.6,107.8,38.4,No,,,,Yes,,Ductal carcinoma in situ,10/6/2022,Left,8/31/2022,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0(i+),M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",95,3,95,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,13,,,,,,
BCSB0315,,,167.6,107.8,38.4,No,,,,Yes,,Ductal carcinoma in situ,10/6/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.9,,,,,,,,,,13,,,,,,
BCSB0315,,,167.6,107.8,38.4,No,,,,Yes,,Ductal carcinoma in situ,10/6/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,0.6,"after surgical intervention, but before chemo or radiation",0.9,0.2,,13,,,,,,
BCSB0316,,,163.8,71.7,26.7,No,,,,No,,,,,12/13/2019,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,,X,,,Ductal,,1,,," ER+, PR-, HER2-",100,3,0,0,1,Unknown,ER+ PR- HER2-,,,,,,,,,,,,,,,,,10,,,,,,
BCSB0316,,,163.8,71.7,26.7,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.8,,,,,,,,,,10,,,,,,
BCSB0316,,,163.8,71.7,26.7,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.4,1.5,"after surgical intervention, but before chemo or radiation",1.6,1,,10,,,,,,
BCSB0313,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0320,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0326,,,152.4,70.7,30.4,Yes,Fibrocystic Breast Changes,12/6/2021,Right,Yes,,Ductal carcinoma in situ,12/6/2021,Left,10/12/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,X,Ductal,,2,,," ER+, PR+, HER2-",95,3,95,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,24,,,,,,
BCSB0326,,,152.4,70.7,30.4,Yes,Fibrocystic Breast Changes,12/6/2021,Right,Yes,,Ductal carcinoma in situ,12/6/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.9,and a 1.0cm tumor,,,,,,,,,24,,,,,,
BCSB0326,,,152.4,70.7,30.4,Yes,Fibrocystic Breast Changes,12/6/2021,Right,Yes,,Ductal carcinoma in situ,12/6/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.1,2.7,"after surgical intervention, but before chemo or radiation",4.2,0.7,and a 1.1cm tumor,24,,,,,,
BCSB0323,,,154.9,69.4,28.9,Yes,Calcifications,3/15/2018,Bilateral,,,,,,3/19/2018,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),,T2:Tumor >2.0 cm but <=5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,,,X,,,X,Ductal,,1,,," ER+, PR+, HER2-",100,,98,,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0323,,,154.9,69.4,28.9,Yes,Calcifications,3/15/2018,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.4,,,,,,,,,,,,,,,,
BCSB0323,,,154.9,69.4,28.9,Yes,Calcifications,3/15/2018,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",3.1,0.6,,,,,,,,
BCSB0325,,,167.6,111,39.5,Yes,Calcifications,6/1/1992,Right,Yes,,Ductal carcinoma in situ,5/3/2020,Right,6/8/2020,Invasive ductal carcinoma,,,,T2:Tumor >2.0 cm but <=5.0 cm,pN0(i+),,Stage IIa,,X,,X,Ductal,,3,,," ER+, PR+, HER2-",80,2,70,2,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0325,,,167.6,111,39.5,Yes,Calcifications,6/1/1992,Right,Yes,,Ductal carcinoma in situ,5/3/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,Local,,,"reported on 2/16/25, 18 month follow up",,,,,,,,,,,,,,,,,,,
BCSB0325,,,167.6,111,39.5,Yes,Calcifications,6/1/1992,Right,Yes,,Ductal carcinoma in situ,5/3/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.1,,,,,,,,,,,,,,,,
BCSB0325,,,167.6,111,39.5,Yes,Calcifications,6/1/1992,Right,Yes,,Ductal carcinoma in situ,5/3/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.2,1.2,"after surgical intervention, but before chemo or radiation",3.1,0.1,"3 more foci: 2.5cm, 0.2cm, and 0.4cm",,,,,,,
BCSB0308,,,,,,Unknown,,,,Unknown,,,,,7/9/2019,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,,," ER+, PR-, HER2-",100,3,0,0,0,Unknown,ER+ PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0308,,,,,,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,,,,,,,
BCSB0308,,,,,,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.1,"after surgical intervention, but before chemo or radiation",1.1,0,,,,,,,,
BCSB0317,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0328,,,156.2,73.6,30.2,Yes,Calcifications,10/19/2021,Right,Yes,,Ductal carcinoma in situ,11/9/2021,Right,11/9/2021,Invasive ductal carcinoma,,,MX: cannot be assessed,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,,X,,,Ductal,,2,,," ER+, PR+, HER2-",81,2,100,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,24,,,,,,
BCSB0328,,,156.2,73.6,30.2,Yes,Calcifications,10/19/2021,Right,Yes,,Ductal carcinoma in situ,11/9/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.4,,,,,,,,,,24,,,,,,
BCSB0328,,,156.2,73.6,30.2,Yes,Calcifications,10/19/2021,Right,Yes,,Ductal carcinoma in situ,11/9/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3,0.4,"after surgical intervention, but before chemo or radiation",0.4,,,24,,,,,,
BCSB0331,,Kaiser,170.2,58.5,20.2,No,,,,No,,,,,1/16/2019,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,X,Ductal,,2,,," ER+, PR+, HER2+",1,1,30,1,3+,Unknown,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0331,,Kaiser,170.2,58.5,20.2,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.8,,,,,,,,,,,,,,,,
BCSB0331,,Kaiser,170.2,58.5,20.2,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,2.8,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0332,,,160,57.3,22.4,Yes,Fibrocystic Breast Changes,11/8/2018,Right,Yes,,Ductal carcinoma in situ,11/8/2018,Right,10/23/2018,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,,," ER+, PR+, HER2-",90,3,70,2,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,15,,,,,,
BCSB0332,,,160,57.3,22.4,Yes,Fibrocystic Breast Changes,11/8/2018,Right,Yes,,Ductal carcinoma in situ,11/8/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.2,,,,,,,,,,15,,,,,,
BCSB0332,,,160,57.3,22.4,Yes,Fibrocystic Breast Changes,11/8/2018,Right,Yes,,Ductal carcinoma in situ,11/8/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,1.2,"after surgical intervention, but before chemo or radiation",1.4,0.1,,15,,,,,,
BCSB0336,,,,93.2,,Yes,Calcifications,1/14/2021,Right,Yes,,Ductal carcinoma in situ,1/14/2021,Right,10/2/2020,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage IIIa,,X,,,Ductal,,2,25,High," ER+, PR+, HER2-",90,,90,,,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,3,,,,,,
BCSB0336,,,,93.2,,Yes,Calcifications,1/14/2021,Right,Yes,,Ductal carcinoma in situ,1/14/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.1,,,,,,,,,,3,,,,,,
BCSB0336,,,,93.2,,Yes,Calcifications,1/14/2021,Right,Yes,,Ductal carcinoma in situ,1/14/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.1,"after surgical intervention, after neoadjuvant treatment",1.8,,,3,,,,,,
BCSB0337,,BLUE CROSS AND BLUE SHIELD,162.6,60.7,23,Yes,Atypical Ductal Hyperplasia,1/12/2022,Right,Yes,,Ductal carcinoma in situ,1/12/2022,Right,6/9/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,,Stage IIa,,X,,X,Ductal,,2,,," ER+, PR+, HER2+",67,2,10,2,3+,Amplified,ER+ PR+ HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0337,,BLUE CROSS AND BLUE SHIELD,162.6,60.7,23,Yes,Atypical Ductal Hyperplasia,1/12/2022,Right,Yes,,Ductal carcinoma in situ,1/12/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.4,,,,,,,,,,,,,,,,
BCSB0337,,BLUE CROSS AND BLUE SHIELD,162.6,60.7,23,Yes,Atypical Ductal Hyperplasia,1/12/2022,Right,Yes,,Ductal carcinoma in situ,1/12/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.7,"after surgical intervention, after neoadjuvant treatment",0.9,0.1,,,,,,,,
BCSB0338,,,160,133,52,No,,,,Yes,,Ductal carcinoma in situ,6/11/2021,Left,12/9/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,X,,,X,Ductal,,3,,," ER+, PR+, HER2-",70,3,45,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0338,,,160,133,52,No,,,,Yes,,Ductal carcinoma in situ,6/11/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,5.7,,,,,,,,,,,,,,,,
BCSB0338,,,160,133,52,No,,,,Yes,,Ductal carcinoma in situ,6/11/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,5.7,"after surgical intervention, after neoadjuvant treatment",1.2,0.1,,,,,,,,
BCSB0318,,,153.4,75,31.9,Yes,Atypical Ductal Hyperplasia,1/1/1998,Left,No,,,,,10/17/2016,Invasive lobular carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,X,Lobular,,1,5,Low," ER+, PR+, HER2-",95,3,70,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,18,,,,,,
BCSB0318,,,153.4,75,31.9,Yes,Atypical Ductal Hyperplasia,1/1/1998,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,18,,,,,,
BCSB0318,,,153.4,75,31.9,Yes,Atypical Ductal Hyperplasia,1/1/1998,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.1,"after surgical intervention, but before chemo or radiation",1,0.6,,18,,,,,,
BCSB0334,,,170,67.1,23.2,Yes,Atypical Ductal Hyperplasia,10/19/2020,Left,No,,,,,9/16/2020,Mixed IDC+ILC (50 -90% each component),T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,2,,," ER+, PR+, HER2-",95,3,95,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,7,,,,,,
BCSB0334,,,170,67.1,23.2,Yes,Atypical Ductal Hyperplasia,10/19/2020,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.8,,,,,,,,,,7,,,,,,
BCSB0334,,,170,67.1,23.2,Yes,Atypical Ductal Hyperplasia,10/19/2020,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",2.2,0.1,,7,,,,,,
BCSB0339,,Cigna HMO,,99.9,,Yes,Atypical Ductal Hyperplasia,5/16/2022,Right,Yes,,Ductal carcinoma in situ,5/16/2022,Right,6/3/2022,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0(i+),MX: cannot be assessed,Stage Ia,,X,,,Ductal,,1,5,Low," ER+, PR+, HER2-",100,3,100,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,8,,,,,,
BCSB0339,,Cigna HMO,,99.9,,Yes,Atypical Ductal Hyperplasia,5/16/2022,Right,Yes,,Ductal carcinoma in situ,5/16/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.9,,,,,,,,,,8,,,,,,
BCSB0339,,Cigna HMO,,99.9,,Yes,Atypical Ductal Hyperplasia,5/16/2022,Right,Yes,,Ductal carcinoma in situ,5/16/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,4,0.9,"after surgical intervention, but before chemo or radiation",2,0,,8,,,,,,
BCSB0344,,,164,82.8,30.8,No,,,,Yes,,Ductal carcinoma in situ,3/1/2022,Right,9/20/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,,X,,,Ductal,,2,45,High," ER+, PR+, HER2-",98,3,96,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0344,,,164,82.8,30.8,No,,,,Yes,,Ductal carcinoma in situ,3/1/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,3,,,,,,,,,,,,,,,,
BCSB0344,,,164,82.8,30.8,No,,,,Yes,,Ductal carcinoma in situ,3/1/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,3,"after surgical intervention, after neoadjuvant treatment",2.2,0.2,,,,,,,,
BCSB0342,,,170.1,75.7,26.2,No,,,,Yes,,Ductal carcinoma in situ,12/1/2016,Left,11/2/2016,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,NX: Regional LNs cannot be assessed,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",90,3,76,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,14,,,,,,
BCSB0342,,,170.1,75.7,26.2,No,,,,Yes,,Ductal carcinoma in situ,12/1/2016,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.7,,,,,,,,,,14,,,,,,
BCSB0342,,,170.1,75.7,26.2,No,,,,Yes,,Ductal carcinoma in situ,12/1/2016,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,0.7,"after surgical intervention, but before chemo or radiation",0.9,0.4,,14,,,,,,
BCSB0350,,,159.8,78.5,30.7,No,,,,No,,,,,12/28/2020,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,X,,,,Ductal,,3,62,High," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,1,4 Negative Signatera Tests
BCSB0350,,,159.8,78.5,30.7,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,3.1,,,,,,,,,,,,,,,1,4 Negative Signatera Tests
BCSB0350,,,159.8,78.5,30.7,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,1.5,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,1,4 Negative Signatera Tests
BCSB0358,,,160,55.8,21.8,Yes,Atypical Lobular Hyperplasia,12/29/2022,Right,Yes,,Ductal carcinoma in situ,11/4/2022,"Left, LCIS in Right",11/4/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,10,Low," ER+, PR+, HER2-",90,3,5,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,21,,,,,,Tyrer-Cuzick breast cancer risk assessment: 14.7%
BCSB0358,,,160,55.8,21.8,Yes,Atypical Lobular Hyperplasia,12/29/2022,Right,Yes,,Ductal carcinoma in situ,11/4/2022,"Left, LCIS in Right",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,0.9,,,,,,,,,,21,,,,,,Tyrer-Cuzick breast cancer risk assessment: 14.7%
BCSB0358,,,160,55.8,21.8,Yes,Atypical Lobular Hyperplasia,12/29/2022,Right,Yes,,Ductal carcinoma in situ,11/4/2022,"Left, LCIS in Right",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.9,"after surgical intervention, but before chemo or radiation",0.6,0.1,,21,,,,,,Tyrer-Cuzick breast cancer risk assessment: 14.7%
BCSB0359,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0346,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0349,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0360,,,170.2,121.1,41.8,Yes,Atypical Lobular Hyperplasia,1/1/2001,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/14/2017,"and DCIS , Left",12/14/2017,Mixed IDC+ILC (50 -90% each component),,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,X,Other,,2,,," ER+, PR+, HER2-",95,3,90,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,7,,,,,,
BCSB0360,,,170.2,121.1,41.8,Yes,Atypical Lobular Hyperplasia,1/1/2001,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/14/2017,"and DCIS , Left",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.5,and 1.6cm,,,,,,,,,7,,,,,,
BCSB0360,,,170.2,121.1,41.8,Yes,Atypical Lobular Hyperplasia,1/1/2001,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/14/2017,"and DCIS , Left",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,3.5,"after surgical intervention, but before chemo or radiation",2.5,1,other focus: 1cm,7,,,,,,
BCSB0365,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0368,,,175.3,70.3,22.9,Yes,Fibrocystic Breast Changes,10/1/2003,Right,Yes,,Ductal carcinoma in situ,8/19/2022,Right,8/19/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,,X,,,Ductal,Favorable: mucinous,3,,," ER+, PR+, HER2+",100,3,100,3,3+,Amplified,ER+ PR+ HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0368,,,175.3,70.3,22.9,Yes,Fibrocystic Breast Changes,10/1/2003,Right,Yes,,Ductal carcinoma in situ,8/19/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.9,,,,,,,,,,,,,,,,
BCSB0368,,,175.3,70.3,22.9,Yes,Fibrocystic Breast Changes,10/1/2003,Right,Yes,,Ductal carcinoma in situ,8/19/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,4.9,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0364,,,,,,No,,,,Yes,,Ductal carcinoma in situ,3/19/2021,Right,3/19/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,,,X,,,Ductal,,2,,," ER+, PR+, HER2-",94,3,97,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0364,,,,,,No,,,,Yes,,Ductal carcinoma in situ,3/19/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.2,MRI midway through Neoadjuvant chemo,,,,,,,,,,,,,,,
BCSB0364,,,,,,No,,,,Yes,,Ductal carcinoma in situ,3/19/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,4.2,"after surgical intervention, after neoadjuvant treatment",0.2,1.2,,,,,,,,
BCSB0310,,,157,111,45,No,,,,Yes,,Ductal carcinoma in situ,2/19/2021,,12/18/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,3,40,High," ER+, PR+, HER2-",90,2,70,2,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,27,,,,,,
BCSB0310,,,157,111,45,No,,,,Yes,,Ductal carcinoma in situ,2/19/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.5,,,,,,,,,,27,,,,,,
BCSB0310,,,157,111,45,No,,,,Yes,,Ductal carcinoma in situ,2/19/2021,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,0.5,"after surgical intervention, but before chemo or radiation",1.2,0.5,,27,,,,,,
BCSB0351,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0366,,,160,79.1,30.9,Yes,Atypical Ductal Hyperplasia,11/15/2019,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/7/2019,Right,10/7/2019,Mixed IDC+ILC (50 -90% each component),,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Lobular,,2,,," ER+, PR+, HER2-",67.2,3,67.8,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,19,,,,,,
BCSB0366,,,160,79.1,30.9,Yes,Atypical Ductal Hyperplasia,11/15/2019,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/7/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.6,,,,,,,,,,19,,,,,,
BCSB0366,,,160,79.1,30.9,Yes,Atypical Ductal Hyperplasia,11/15/2019,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/7/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.2,0.6,"after surgical intervention, but before chemo or radiation",0.9,0.5,,19,,,,,,
BCSB0373,,,167.6,76.7,27.3,Yes,Fibrocystic Breast Changes,12/12/2017,Left,Yes,,Ductal carcinoma in situ,12/12/2017,Right,11/2/2017,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,3,,," ER+, PR+, HER2-",100,3,70,1,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,31,,,,,,
BCSB0373,,,167.6,76.7,27.3,Yes,Fibrocystic Breast Changes,12/12/2017,Left,Yes,,Ductal carcinoma in situ,12/12/2017,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,31,,,,,,
BCSB0373,,,167.6,76.7,27.3,Yes,Fibrocystic Breast Changes,12/12/2017,Left,Yes,,Ductal carcinoma in situ,12/12/2017,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,1,"after surgical intervention, but before chemo or radiation",2,1.1,,31,,,,,,
BCSB0280,,,172.7,95.6,32.1,Yes,Calcifications,1/19/2021,Right,Yes,,Ductal carcinoma in situ,4/13/2021,"Right, LCIS also present",4/13/2021,Invasive ductal carcinoma,,,,T1a:>0.1 but <=0.5 cm,pN1a:Only micrometastasis <=0.2 cm,,Stage Ia,,X,,X,Ductal,,2,15,Low," ER+, PR+, HER2-",100,3,95,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,EndoPredict EPclin Risk Score: 3.4
BCSB0280,,,172.7,95.6,32.1,Yes,Calcifications,1/19/2021,Right,Yes,,Ductal carcinoma in situ,4/13/2021,"Right, LCIS also present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,,,,,,,EndoPredict EPclin Risk Score: 3.4
BCSB0280,,,172.7,95.6,32.1,Yes,Calcifications,1/19/2021,Right,Yes,,Ductal carcinoma in situ,4/13/2021,"Right, LCIS also present",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1,"after surgical intervention, but before chemo or radiation",0.3,1,,,,,,,,EndoPredict EPclin Risk Score: 3.4
BCSB0370,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0375,,,157.5,52.2,21,Yes,Atypical Lobular Hyperplasia,5/12/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/16/2021,Right,4/16/2021,Invasive lobular carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0(i+),M0: No distant metastasis,Stage Ia,,X,,X,Lobular,,2,10,Low," ER+, PR+, HER2-",98,3,10,1,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,23,,,,,,
BCSB0375,,,157.5,52.2,21,Yes,Atypical Lobular Hyperplasia,5/12/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/16/2021,Right,5/12/2021,Invasive lobular carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pNX: Regional LNs cannot be assessed,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,2,,," ER+, PR-, HER2-",100,3,0,0,2,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,23,,,,,,
BCSB0375,,,157.5,52.2,21,Yes,Atypical Lobular Hyperplasia,5/12/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/16/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.8,Right,,,,,,,,,23,,,,,,
BCSB0375,,,157.5,52.2,21,Yes,Atypical Lobular Hyperplasia,5/12/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/16/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.8,"after surgical intervention, but before chemo or radiation",1.2,0.1,"Right, another focus 0.1cm",23,,,,,,
BCSB0375,,,157.5,52.2,21,Yes,Atypical Lobular Hyperplasia,5/12/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/16/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,,,,"after surgical intervention, but before chemo or radiation",0.5,0.4,Left,23,,,,,,
BCSB0149,,,162.6,59,22.3,Yes,Breast Cysts,1/1/2007,Right,No,,,,,9/9/2022,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage Ia,,X,,,Ductal,,2,27,High," ER+, PR+, HER2-",100,3,5,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,17,,,,,,
BCSB0149,,,162.6,59,22.3,Yes,Breast Cysts,1/1/2007,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.2,,,,,,,,,,17,,,,,,
BCSB0149,,,162.6,59,22.3,Yes,Breast Cysts,1/1/2007,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.2,"after surgical intervention, but before chemo or radiation",1.5,0.2,,17,,,,,,
BCSB0379,,,177.8,145.6,46.1,Yes,Fibroadenoma,5/24/2022,Right,Yes,,Ductal carcinoma in situ,3/17/2022,Left,3/17/2022,Invasive ductal carcinoma,T1mic:Microinvasion <=0.1 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,X,,,X,Ductal,,2,25,High," ER+, PR+, HER2-",90,3,90,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,HIGH risk,,,,,
BCSB0379,,,177.8,145.6,46.1,Yes,Fibroadenoma,5/24/2022,Right,Yes,,Ductal carcinoma in situ,3/17/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,,,,,,,,,,,,HIGH risk,,,,,
BCSB0379,,,177.8,145.6,46.1,Yes,Fibroadenoma,5/24/2022,Right,Yes,,Ductal carcinoma in situ,3/17/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3.6,,"after surgical intervention, but before chemo or radiation",1.2,1.4,,,HIGH risk,,,,,
BCSB0382,,,165.1,,,No,,,,Yes,,Ductal carcinoma in situ,3/8/2023,Left,3/8/2023,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,,,X,,,,Ductal,,1,,," ER+, PR-, HER2-",95,3,0,0,1,Unknown,ER+ PR- HER2-,,,,,,,,,,,,,,,,,18,,,,,,
BCSB0382,,,165.1,,,No,,,,Yes,,Ductal carcinoma in situ,3/8/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.9,,,,,,,,,,18,,,,,,
BCSB0382,,,165.1,,,No,,,,Yes,,Ductal carcinoma in situ,3/8/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.9,0.9,"after surgical intervention, but before chemo or radiation",0.9,0.5,,18,,,,,,
BCSB0387,,,165.1,65.7,24.1,Yes,Fibrocystic Breast Changes,8/30/2017,Left,Yes,,Ductal carcinoma in situ,8/30/2017,Left,8/2/2017,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,3,65,High," ER+, PR+, HER2-",,,,,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0387,,,165.1,65.7,24.1,Yes,Fibrocystic Breast Changes,8/30/2017,Left,Yes,,Ductal carcinoma in situ,8/30/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.4,,,,,,,,,,,,,,,,
BCSB0387,,,165.1,65.7,24.1,Yes,Fibrocystic Breast Changes,8/30/2017,Left,Yes,,Ductal carcinoma in situ,8/30/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.4,"after surgical intervention, but before chemo or radiation",2,0.5,,,,,,,,
BCSB0389,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0232,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0386,,,165.1,58.7,21.5,Yes,Calcifications,2/4/2022,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/4/2022,Right,1/1/1994,Invasive ductal carcinoma,,,,,,,,X,,,,,,,,," ER+, PR+, HER2-",,,,,,,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0386,,,165.1,58.7,21.5,Yes,Calcifications,2/4/2022,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/4/2022,Right,2/4/2022,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,,X,,,Lobular,,2,,," ER-, PR-, HER2-",0,0,0,0,2,Non-amplified,ER- PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0386,,,165.1,58.7,21.5,Yes,Calcifications,2/4/2022,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/4/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.6,,,,,,,,,,,,,,,,
BCSB0386,,,165.1,58.7,21.5,Yes,Calcifications,2/4/2022,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/4/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,1,"after surgical intervention, but before chemo or radiation",1.3,0.4,,,,,,,,
BCSB0197,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0391,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0283,,,146.2,82.7,38.7,Unknown,,,,Yes,,Ductal carcinoma in situ,10/2/2001,Left,11/17/2020,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,,Ductal,,3,,," ER+, PR+, HER2-",100,,2,,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,27,,,,,,
BCSB0283,,,146.2,82.7,38.7,Unknown,,,,Yes,,Ductal carcinoma in situ,10/2/2001,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.4,,,,,,,,,,27,,,,,,
BCSB0283,,,146.2,82.7,38.7,Unknown,,,,Yes,,Ductal carcinoma in situ,10/2/2001,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.4,"after surgical intervention, but before chemo or radiation",2,0,,27,,,,,,
BCSB0392,,,158.8,104.4,41.4,No,,,,Yes,,Ductal carcinoma in situ,12/11/2020,Right,12/11/2020,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,,," ER+, PR+, HER2-",100,3,70,2,0,,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0392,,,158.8,104.4,41.4,No,,,,Yes,,Ductal carcinoma in situ,12/11/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.6,,,,,,,,,,,,,,,,
BCSB0392,,,158.8,104.4,41.4,No,,,,Yes,,Ductal carcinoma in situ,12/11/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3.3,0.6,"after surgical intervention, but before chemo or radiation",0.7,0.2,,,,,,,,
BCSB0394,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0401,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0406,,,161.3,91.4,35.1,Yes,Fibrocystic Breast Changes,12/2/2021,Right,Yes,,Ductal carcinoma in situ,12/2/2021,Right,12/2/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage IIa,,X,,,Ductal,,2,,," ER+, PR+, HER2-",100,3,100,2,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,4,,,,,,
BCSB0406,,,161.3,91.4,35.1,Yes,Fibrocystic Breast Changes,12/2/2021,Right,Yes,,Ductal carcinoma in situ,12/2/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.4,,,,,,,,,,4,,,,,,
BCSB0406,,,161.3,91.4,35.1,Yes,Fibrocystic Breast Changes,12/2/2021,Right,Yes,,Ductal carcinoma in situ,12/2/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.6,"after surgical intervention, but before chemo or radiation",2.1,0.7,,4,,,,,,
BCSB0410,,,167.6,106.1,37.8,Yes,Atypical Ductal Hyperplasia,5/10/2023,"Right, Also fibrocystic changes, complex fibroadenoma with atypical
lobular hyperplasia (ALH)",No,,,,,3/6/2023,Invasive ductal carcinoma,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,7,Low," ER+, PR+, HER2-",90,3,90,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,16,,,,,,
BCSB0410,,,167.6,106.1,37.8,Yes,Atypical Ductal Hyperplasia,5/10/2023,"Right, Also fibrocystic changes, complex fibroadenoma with atypical
lobular hyperplasia (ALH)",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,0.5,,,,,,,,,,16,,,,,,
BCSB0410,,,167.6,106.1,37.8,Yes,Atypical Ductal Hyperplasia,5/10/2023,"Right, Also fibrocystic changes, complex fibroadenoma with atypical
lobular hyperplasia (ALH)",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,0.5,"after surgical intervention, but before chemo or radiation",0.8,0.2,,16,,,,,,
BCSB0319,,,168,71.5,25.3,Yes,Calcifications,1/14/2022,Both breasts,No,,,,,2/2/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,,Stage IIa,,X,,X,Ductal,,2,,," ER-, PR-, HER2-",0,0,0,0,2,Non-amplified,ER- PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0319,,,168,71.5,25.3,Yes,Calcifications,1/14/2022,Both breasts,No,,,,,2/2/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,,Stage IIa,,X,,X,Ductal,,3,80,High," ER+, PR-, HER2-",90,3,0,0,1,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0319,,,168,71.5,25.3,Yes,Calcifications,1/14/2022,Both breasts,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.5,TNBC,,,,,,,,,,,,,,,
BCSB0319,,,168,71.5,25.3,Yes,Calcifications,1/14/2022,Both breasts,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,3,ER+,,,,,,,,,,,,,,,
BCSB0319,,,168,71.5,25.3,Yes,Calcifications,1/14/2022,Both breasts,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,2.5,"after surgical intervention, after neoadjuvant treatment",0,0,TNBC,,,,,,,
BCSB0319,,,168,71.5,25.3,Yes,Calcifications,1/14/2022,Both breasts,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,1.5,3,"after surgical intervention, after neoadjuvant treatment",0,0,ER+,,,,,,,
BCSB0399,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0402,,,167.6,95.7,34.1,Yes,Atypical Ductal Hyperplasia,1/1/2011,Right,Yes,,Ductal carcinoma in situ,10/20/2020,"Left, and LCIS",10/9/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,,," ER+, PR+, HER2-",54,3,56,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,"Right Breast Oncotype: 11
Left Breast Oncotype: 4"
BCSB0402,,,167.6,95.7,34.1,Yes,Atypical Ductal Hyperplasia,1/1/2011,Right,Yes,,Ductal carcinoma in situ,10/20/2020,"Left, and LCIS",10/20/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",98,3,95,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,"Right Breast Oncotype: 11
Left Breast Oncotype: 4"
BCSB0402,,,167.6,95.7,34.1,Yes,Atypical Ductal Hyperplasia,1/1/2011,Right,Yes,,Ductal carcinoma in situ,10/20/2020,"Left, and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.5,Right,,,,,,,,,11,,,,,,"Right Breast Oncotype: 11
Left Breast Oncotype: 4"
BCSB0402,,,167.6,95.7,34.1,Yes,Atypical Ductal Hyperplasia,1/1/2011,Right,Yes,,Ductal carcinoma in situ,10/20/2020,"Left, and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,No,1,Left,,,,,,,,,11,,,,,,"Right Breast Oncotype: 11
Left Breast Oncotype: 4"
BCSB0402,,,167.6,95.7,34.1,Yes,Atypical Ductal Hyperplasia,1/1/2011,Right,Yes,,Ductal carcinoma in situ,10/20/2020,"Left, and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,0.5,"after surgical intervention, but before chemo or radiation",0.6,1.4,Right,11,,,,,,"Right Breast Oncotype: 11
Left Breast Oncotype: 4"
BCSB0402,,,167.6,95.7,34.1,Yes,Atypical Ductal Hyperplasia,1/1/2011,Right,Yes,,Ductal carcinoma in situ,10/20/2020,"Left, and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,1.3,0.7,"after surgical intervention, but before chemo or radiation",1.2,1,Left,11,,,,,,"Right Breast Oncotype: 11
Left Breast Oncotype: 4"
BCSB0408,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0419,,,162.6,85,32.1,No,,,,Yes,,Ductal carcinoma in situ,4/27/2020,Left,4/27/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,10,Low," ER+, PR-, HER2-",50,3,0,0,2,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,16,,,,,,
BCSB0419,,,162.6,85,32.1,No,,,,Yes,,Ductal carcinoma in situ,4/27/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.6,,,,,,,,,,16,,,,,,
BCSB0419,,,162.6,85,32.1,No,,,,Yes,,Ductal carcinoma in situ,4/27/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,0.5,"after surgical intervention, but before chemo or radiation",0.7,0.3,,16,,,,,,
BCSB0371,,,163.8,129.3,48.2,Yes,Atypical Ductal Hyperplasia,10/17/2022,Bilateral,Yes,,Ductal carcinoma in situ,11/9/2022,Left,9/29/2022,Mucinous (colloid) carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,X,Other,Favorable: mucinous,2,,," ER+, PR+, HER2-",100,3,100,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,16,,,,,,
BCSB0371,,,163.8,129.3,48.2,Yes,Atypical Ductal Hyperplasia,10/17/2022,Bilateral,Yes,,Ductal carcinoma in situ,11/9/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.6,,,,,,,,,,16,,,,,,
BCSB0371,,,163.8,129.3,48.2,Yes,Atypical Ductal Hyperplasia,10/17/2022,Bilateral,Yes,,Ductal carcinoma in situ,11/9/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.8,2.6,"after surgical intervention, but before chemo or radiation",2.9,7.2,,16,,,,,,
BCSB0413,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0418,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0422,,,167.6,118,42,Yes,Fibroadenoma,8/13/2021,Left,Yes,,Ductal carcinoma in situ,8/13/2021,Right,8/13/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,3,20,High," ER+, PR+, HER2-",90,2,30,2,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,"high risk score, luminal B subtype",,,,,
BCSB0422,,,167.6,118,42,Yes,Fibroadenoma,8/13/2021,Left,Yes,,Ductal carcinoma in situ,8/13/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.7,,,,,,,,,,,"high risk score, luminal B subtype",,,,,
BCSB0422,,,167.6,118,42,Yes,Fibroadenoma,8/13/2021,Left,Yes,,Ductal carcinoma in situ,8/13/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.3,"after surgical intervention, but before chemo or radiation",4.5,0,,,"high risk score, luminal B subtype",,,,,
BCSB0428,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0414,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0426,,,170.1,95.2,32.9,Yes,Breast Cysts,1/1/2001,Right,No,,,,,8/2/2019,Invasive ductal carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,,Ductal,,1,5,Low," ER+, PR+, HER2-",92,,96,,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,16,,,,,,
BCSB0426,,,170.1,95.2,32.9,Yes,Breast Cysts,1/1/2001,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.7,,,,,,,,,,16,,,,,,
BCSB0426,,,170.1,95.2,32.9,Yes,Breast Cysts,1/1/2001,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.7,"after surgical intervention, but before chemo or radiation",1.7,0.8,,16,,,,,,
BCSB0369,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0398,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0440,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0423,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0447,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0450,,,157,70.3,28.5,Yes,Calcifications,2/26/2020,Right,Yes,,Ductal carcinoma in situ,7/9/2021,Right,2/26/2020,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN3: to ipsilateral internal mammary LN(s),M0: No distant metastasis,Stage IIb,,X,,,Ductal,,1,12,Low," ER+, PR+, HER2-",100,3,100,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0450,,,157,70.3,28.5,Yes,Calcifications,2/26/2020,Right,Yes,,Ductal carcinoma in situ,7/9/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.2,,,,,,,,,,,,,,,,
BCSB0450,,,157,70.3,28.5,Yes,Calcifications,2/26/2020,Right,Yes,,Ductal carcinoma in situ,7/9/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,1.2,during neoadjuvant treatment,2.5,0.4,,,,,,,,
BCSB0445,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0442,,,163.8,95.9,35.7,Yes,Calcifications,3/1/2018,Left,Yes,,Ductal carcinoma in situ,3/30/2018,Left,3/30/2018,Invasive ductal carcinoma,,,,T1mic:Microinvasion <=0.1 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,X,Ductal,,,,," ER+, HER2+, PR-",90,2,0,0,3+,Unknown,ER+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0442,,,163.8,95.9,35.7,Yes,Calcifications,3/1/2018,Left,Yes,,Ductal carcinoma in situ,3/30/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.2,Tumor Bed size,,,,,,,,,,,,,,,
BCSB0442,,,163.8,95.9,35.7,Yes,Calcifications,3/1/2018,Left,Yes,,Ductal carcinoma in situ,3/30/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",0.1,0.7,,,,,,,,
BCSB0443,,,165.1,102.8,37.7,No,,,,Yes,,Ductal carcinoma in situ,11/24/2021,Left,10/22/2021,Invasive ductal carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,,Ductal,,1,,," ER+, PR+, HER2-",100,3,5,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,12,,,,,,
BCSB0443,,,165.1,102.8,37.7,No,,,,Yes,,Ductal carcinoma in situ,11/24/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.8,,,,,,,,,,12,,,,,,
BCSB0443,,,165.1,102.8,37.7,No,,,,Yes,,Ductal carcinoma in situ,11/24/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.8,"after surgical intervention, but before chemo or radiation",1.2,0.1,,12,,,,,,
BCSB0453,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0455,,,154.9,63.5,26.5,No,,,,Yes,,Ductal carcinoma in situ,10/25/2016,Right,9/14/2016,Papillary carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T3:Tumor >5.0 cm,pN1: movable ipsilateral axillary LN(s),MX: cannot be assessed,Stage IIIa,,X,,,Other,Favorable: papillary,,,," ER+, PR+, HER2-",90,3,90,3,2,Unknown,"ER+ PR+ HER2-, HER2 Ratio 1.2 copy 4.4 So Essentially Negative",,,,,,,,,,,,,,,,,0,,,,,,
BCSB0455,,,154.9,63.5,26.5,No,,,,Yes,,Ductal carcinoma in situ,10/25/2016,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,3.9,,,,,,,,,,0,,,,,,
BCSB0455,,,154.9,63.5,26.5,No,,,,Yes,,Ductal carcinoma in situ,10/25/2016,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3.9,3.9,"after surgical intervention, but before chemo or radiation",7.5,0.1,,0,,,,,,
BCSB0466,,,162.6,106.1,40.1,Yes,Calcifications,7/21/2021,Both breasts,Yes,,Ductal carcinoma in situ,7/28/2021,Left,7/28/2021,Invasive ductal carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ib,X,,,,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,1,Unknown,ER- PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0466,,,162.6,106.1,40.1,Yes,Calcifications,7/21/2021,Both breasts,Yes,,Ductal carcinoma in situ,7/28/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.8,,,,,,,,,,,,,,,,
BCSB0466,,,162.6,106.1,40.1,Yes,Calcifications,7/21/2021,Both breasts,Yes,,Ductal carcinoma in situ,7/28/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,1.2,"after surgical intervention, after neoadjuvant treatment",1.3,0.2,,,,,,,,
BCSB0457,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0400,,,167.6,116.2,41.4,Yes,Calcifications,7/19/2021,Right,Yes,,Ductal carcinoma in situ,8/26/2021,Right,7/19/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,8,Low," ER+, PR+, HER2-",99,3,30,2,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,17,,,,,,
BCSB0400,,,167.6,116.2,41.4,Yes,Calcifications,7/19/2021,Right,Yes,,Ductal carcinoma in situ,8/26/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.7,,,,,,,,,,17,,,,,,
BCSB0400,,,167.6,116.2,41.4,Yes,Calcifications,7/19/2021,Right,Yes,,Ductal carcinoma in situ,8/26/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.5,0.7,"after surgical intervention, but before chemo or radiation",2,0.5,,17,,,,,,
BCSB0469,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0470,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0473,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0292,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0458,,,,,,No,,,,Yes,,Ductal carcinoma in situ,12/9/2020,Left,12/9/2020,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,,,X,,,X,Ductal,,2,2,Low," ER+, PR+, HER2-",98,3,98,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0458,,,,,,No,,,,Yes,,Ductal carcinoma in situ,12/9/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.6,,,,,,,,,,,,,,,,
BCSB0458,,,,,,No,,,,Yes,,Ductal carcinoma in situ,12/9/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,3.6,"after surgical intervention, after neoadjuvant treatment",1.8,0.6,,,,,,,,
BCSB0343,,,177.8,112,35.4,Yes,Breast Cysts,1/1/2006,Right,No,,,,,2/8/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,5,Low," ER+, PR+, HER2-",95,3,70,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,19,,,,,,
BCSB0343,,,177.8,112,35.4,Yes,Breast Cysts,1/1/2006,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.9,,,,,,,,,,19,,,,,,
BCSB0343,,,177.8,112,35.4,Yes,Breast Cysts,1/1/2006,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,0.6,"after surgical intervention, but before chemo or radiation",0.7,0.8,,19,,,,,,
BCSB0496,,,170,73,25.3,Yes,Fibrocystic Breast Changes,1/29/2020,Right,No,,,,,1/29/2020,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,3,,," HER2+, ER-, PR-",0,0,0,0,2,Amplified,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0496,,,170,73,25.3,Yes,Fibrocystic Breast Changes,1/29/2020,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.6,,,,,,,,,,,,,,,,
BCSB0496,,,170,73,25.3,Yes,Fibrocystic Breast Changes,1/29/2020,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3,0.6,"after surgical intervention, but before chemo or radiation",0,0,Tumor was removed at the time of biopsy.,,,,,,,
BCSB0462,,,167.6,78.9,28.1,Yes,Breast Cysts,1/1/1983,"Left, And 1985",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/9/2023,Right,2/9/2023,Invasive lobular carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,,Lobular,,2,25,High," ER+, PR+, HER2-",97,3,99,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0462,,,167.6,78.9,28.1,Yes,Breast Cysts,1/1/1983,"Left, And 1985",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/9/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.5,,,,,,,,,,,,,,,,
BCSB0462,,,167.6,78.9,28.1,Yes,Breast Cysts,1/1/1983,"Left, And 1985",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/9/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.1,0.5,"after surgical intervention, but before chemo or radiation",1.7,,,,,,,,,
BCSB0490,,,,107.9,,Unknown,,,,Yes,,Ductal carcinoma in situ,2/5/2016,Left,1/14/2016,Invasive ductal carcinoma,,,,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,,Stage IIa,X,,,X,Ductal,,,,," ER+, PR+, HER2-",,,,,,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0490,,,,107.9,,Unknown,,,,Yes,,Ductal carcinoma in situ,2/5/2016,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,2.2,,,,,,,,,,,,,,,,
BCSB0490,,,,107.9,,Unknown,,,,Yes,,Ductal carcinoma in situ,2/5/2016,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.2,"after surgical intervention, but before chemo or radiation",2.3,,1.2 cm and 1.0cm,,,,,,,
BCSB0435,,,160.1,106,41.4,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/30/2020,"Right, plus DCIS",9/30/2020,Invasive lobular carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Lobular,,2,,," ER+, PR+, HER2-",100,3,95,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,14,,,,,,
BCSB0435,,,160.1,106,41.4,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/30/2020,"Right, plus DCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.2,,,,,,,,,,14,,,,,,
BCSB0435,,,160.1,106,41.4,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/30/2020,"Right, plus DCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,1.2,"after surgical intervention, but before chemo or radiation",2,0.1,,14,,,,,,
BCSB0485,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0494,,,170.2,78,26.9,Yes,Fibrocystic Breast Changes,10/14/2022,Right,Yes,,Ductal carcinoma in situ,10/14/2022,Right,9/30/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,3,28,High," ER+, PR+, HER2-",97,,64,,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,21,,,,,,
BCSB0494,,,170.2,78,26.9,Yes,Fibrocystic Breast Changes,10/14/2022,Right,Yes,,Ductal carcinoma in situ,10/14/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,0.7,,,,,,,,,,21,,,,,,
BCSB0494,,,170.2,78,26.9,Yes,Fibrocystic Breast Changes,10/14/2022,Right,Yes,,Ductal carcinoma in situ,10/14/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.7,"after surgical intervention, but before chemo or radiation",0.9,0,,21,,,,,,
BCSB0508,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0509,,,152.4,54.4,23.4,Yes,Calcifications,4/23/2018,Right,Yes,,Ductal carcinoma in situ,4/23/2018,Right,4/23/2018,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,,," ER+, PR+, HER2-",95,3,95,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,16,,,,,,
BCSB0509,,,152.4,54.4,23.4,Yes,Calcifications,4/23/2018,Right,Yes,,Ductal carcinoma in situ,4/23/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,16,,,,,,
BCSB0509,,,152.4,54.4,23.4,Yes,Calcifications,4/23/2018,Right,Yes,,Ductal carcinoma in situ,4/23/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.1,"after surgical intervention, but before chemo or radiation",1.2,0.6,,16,,,,,,
BCSB0512,,,165.1,95.7,35.1,No,,,,Yes,,Ductal carcinoma in situ,9/14/2022,Left,9/14/2022,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage IIb,X,,,X,Ductal,,2,20,High," ER+, PR+, HER2-",91,3,93,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,22,,,,,,
BCSB0512,,,165.1,95.7,35.1,No,,,,Yes,,Ductal carcinoma in situ,9/14/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2,,,,,,,,,,22,,,,,,
BCSB0512,,,165.1,95.7,35.1,No,,,,Yes,,Ductal carcinoma in situ,9/14/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,2,"after surgical intervention, but before chemo or radiation",2.5,0.7,second focus: 0.8cm,22,,,,,,
BCSB0460,,,175.3,83.9,27.3,,,,,,,,,,5/9/2022,Invasive ductal carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,,Ductal,,3,65,High," ER+, PR+, HER2-",94,,22,,1,,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,31,,,,,,
BCSB0460,,,175.3,83.9,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,1.5,,,,,,,,,,31,,,,,,
BCSB0460,,,175.3,83.9,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",1.9,,,31,,,,,,
BCSB0499,,,166.4,75.1,27.1,Yes,Breast Cysts,1/1/1988,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/13/2023,Left,3/14/2023,Invasive lobular carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,,X,,,,Lobular,,2,,," ER+, PR+, HER2-",99,3,50,2,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,12,,,,,,
BCSB0499,,,166.4,75.1,27.1,Yes,Breast Cysts,1/1/1988,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/13/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.7,,,,,,,,,,12,,,,,,
BCSB0499,,,166.4,75.1,27.1,Yes,Breast Cysts,1/1/1988,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/13/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,1.7,"after surgical intervention, but before chemo or radiation",1.9,0.2,,12,,,,,,
BCSB0502,,,160,106.6,41.6,Yes,Fibrocystic Breast Changes,12/23/2021,Left,Yes,,Ductal carcinoma in situ,12/23/2021,"Left, and LCIS",12/23/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",80,2,99,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,ULTRA LOW RISK (Index: +0.562),,,,,
BCSB0502,,,160,106.6,41.6,Yes,Fibrocystic Breast Changes,12/23/2021,Left,Yes,,Ductal carcinoma in situ,12/23/2021,"Left, and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.8,,,,,,,,,,,ULTRA LOW RISK (Index: +0.562),,,,,
BCSB0502,,,160,106.6,41.6,Yes,Fibrocystic Breast Changes,12/23/2021,Left,Yes,,Ductal carcinoma in situ,12/23/2021,"Left, and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.8,"after surgical intervention, but before chemo or radiation",1.5,1,,,ULTRA LOW RISK (Index: +0.562),,,,,
BCSB0505,,,162.6,101.9,38.5,Unknown,,,,Yes,,Ductal carcinoma in situ,3/30/2020,Right,2/18/2020,Mixed IDC+ILC (50 -90% each component),,,,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,,Other,,2,13,Low," ER+, PR+, HER2-",100,3,50,2,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,4,,,,,,
BCSB0505,,,162.6,101.9,38.5,Unknown,,,,Yes,,Ductal carcinoma in situ,3/30/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,2,,,,,,,,,,4,,,,,,
BCSB0505,,,162.6,101.9,38.5,Unknown,,,,Yes,,Ductal carcinoma in situ,3/30/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.7,2,"after surgical intervention, but before chemo or radiation",2.3,1.2,,4,,,,,,
BCSB0506,,,162.5,121,45.8,Yes,Fibrocystic Breast Changes,4/21/2022,Right,Yes,,Ductal carcinoma in situ,4/21/2022,Right,3/15/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,16.5,Low," ER+, PR+, HER2-",70.6,2,92.9,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,23,,,,,,
BCSB0506,,,162.5,121,45.8,Yes,Fibrocystic Breast Changes,4/21/2022,Right,Yes,,Ductal carcinoma in situ,4/21/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.1,,,,,,,,,,23,,,,,,
BCSB0506,,,162.5,121,45.8,Yes,Fibrocystic Breast Changes,4/21/2022,Right,Yes,,Ductal carcinoma in situ,4/21/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,1.1,"after surgical intervention, but before chemo or radiation",1.2,0.5,,23,,,,,,
BCSB0510,,,162.5,62.8,23.8,No,,,,Yes,,Ductal carcinoma in situ,12/3/2020,Right,12/3/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,,X,,,Ductal,,3,,," ER+, PR+, HER2-",90,3,90,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,26,,,,,,
BCSB0510,,,162.5,62.8,23.8,No,,,,Yes,,Ductal carcinoma in situ,12/3/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2,,,,,,,,,,26,,,,,,
BCSB0510,,,162.5,62.8,23.8,No,,,,Yes,,Ductal carcinoma in situ,12/3/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2,"after surgical intervention, but before chemo or radiation",3.3,,,26,,,,,,
BCSB0514,,,165.1,83.5,30.6,Yes,Atypical Lobular Hyperplasia,6/13/2019,"Left, Right diagnosed on 07/09/2019",Yes,,Ductal carcinoma in situ,6/13/2019,"Left , and LCIS",6/13/2019,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,,," ER+, PR+, HER2-",90,3,800,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,9,,,,,,
BCSB0514,,,165.1,83.5,30.6,Yes,Atypical Lobular Hyperplasia,6/13/2019,"Left, Right diagnosed on 07/09/2019",Yes,,Ductal carcinoma in situ,6/13/2019,"Left , and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.8,,,,,,,,,,9,,,,,,
BCSB0514,,,165.1,83.5,30.6,Yes,Atypical Lobular Hyperplasia,6/13/2019,"Left, Right diagnosed on 07/09/2019",Yes,,Ductal carcinoma in situ,6/13/2019,"Left , and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3.5,0.8,"after surgical intervention, but before chemo or radiation",0.9,0.4,,9,,,,,,
BCSB0286,,,175.2,72,23.5,No,,,,No,,,,,9/7/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,,," ER+, PR+, HER2-",95,3,95,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,0,,,,,,
BCSB0286,,,175.2,72,23.5,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.6,,,,,,,,,,0,,,,,,
BCSB0286,,,175.2,72,23.5,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,1.6,"after surgical intervention, but before chemo or radiation",1.8,0.2,,0,,,,,,
BCSB0461,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0530,,,167.6,84,29.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/22/2022,Right,1/20/2022,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Lobular,,2,,," ER+, PR+, HER2-",97,3,96,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,15,,,,,,
BCSB0530,,,167.6,84,29.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/22/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.7,,,,,,,,,,15,,,,,,
BCSB0530,,,167.6,84,29.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/22/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.9,"after surgical intervention, but before chemo or radiation",1.8,0.2,,15,,,,,,
BCSB0531,,,160,93,36.3,No,,,,No,,,,,3/22/2023,Mixed IDC+ILC (50 -90% each component),,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,X,,,X,Ductal,,2,,," ER+, PR+, HER2-",98,,20,,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,14,,,,,,
BCSB0531,,,160,93,36.3,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.5,and 1.4cm,,,,,,,,,14,,,,,,
BCSB0531,,,160,93,36.3,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,2.5,"after surgical intervention, but before chemo or radiation",2.2,0.2,and 1.2cm,14,,,,,,
BCSB0533,,,172,64.6,21.8,No,,,,No,,,,,7/16/2020,Mucinous (colloid) carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,,X,,,Other,Favorable: mucinous,2,,," ER+, PR+, HER2-",100,3,99,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,18,,,,,,
BCSB0533,,,172,64.6,21.8,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.8,,,,,,,,,,18,,,,,,
BCSB0533,,,172,64.6,21.8,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,2.4,"after surgical intervention, but before chemo or radiation",2.6,0.2,,18,,,,,,
BCSB0421,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0501,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0459,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0537,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0539,,,165,67.4,24.8,Yes,Fibroadenoma,2/28/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/19/2022,"Left, DCIS in Right Breast 02/28/2022",1/19/2022,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,2,5,Low," ER+, PR+, HER2-",95,3,95,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,29,,,,,,
BCSB0539,,,165,67.4,24.8,Yes,Fibroadenoma,2/28/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/19/2022,"Left, DCIS in Right Breast 02/28/2022",2/28/2022,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,,," ER+, PR+, HER2-",100,3,100,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,29,,,,,,
BCSB0539,,,165,67.4,24.8,Yes,Fibroadenoma,2/28/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/19/2022,"Left, DCIS in Right Breast 02/28/2022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.4,Left,,,,,,,,,29,,,,,,
BCSB0539,,,165,67.4,24.8,Yes,Fibroadenoma,2/28/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/19/2022,"Left, DCIS in Right Breast 02/28/2022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,0.8,Right,,,,,,,,,29,,,,,,
BCSB0539,,,165,67.4,24.8,Yes,Fibroadenoma,2/28/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/19/2022,"Left, DCIS in Right Breast 02/28/2022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.4,"after surgical intervention, but before chemo or radiation",1.4,1.3,Left,29,,,,,,
BCSB0539,,,165,67.4,24.8,Yes,Fibroadenoma,2/28/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/19/2022,"Left, DCIS in Right Breast 02/28/2022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,2,0.8,"after surgical intervention, but before chemo or radiation",0.6,1.1,Right,29,,,,,,
BCSB0427,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0479,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0528,,,162,92.2,35.1,Yes,Breast Cysts,3/23/2022,Right,No,,,,,9/14/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,,X,,X,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,2,Non-amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0528,,,162,92.2,35.1,Yes,Breast Cysts,3/23/2022,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.2,,,,,,,,,,,,,,,,
BCSB0528,,,162,92.2,35.1,Yes,Breast Cysts,3/23/2022,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.6,"after surgical intervention, after neoadjuvant treatment",0,0,"other foci: 1.7cm, 1.3cm, 1.7cm, 0.8cm",,,,,,,
BCSB0536,,,157,58.2,23.6,Yes,Calcifications,11/30/2020,Left,Yes,,Ductal carcinoma in situ,11/30/2020,Left,11/30/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,26,High," ER+, PR+, HER2-",69,3,32,1,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,10,,,,,,
BCSB0536,,,157,58.2,23.6,Yes,Calcifications,11/30/2020,Left,Yes,,Ductal carcinoma in situ,11/30/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.7,,,,,,,,,,10,,,,,,
BCSB0536,,,157,58.2,23.6,Yes,Calcifications,11/30/2020,Left,Yes,,Ductal carcinoma in situ,11/30/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,0.2,"after surgical intervention, but before chemo or radiation",0.2,0,,10,,,,,,
BCSB0540,,,143.5,57.2,27.8,Yes,Calcifications,9/26/2008,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/28/2022,Left,5/17/2022,Invasive lobular carcinoma,T3:Tumor >5.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T3:Tumor >5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,MX: cannot be assessed,Stage IIa,X,,,X,Lobular,,2,21,High," ER+, PR+, HER2-",98,3,100,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,19,,,,,,
BCSB0540,,,143.5,57.2,27.8,Yes,Calcifications,9/26/2008,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/28/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.6,,,,,,,,,,19,,,,,,
BCSB0540,,,143.5,57.2,27.8,Yes,Calcifications,9/26/2008,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/28/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,4.6,"after surgical intervention, but before chemo or radiation",7.7,0.9,,19,,,,,,
BCSB0546,,,162.5,77.1,29.2,No,,,,No,,,,,9/27/2022,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage IIIa,X,,,,Ductal,,3,,," ER+, PR-, HER2-",30,1,0,0,1,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,63,,,,,,
BCSB0546,,,162.5,77.1,29.2,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,7.9,,,,,,,,,,63,,,,,,
BCSB0546,,,162.5,77.1,29.2,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,4,"after surgical intervention, after neoadjuvant treatment",0,0,,63,,,,,,
BCSB0548,,,152.4,69.4,29.9,Yes,Calcifications,12/3/2019,Left,No,,,,,12/3/2019,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,,X,,,,Ductal,,3,30,High," ER+, PR+, HER2-",90,3,90,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,18,,,,,,
BCSB0548,,,152.4,69.4,29.9,Yes,Calcifications,12/3/2019,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,18,,,,,,
BCSB0548,,,152.4,69.4,29.9,Yes,Calcifications,12/3/2019,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.8,1,"after surgical intervention, but before chemo or radiation",1.5,0.1,,18,,,,,,
BCSB0341,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0535,,,172.7,83.9,28.1,Yes,Atypical Lobular Hyperplasia,10/25/2021,Left,Yes,,Ductal carcinoma in situ,10/25/2021,Left,9/21/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,X,Ductal,,2,,," ER+, PR-, HER2-",95,3,0,0,0,Unknown,ER+ PR- HER2-,,,,,,,,,,,,,,,,,19,,,,,,
BCSB0535,,,172.7,83.9,28.1,Yes,Atypical Lobular Hyperplasia,10/25/2021,Left,Yes,,Ductal carcinoma in situ,10/25/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.2,,,,,,,,,,19,,,,,,
BCSB0535,,,172.7,83.9,28.1,Yes,Atypical Lobular Hyperplasia,10/25/2021,Left,Yes,,Ductal carcinoma in situ,10/25/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.2,"after surgical intervention, but before chemo or radiation",0.2,0.15,other focus 0.1cm,19,,,,,,
BCSB0556,,,170.1,55.3,19.1,Unknown,,,,Unknown,,,,,7/14/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,,,," ER+, PR+, HER2-",,,,,,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,High Risk,,,,,
BCSB0556,,,170.1,55.3,19.1,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,,,,,,,,,,,,High Risk,,,,,
BCSB0556,,,170.1,55.3,19.1,Unknown,,,,Unknown,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",,,,,High Risk,,,,,
BCSB0558,,,171.5,99.8,33.9,Yes,Atypical Lobular Hyperplasia,3/23/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/23/2023,Right,2/20/2023,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage Ia,,X,,,Lobular,,2,10,Low," ER+, PR+, HER2-",95,,90,,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0558,,,171.5,99.8,33.9,Yes,Atypical Lobular Hyperplasia,3/23/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/23/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.3,,,,,,,,,,,,,,,,
BCSB0558,,,171.5,99.8,33.9,Yes,Atypical Lobular Hyperplasia,3/23/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/23/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.3,"after surgical intervention, but before chemo or radiation",1.3,0.2,,,,,,,,
BCSB0467,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0483,,,172.7,67.7,22.7,Yes,Fibrocystic Breast Changes,8/31/2021,Left,Yes,,Ductal carcinoma in situ,8/20/2021,Right,8/20/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage Ib,,X,,,Ductal,,2,,," ER+, PR+, HER2-",100,3,100,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,12,,,,,,
BCSB0483,,,172.7,67.7,22.7,Yes,Fibrocystic Breast Changes,8/31/2021,Left,Yes,,Ductal carcinoma in situ,8/20/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.4,,,,,,,,,,12,,,,,,
BCSB0483,,,172.7,67.7,22.7,Yes,Fibrocystic Breast Changes,8/31/2021,Left,Yes,,Ductal carcinoma in situ,8/20/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,2.4,"after surgical intervention, but before chemo or radiation",2.5,0.3,,12,,,,,,
BCSB0550,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0553,,,167.6,105.6,37.6,Yes,Calcifications,6/1/2020,Left,No,,,,,6/1/2020,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,3,58,High," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0553,,,167.6,105.6,37.6,Yes,Calcifications,6/1/2020,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.6,,,,,,,,,,,,,,,,
BCSB0553,,,167.6,105.6,37.6,Yes,Calcifications,6/1/2020,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,2.6,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0554,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0572,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0581,,,176.5,88.6,28.4,Yes,Fibroadenoma,2/11/2020,Right,Yes,,Ductal carcinoma in situ,2/11/2020,Left,4/6/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,20,High," ER+, PR+, HER2-",90,,20,,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,
BCSB0581,,,176.5,88.6,28.4,Yes,Fibroadenoma,2/11/2020,Right,Yes,,Ductal carcinoma in situ,2/11/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,,,,,,,,,,,11,,,,,,
BCSB0581,,,176.5,88.6,28.4,Yes,Fibroadenoma,2/11/2020,Right,Yes,,Ductal carcinoma in situ,2/11/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",1.4,,,11,,,,,,
BCSB0585,,,160,75.3,29.4,No,,,,Yes,,Ductal carcinoma in situ,11/7/2019,Left,9/11/2019,Invasive ductal carcinoma,,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage IIb,,X,,,Ductal,,2,,," ER+, PR+, HER2-",90,3,80,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0585,,,160,75.3,29.4,No,,,,Yes,,Ductal carcinoma in situ,11/7/2019,Left,11/7/2019,Invasive ductal carcinoma,,,MX: cannot be assessed,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",90,3,10,2,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0585,,,160,75.3,29.4,No,,,,Yes,,Ductal carcinoma in situ,11/7/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.7,Right,,,,,,,,,,,,,,,
BCSB0585,,,160,75.3,29.4,No,,,,Yes,,Ductal carcinoma in situ,11/7/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,1.1,Left,,,,,,,,,,,,,,,
BCSB0585,,,160,75.3,29.4,No,,,,Yes,,Ductal carcinoma in situ,11/7/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,2.7,"after surgical intervention, but before chemo or radiation",3.5,0.1,Right,,,,,,,
BCSB0585,,,160,75.3,29.4,No,,,,Yes,,Ductal carcinoma in situ,11/7/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,0.5,1.1,"after surgical intervention, but before chemo or radiation",0.8,0.4,Left,,,,,,,
BCSB0586,,,154,71.6,30.2,Yes,Calcifications,8/10/2020,Bilateral,Yes,,Ductal carcinoma in situ,2/14/2023,Right,2/14/2023,Invasive ductal carcinoma,,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage IIa,,X,,,Ductal,,2,,," ER+, PR-, HER2-",90,3,0,0,Unknown,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,32,,,,,,
BCSB0586,,,154,71.6,30.2,Yes,Calcifications,8/10/2020,Bilateral,Yes,,Ductal carcinoma in situ,2/14/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,Total suspicious area measured 2.9x7.6x4.3cm,,,,,,,,,32,,,,,,
BCSB0586,,,154,71.6,30.2,Yes,Calcifications,8/10/2020,Bilateral,Yes,,Ductal carcinoma in situ,2/14/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,1.3,"after surgical intervention, but before chemo or radiation",3,3,,32,,,,,,
BCSB0588,,,172,103.8,35.1,No,,,,No,,,,,1/26/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,,X,,,,Ductal,,3,75,High," ER-, PR-, HER2-",0,0,0,0,0,Non-amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0588,,,172,103.8,35.1,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.8,,,,,,,,,,,,,,,,
BCSB0588,,,172,103.8,35.1,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,3.8,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0568,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0570,,,154.9,83.5,34.8,Yes,Calcifications,5/3/2022,Right,Yes,,Ductal carcinoma in situ,5/3/2022,Right,5/3/2022,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,NX: Regional LNs cannot be assessed,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,X,Ductal,,2,,," ER+, PR+, HER2-",99,3,98,2,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,3,,,,,,
BCSB0570,,,154.9,83.5,34.8,Yes,Calcifications,5/3/2022,Right,Yes,,Ductal carcinoma in situ,5/3/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.8,,,,,,,,,,3,,,,,,
BCSB0570,,,154.9,83.5,34.8,Yes,Calcifications,5/3/2022,Right,Yes,,Ductal carcinoma in situ,5/3/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.3,1.2,"after surgical intervention, but before chemo or radiation",1.3,0.5,another focus: 0.5cm,3,,,,,,
BCSB0575,,,160,90.7,35.4,Yes,Fibrocystic Breast Changes,10/17/2022,Right,Yes,,Ductal carcinoma in situ,10/17/2022,Left,8/25/2022,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,2,30,High," ER+, PR+, HER2+",100,3,60,3,2,Amplified,Triple positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0575,,,160,90.7,35.4,Yes,Fibrocystic Breast Changes,10/17/2022,Right,Yes,,Ductal carcinoma in situ,10/17/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.8,,,,,,,,,,,,,,,,
BCSB0575,,,160,90.7,35.4,Yes,Fibrocystic Breast Changes,10/17/2022,Right,Yes,,Ductal carcinoma in situ,10/17/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,0.6,"after surgical intervention, but before chemo or radiation",1.1,2.5,,,,,,,,
BCSB0590,,,172.7,181.4,60.8,Unknown,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/4/2017,Right,10/4/2017,Invasive lobular carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,,X,,,Lobular,,2,7,Low," ER+, PR+, HER2-",95,3,95,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,20,,,,,,
BCSB0590,,,172.7,181.4,60.8,Unknown,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/4/2017,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,,,,,,,,,,20,,,,,,
BCSB0590,,,172.7,181.4,60.8,Unknown,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/4/2017,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.3,"after surgical intervention, but before chemo or radiation",2.9,0.1,,20,,,,,,
BCSB0596,,,162.5,76.7,29,Yes,Atypical Lobular Hyperplasia,8/23/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/23/2022,Left,8/23/2022,Invasive lobular carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,2,18,Low," ER+, PR+, HER2-",100,3,39,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,21,,,,,,
BCSB0596,,,162.5,76.7,29,Yes,Atypical Lobular Hyperplasia,8/23/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/23/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,21,,,,,,
BCSB0596,,,162.5,76.7,29,Yes,Atypical Lobular Hyperplasia,8/23/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/23/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,1.2,"after surgical intervention, but before chemo or radiation",2,1,,21,,,,,,
BCSB0598,,,167.6,64.9,23.1,Yes,Central Intraductal Papilloma,7/23/2020,Right,Yes,,Ductal carcinoma in situ,7/23/2020,Right,7/23/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,2,,," ER+, PR+, HER2-",95,3,95,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,9,,,,,,
BCSB0598,,,167.6,64.9,23.1,Yes,Central Intraductal Papilloma,7/23/2020,Right,Yes,,Ductal carcinoma in situ,7/23/2020,Right,7/23/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,,," ER+, PR+, HER2-",95,3,95,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,9,,,,,,
BCSB0598,,,167.6,64.9,23.1,Yes,Central Intraductal Papilloma,7/23/2020,Right,Yes,,Ductal carcinoma in situ,7/23/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.2,Left,,,,,,,,,9,,,,,,
BCSB0598,,,167.6,64.9,23.1,Yes,Central Intraductal Papilloma,7/23/2020,Right,Yes,,Ductal carcinoma in situ,7/23/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,0.8,Right,,,,,,,,,9,,,,,,
BCSB0598,,,167.6,64.9,23.1,Yes,Central Intraductal Papilloma,7/23/2020,Right,Yes,,Ductal carcinoma in situ,7/23/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,1.2,"after surgical intervention, but before chemo or radiation",1.5,1.2,Left,9,,,,,,
BCSB0598,,,167.6,64.9,23.1,Yes,Central Intraductal Papilloma,7/23/2020,Right,Yes,,Ductal carcinoma in situ,7/23/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,4,0.4,"after surgical intervention, but before chemo or radiation",0.4,2,Right,9,,,,,,
BCSB0552,,,167.6,64.8,23.1,Yes,Fibrocystic Breast Changes,4/10/2008,and BREAST CYST 12/20/2010,No,,,,,3/7/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,,," ER+, PR+, HER2-",100,3,90,2,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,15,,,,,,
BCSB0552,,,167.6,64.8,23.1,Yes,Fibrocystic Breast Changes,4/10/2008,and BREAST CYST 12/20/2010,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.5,,,,,,,,,,15,,,,,,
BCSB0552,,,167.6,64.8,23.1,Yes,Fibrocystic Breast Changes,4/10/2008,and BREAST CYST 12/20/2010,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,2.5,"after surgical intervention, but before chemo or radiation",2.7,1,,15,,,,,,
BCSB0602,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0604,,,160,71.3,27.9,No,,,,Yes,,Ductal carcinoma in situ,3/29/2017,Left,3/29/2017,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,,," ER+, PR+, HER2-",90,3,50,3,Unknown,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,14,,,,,,
BCSB0604,,,160,71.3,27.9,No,,,,Yes,,Ductal carcinoma in situ,3/29/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.9,,,,,,,,,,14,,,,,,
BCSB0604,,,160,71.3,27.9,No,,,,Yes,,Ductal carcinoma in situ,3/29/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,0.8,"after surgical intervention, but before chemo or radiation",0.7,1.1,,14,,,,,,
BCSB0547,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0606,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0607,,,167.6,65.4,23.3,Yes,Calcifications,12/18/2020,"Left, And atypical lobular hyperplasia",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/14/2021,Left,1/14/2021,Invasive lobular carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,2,,," ER+, PR+, HER2-",100,3,100,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,5,,,,,,
BCSB0607,,,167.6,65.4,23.3,Yes,Calcifications,12/18/2020,"Left, And atypical lobular hyperplasia",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/14/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,,,,,,,,,,,5,,,,,,
BCSB0607,,,167.6,65.4,23.3,Yes,Calcifications,12/18/2020,"Left, And atypical lobular hyperplasia",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/14/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,4,1.2,"after surgical intervention, but before chemo or radiation",1.2,,,5,,,,,,
BCSB0608,,,157.5,77.6,31.3,Yes,Fibrocystic Breast Changes,4/26/2023,Left,Yes,,Ductal carcinoma in situ,4/26/2023,Right,4/26/2023,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,7,Low," ER+, PR+, HER2-",74,3,84,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,19,,,,,,EndoPredict test: Low risk 2.9
BCSB0608,,,157.5,77.6,31.3,Yes,Fibrocystic Breast Changes,4/26/2023,Left,Yes,,Ductal carcinoma in situ,4/26/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.8,,,,,,,,,,19,,,,,,EndoPredict test: Low risk 2.9
BCSB0608,,,157.5,77.6,31.3,Yes,Fibrocystic Breast Changes,4/26/2023,Left,Yes,,Ductal carcinoma in situ,4/26/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,1.8,"after surgical intervention, but before chemo or radiation",2,0.1,,19,,,,,,EndoPredict test: Low risk 2.9
BCSB0449,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0611,,,,,,No,,,,Yes,,Ductal carcinoma in situ,12/14/2021,Left,12/14/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,,," ER-, PR-, HER2-",0,0,0,0,2,Non-amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0611,,,,,,No,,,,Yes,,Ductal carcinoma in situ,12/14/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.7,,,,,,,,,,,,,,,,
BCSB0611,,,,,,No,,,,Yes,,Ductal carcinoma in situ,12/14/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.2,0.1,"after surgical intervention, but before chemo or radiation",0.5,0.8,,,,,,,,
BCSB0615,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0619,,,163.2,100.2,37.6,Unknown,,,,Yes,,Ductal carcinoma in situ,2/15/2017,Left,9/19/2016,Inflammatory breast cancer,T4d:Inflammatory carcinoma,N2: Ipsilateral axillary LN(s) fixed,M0: No distant metastasis,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIb,X,,,,Other,Unfavorable: Inflammatory,2,,," ER+, PR+, HER2+",,,,,,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0619,,,163.2,100.2,37.6,Unknown,,,,Yes,,Ductal carcinoma in situ,2/15/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,,,,,,,,,,,,,,,,,
BCSB0619,,,163.2,100.2,37.6,Unknown,,,,Yes,,Ductal carcinoma in situ,2/15/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0620,,,172.7,87,29.2,Yes,Fibroadenoma,12/18/2019,Left,Yes,,Ductal carcinoma in situ,11/19/2019,Left,12/2/2019,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,X,Ductal,,2,,," HER2+, ER-, PR-",0,0,0,0,2,Amplified,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0620,,,172.7,87,29.2,Yes,Fibroadenoma,12/18/2019,Left,Yes,,Ductal carcinoma in situ,11/19/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,,,,,,,,,,,,,,,,
BCSB0620,,,172.7,87,29.2,Yes,Fibroadenoma,12/18/2019,Left,Yes,,Ductal carcinoma in situ,11/19/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,1.3,"after surgical intervention, but before chemo or radiation",1.1,1,,,,,,,,
BCSB0594,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0623,,,149.9,64.9,28.9,Yes,Calcifications,11/15/2017,Left,Yes,,Ductal carcinoma in situ,10/19/2018,Left,7/6/2018,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,2,,," ER+, PR-, HER2-",95,3,0,0,Not performed,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,31,,,,,,
BCSB0623,,,149.9,64.9,28.9,Yes,Calcifications,11/15/2017,Left,Yes,,Ductal carcinoma in situ,10/19/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.6,,,,,,,,,,31,,,,,,
BCSB0623,,,149.9,64.9,28.9,Yes,Calcifications,11/15/2017,Left,Yes,,Ductal carcinoma in situ,10/19/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,0.6,"after surgical intervention, but before chemo or radiation",0.8,0.5,,31,,,,,,
BCSB0610,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0621,,,170.1,79.3,27.4,No,,,,No,,,,,10/5/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,,X,,,Ductal,,3,,," ER+, PR+, HER2+",80,2,90,2,3+,Unknown,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0621,,,170.1,79.3,27.4,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,,,,,,,,,,,,,,,,
BCSB0621,,,170.1,79.3,27.4,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,1.2,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0624,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0630,,,157.5,127.1,51.2,No,,,,Yes,,Ductal carcinoma in situ,9/21/2021,Right,8/23/2021,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,,X,,,Ductal,,3,80,High," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0630,,,157.5,127.1,51.2,No,,,,Yes,,Ductal carcinoma in situ,9/21/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.8,,,,,,,,,,,,,,,,
BCSB0630,,,157.5,127.1,51.2,No,,,,Yes,,Ductal carcinoma in situ,9/21/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.8,"after surgical intervention, but before chemo or radiation",1.1,0.1,,,,,,,,
BCSB0637,,,160,61.2,23.9,Yes,Breast Cysts,7/5/2018,Left,Yes,,Ductal carcinoma in situ,9/14/2021,Bilateral,9/14/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,,Ductal,,3,20,High," ER+, PR+, HER2-",100,3,100,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,10,Low Risk Luminal type B,,,,,
BCSB0637,,,160,61.2,23.9,Yes,Breast Cysts,7/5/2018,Left,Yes,,Ductal carcinoma in situ,9/14/2021,Bilateral,9/14/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,,,X,,X,Ductal,,2,15,Low," ER+, PR+, HER2-",100,3,100,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,10,Low Risk Luminal type B,,,,,
BCSB0637,,,160,61.2,23.9,Yes,Breast Cysts,7/5/2018,Left,Yes,,Ductal carcinoma in situ,9/14/2021,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,Local,6/1/2024,,"flap recurrence in June 2024, started letrazole/zoladex, surgery on 7/17/24, and finished radiation 10/9/24",,,,,,,,,,,,,10,Low Risk Luminal type B,,,,,
BCSB0637,,,160,61.2,23.9,Yes,Breast Cysts,7/5/2018,Left,Yes,,Ductal carcinoma in situ,9/14/2021,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.4,Left,,,,,,,,,10,Low Risk Luminal type B,,,,,
BCSB0637,,,160,61.2,23.9,Yes,Breast Cysts,7/5/2018,Left,Yes,,Ductal carcinoma in situ,9/14/2021,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,1.5,Right,,,,,,,,,10,Low Risk Luminal type B,,,,,
BCSB0637,,,160,61.2,23.9,Yes,Breast Cysts,7/5/2018,Left,Yes,,Ductal carcinoma in situ,9/14/2021,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3.3,1.4,"after surgical intervention, but before chemo or radiation",1.3,1,Left,10,Low Risk Luminal type B,,,,,
BCSB0637,,,160,61.2,23.9,Yes,Breast Cysts,7/5/2018,Left,Yes,,Ductal carcinoma in situ,9/14/2021,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,4.5,1.5,"after surgical intervention, but before chemo or radiation",1.2,0.2,"Right, plus 1.0cm and 0.45cm tumors",10,Low Risk Luminal type B,,,,,
BCSB0643,,,165.1,86.1,31.6,Yes,Fibroadenoma,8/4/2016,Left,No,,,,,1/22/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0643,,,165.1,86.1,31.6,Yes,Fibroadenoma,8/4/2016,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,,,,,,,,,,,,,,,,
BCSB0643,,,165.1,86.1,31.6,Yes,Fibroadenoma,8/4/2016,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.3,1,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0634,,,168,82,29.1,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/2/2017,Left,3/30/2017,Invasive lobular carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Lobular,,2,16,Low," ER+, PR+, HER2-",90,3,90,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,LOW RISK LUMINAL-TYPE A,,,,,
BCSB0634,,,168,82,29.1,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/2/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,,LOW RISK LUMINAL-TYPE A,,,,,
BCSB0634,,,168,82,29.1,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/2/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.7,1.1,"after surgical intervention, but before chemo or radiation",4.7,0.1,,,LOW RISK LUMINAL-TYPE A,,,,,
BCSB0652,,Kaiser,157.5,89.6,36.1,Yes,Atypical Lobular Hyperplasia,10/18/2022,Left,No,,,,,8/24/2022,Invasive ductal carcinoma,,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage IIa,X,,,,Ductal,,2,,," ER+, PR+, HER2-",100,3,30,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,38,,,,,,
BCSB0652,,Kaiser,157.5,89.6,36.1,Yes,Atypical Lobular Hyperplasia,10/18/2022,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.3,,,,,,,,,,38,,,,,,
BCSB0652,,Kaiser,157.5,89.6,36.1,Yes,Atypical Lobular Hyperplasia,10/18/2022,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,2.5,"after surgical intervention, but before chemo or radiation",2.1,1.4,,38,,,,,,
BCSB0654,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0636,,,154.9,68.4,28.5,Yes,Fibrocystic Breast Changes,,"Right

",No,,,,,9/11/2017,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,X,,,X,Ductal,,2,,," ER+, PR+, HER2+",99,3,92,3,2,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0636,,,154.9,68.4,28.5,Yes,Fibrocystic Breast Changes,,"Right

",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,1.5,,,,,,,,,,,,,,,,
BCSB0636,,,154.9,68.4,28.5,Yes,Fibrocystic Breast Changes,,"Right

",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.5,"after surgical intervention, but before chemo or radiation",1.5,0.7,and 1.2cm,,,,,,,
BCSB0661,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0639,,,170.2,75.8,26.2,Yes,Atypical Ductal Hyperplasia,7/2/2018,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/20/2018,Right,7/2/2018,Invasive lobular carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Lobular,,1,,," ER+, PR+, HER2-",90,3,95,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0639,,,170.2,75.8,26.2,Yes,Atypical Ductal Hyperplasia,7/2/2018,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/20/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3,,,,,,,,,,,,,,,,
BCSB0639,,,170.2,75.8,26.2,Yes,Atypical Ductal Hyperplasia,7/2/2018,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/20/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,3,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0674,,,173,70,23.4,Yes,Atypical Lobular Hyperplasia,2/15/2019,Left,Yes,,Ductal carcinoma in situ,2/15/2019,Right,1/28/2019,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,2,,," ER+, PR+, HER2-",90,2,99,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,18,,,,,,
BCSB0674,,,173,70,23.4,Yes,Atypical Lobular Hyperplasia,2/15/2019,Left,Yes,,Ductal carcinoma in situ,2/15/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,,,,,,,,,,18,,,,,,
BCSB0674,,,173,70,23.4,Yes,Atypical Lobular Hyperplasia,2/15/2019,Left,Yes,,Ductal carcinoma in situ,2/15/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,1.9,"after surgical intervention, but before chemo or radiation",2.2,0,,18,,,,,,
BCSB0629,,,165.1,56.7,20.8,No,,,,Yes,,Ductal carcinoma in situ,2/8/2023,Left,3/1/2023,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,6,Low," ER+, PR+, HER2-",96,3,11,1,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0629,,,165.1,56.7,20.8,No,,,,Yes,,Ductal carcinoma in situ,2/8/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.8,,,,,,,,,,,,,,,,
BCSB0629,,,165.1,56.7,20.8,No,,,,Yes,,Ductal carcinoma in situ,2/8/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.2,0.8,"after surgical intervention, but before chemo or radiation",0.6,0.6,,,,,,,,
BCSB0677,,,165.1,58.5,21.5,Yes,Fibrocystic Breast Changes,12/9/2014,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/17/2020,Left,8/29/2019,Invasive lobular carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T3:Tumor >5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,X,,,,Lobular,,1,,," ER+, PR+, HER2-",98,2,2,1,Not performed,Non-amplified,"ER+ PR+ (Low Positive, Borderline) HER2-",,,,,,,,,,,,,,,,,,,,,,,
BCSB0677,,,165.1,58.5,21.5,Yes,Fibrocystic Breast Changes,12/9/2014,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/17/2020,Left,8/29/2019,Invasive lobular carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T3:Tumor >5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,X,,,,Lobular,,1,,," ER-, PR-, HER2-",0,0,0,0,Not performed,Non-amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0677,,,165.1,58.5,21.5,Yes,Fibrocystic Breast Changes,12/9/2014,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/17/2020,Left,3/17/2020,Invasive lobular carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T3:Tumor >5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,X,,,,Lobular,,2,,," ER+, PR-, HER2-",8,1,0,0,Not performed,Non-amplified,"ER+ (Low positive, Borderline) PR- HER2-",,,,,,,,,,,,,,,,,,,,,,,
BCSB0677,,,165.1,58.5,21.5,Yes,Fibrocystic Breast Changes,12/9/2014,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/17/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.7,,,,,,,,,,,,,,,,
BCSB0677,,,165.1,58.5,21.5,Yes,Fibrocystic Breast Changes,12/9/2014,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/17/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,3.7,"after surgical intervention, after neoadjuvant treatment",5.4,0.8,,,,,,,,
BCSB0646,,,162.5,74.8,28.3,No,,,,No,,,,,12/14/2018,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,,," ER+, PR+, HER2-",100,3,90,2,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,26,,,,,,
BCSB0646,,,162.5,74.8,28.3,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.3,,,,,,,,,,26,,,,,,
BCSB0646,,,162.5,74.8,28.3,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.1,2.3,"after surgical intervention, but before chemo or radiation",2.5,0.8,,26,,,,,,
BCSB0668,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0675,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0676,,,157.5,62.1,25,Yes,Atypical Lobular Hyperplasia,10/28/2022,Left,Yes,,Ductal carcinoma in situ,10/28/2022,"and LCIS, Left",10/28/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,18,Low," ER+, PR+, HER2-",83,3,93,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,7,,,,,,
BCSB0676,,,157.5,62.1,25,Yes,Atypical Lobular Hyperplasia,10/28/2022,Left,Yes,,Ductal carcinoma in situ,10/28/2022,"and LCIS, Left",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.4,,,,,,,,,,7,,,,,,
BCSB0676,,,157.5,62.1,25,Yes,Atypical Lobular Hyperplasia,10/28/2022,Left,Yes,,Ductal carcinoma in situ,10/28/2022,"and LCIS, Left",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,1.4,"after surgical intervention, but before chemo or radiation",1.2,0.5,,7,,,,,,
BCSB0678,,,154.9,83.5,34.8,Yes,Breast Cysts,4/28/2017,Left,Yes,,Ductal carcinoma in situ,7/26/2018,"Left,  DCIS in the Right breast was diagnosed on 10/16/2018",6/7/2018,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage IIa,,X,,,Ductal,,1,,," ER+, PR+, HER2-",95,3,95,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,Right Side Mammaprint Low,,,,,
BCSB0678,,,154.9,83.5,34.8,Yes,Breast Cysts,4/28/2017,Left,Yes,,Ductal carcinoma in situ,7/26/2018,"Left,  DCIS in the Right breast was diagnosed on 10/16/2018",7/26/2018,Mixed IDC+ILC (50 -90% each component),T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2+",80,3,60,3,Not performed,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,Right Side Mammaprint Low,,,,,
BCSB0678,,,154.9,83.5,34.8,Yes,Breast Cysts,4/28/2017,Left,Yes,,Ductal carcinoma in situ,7/26/2018,"Left,  DCIS in the Right breast was diagnosed on 10/16/2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.5,Right,,,,,,,,,,Right Side Mammaprint Low,,,,,
BCSB0678,,,154.9,83.5,34.8,Yes,Breast Cysts,4/28/2017,Left,Yes,,Ductal carcinoma in situ,7/26/2018,"Left,  DCIS in the Right breast was diagnosed on 10/16/2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,0.9,Left,,,,,,,,,,Right Side Mammaprint Low,,,,,
BCSB0678,,,154.9,83.5,34.8,Yes,Breast Cysts,4/28/2017,Left,Yes,,Ductal carcinoma in situ,7/26/2018,"Left,  DCIS in the Right breast was diagnosed on 10/16/2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,2.5,"after surgical intervention, but before chemo or radiation",2,0.2,Right,,Right Side Mammaprint Low,,,,,
BCSB0678,,,154.9,83.5,34.8,Yes,Breast Cysts,4/28/2017,Left,Yes,,Ductal carcinoma in situ,7/26/2018,"Left,  DCIS in the Right breast was diagnosed on 10/16/2018",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,1.3,0.9,"after surgical intervention, but before chemo or radiation",0.9,1,Left,,Right Side Mammaprint Low,,,,,
BCSB0679,,,147,65.4,30.3,Yes,Breast Cysts,8/11/2020,Left,Yes,,Ductal carcinoma in situ,6/24/2021,Right,8/11/2020,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,MX: cannot be assessed,Stage IIa,,X,,X,Ductal,,2,8,Low," ER+, PR+, HER2-",90,3,90,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0679,,,147,65.4,30.3,Yes,Breast Cysts,8/11/2020,Left,Yes,,Ductal carcinoma in situ,6/24/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.3,,,,,,,,,,,,,,,,
BCSB0679,,,147,65.4,30.3,Yes,Breast Cysts,8/11/2020,Left,Yes,,Ductal carcinoma in situ,6/24/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,2.2,"after surgical intervention, after neoadjuvant treatment",1.9,0.4,,,,,,,,
BCSB0555,,,175,80.6,26.3,Yes,Fibrocystic Breast Changes,6/13/2023,Left,Yes,,Ductal carcinoma in situ,6/13/2023,Right,4/17/2023,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,2,Low," ER+, PR+, HER2-",96,3,95,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,14,,,,,,
BCSB0555,,,175,80.6,26.3,Yes,Fibrocystic Breast Changes,6/13/2023,Left,Yes,,Ductal carcinoma in situ,6/13/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.8,,,,,,,,,,14,,,,,,
BCSB0555,,,175,80.6,26.3,Yes,Fibrocystic Breast Changes,6/13/2023,Left,Yes,,Ductal carcinoma in situ,6/13/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,0.4,"after surgical intervention, but before chemo or radiation",1,0.5,,14,,,,,,
BCSB0617,,,170.1,103.6,35.8,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/2/2022,Left,6/20/2022,Invasive lobular carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,2,,," ER+, PR+, HER2-",95,3,95,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,24,,,,,,
BCSB0617,,,170.1,103.6,35.8,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/2/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.7,,,,,,,,,,24,,,,,,
BCSB0617,,,170.1,103.6,35.8,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/2/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.1,0.4,"after surgical intervention, but before chemo or radiation",0.7,0.4,,24,,,,,,
BCSB0691,,,167.6,103.8,37,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/5/2018,"Left, and DCIS",10/5/2018,Invasive lobular carcinoma,,,M0: No distant metastasis,T3:Tumor >5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIa,X,,,,Lobular,,2,10,Low," ER+, PR+, HER2-",95,3,95,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,19,,,,,,
BCSB0691,,,167.6,103.8,37,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/5/2018,"Left, and DCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,5.4,,,,,,,,,,19,,,,,,
BCSB0691,,,167.6,103.8,37,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/5/2018,"Left, and DCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,5.4,"after surgical intervention, but before chemo or radiation",7.3,1.2,,19,,,,,,
BCSB0549,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0662,,,165.1,55.1,20.2,Yes,Fibroadenoma,1/1/2013,Right,Yes,,Ductal carcinoma in situ,11/8/2021,Left,11/8/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,60,High," ER+, PR+, HER2+",70,1,30,3,3+,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0662,,,165.1,55.1,20.2,Yes,Fibroadenoma,1/1/2013,Right,Yes,,Ductal carcinoma in situ,11/8/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,,,,,,,,,,,,,,,,
BCSB0662,,,165.1,55.1,20.2,Yes,Fibroadenoma,1/1/2013,Right,Yes,,Ductal carcinoma in situ,11/8/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.7,0.5,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0673,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0684,,,,83.1,,Yes,Calcifications,5/25/2023,Left,Yes,,Ductal carcinoma in situ,6/26/2023,Left and Right on 07/20/2023,6/26/2023,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,X,Ductal,,2,29,High," ER+, PR+, HER2-",90,3,88,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,
BCSB0684,,,,83.1,,Yes,Calcifications,5/25/2023,Left,Yes,,Ductal carcinoma in situ,6/26/2023,Left and Right on 07/20/2023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.3,,,,,,,,,,11,,,,,,
BCSB0684,,,,83.1,,Yes,Calcifications,5/25/2023,Left,Yes,,Ductal carcinoma in situ,6/26/2023,Left and Right on 07/20/2023,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.6,1,"after surgical intervention, but before chemo or radiation",0.4,0,two 0.4 cm,11,,,,,,
BCSB0454,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0523,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0525,,,165,68,25,Yes,Breast Cysts,3/11/1996,,Yes,,Ductal carcinoma in situ,10/19/2016,,9/16/2016,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,3,,," ER+, PR+, HER2-",95,3,20,1,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,32,,,,,,
BCSB0525,,,165,68,25,Yes,Breast Cysts,3/11/1996,,Yes,,Ductal carcinoma in situ,10/19/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.2,,,,,,,,,,32,,,,,,
BCSB0525,,,165,68,25,Yes,Breast Cysts,3/11/1996,,Yes,,Ductal carcinoma in situ,10/19/2016,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,2,"after surgical intervention, but before chemo or radiation",2.7,0.5,,32,,,,,,
BCSB0582,,,175,67.2,21.9,No,,,,No,,,,,3/18/2020,Mixed IDC+ILC (50 -90% each component),T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,1,,," ER+, PR+, HER2-",100,3,85,2,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0582,,,175,67.2,21.9,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.8,,,,,,,,,,,,,,,,
BCSB0582,,,175,67.2,21.9,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.4,0.8,"after surgical intervention, but before chemo or radiation",0.4,0.2,,,,,,,,
BCSB0638,,,159.4,47.6,18.7,No,,,,Yes,,Ductal carcinoma in situ,9/18/2017,Right,9/18/2017,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,,," ER+, PR+, HER2-",90,3,90,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0638,,,159.4,47.6,18.7,No,,,,Yes,,Ductal carcinoma in situ,9/18/2017,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,0.7,,,,,,,,,,,,,,,,
BCSB0638,,,159.4,47.6,18.7,No,,,,Yes,,Ductal carcinoma in situ,9/18/2017,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.7,"after surgical intervention, but before chemo or radiation",0.7,1,,,,,,,,
BCSB0692,,,152.4,137.4,59.2,Yes,Atypical Ductal Hyperplasia,4/27/2021,Right,No,,,,,7/30/2020,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ib,,X,,,Ductal,Favorable: mucinous,2,70,High," ER+, PR+, HER2+",100,,80,,3+,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0692,,,152.4,137.4,59.2,Yes,Atypical Ductal Hyperplasia,4/27/2021,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.7,,,,,,,,,,,,,,,,
BCSB0692,,,152.4,137.4,59.2,Yes,Atypical Ductal Hyperplasia,4/27/2021,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.7,"after surgical intervention, after neoadjuvant treatment",2.8,0.1,,,,,,,,
BCSB0693,,,162,71.5,27.2,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/23/2021,Left,9/23/2021,Invasive lobular carcinoma,,,M0: No distant metastasis,T3:Tumor >5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ib,X,,,,Lobular,,2,,," ER+, PR+, HER2-",95,3,80,3,Unknown,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,8,,,,,,
BCSB0693,,,162,71.5,27.2,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/23/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,6.5,,,,,,,,,,8,,,,,,
BCSB0693,,,162,71.5,27.2,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/23/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.5,"after surgical intervention, but before chemo or radiation",6.8,0.2,,8,,,,,,
BCSB0694,,,165.1,91,33.4,Yes,Calcifications,8/21/2022,Left,Yes,,Ductal carcinoma in situ,9/21/2022,Left,8/9/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ib,X,,,X,Ductal,,2,51,High," ER+, PR+, HER2-",95,3,70,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0694,,,165.1,91,33.4,Yes,Calcifications,8/21/2022,Left,Yes,,Ductal carcinoma in situ,9/21/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2,And another 2cm focus,,,,,,,,,,,,,,,
BCSB0694,,,165.1,91,33.4,Yes,Calcifications,8/21/2022,Left,Yes,,Ductal carcinoma in situ,9/21/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,"after surgical intervention, but before chemo or radiation",,2,"after surgical intervention, but before chemo or radiation",3.2,0.4,2.1cm and 0.5cm foci,,,,,,,
BCSB0695,,Kaiser,157.5,63,25.4,No,,,,Yes,,Ductal carcinoma in situ,9/20/2022,Left,9/20/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage Ib,X,,,X,Ductal,,2,,," ER+, PR+, HER2-",95,3,95,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0695,,Kaiser,157.5,63,25.4,No,,,,Yes,,Ductal carcinoma in situ,9/20/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3,,,,,,,,,,,,,,,,
BCSB0695,,Kaiser,157.5,63,25.4,No,,,,Yes,,Ductal carcinoma in situ,9/20/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.4,3,"after surgical intervention, but before chemo or radiation",3.9,0.1,"5 foci: 3.9cm, 1.9cm, 0.9cm, 0.3cm, 0.3cm",,,,,,,
BCSB0709,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0714,,,160.6,73.8,28.6,Yes,Calcifications,9/18/2021,Right,Yes,,Ductal carcinoma in situ,10/27/2021,Right,10/27/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,15,Low," ER+, PR+, HER2-",95,3,95,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,14,,,,,,
BCSB0714,,,160.6,73.8,28.6,Yes,Calcifications,9/18/2021,Right,Yes,,Ductal carcinoma in situ,10/27/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.8,,,,,,,,,,14,,,,,,
BCSB0714,,,160.6,73.8,28.6,Yes,Calcifications,9/18/2021,Right,Yes,,Ductal carcinoma in situ,10/27/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.8,"after surgical intervention, but before chemo or radiation",1.5,,,14,,,,,,
BCSB0710,,,168,96,34,Yes,Atypical Ductal Hyperplasia,4/19/2022,Left,Yes,,Ductal carcinoma in situ,4/19/2022,Right,5/10/2022,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,,X,,,Ductal,,3,,," HER2+, ER-, PR-",0,0,0,0,3+,,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0710,,,168,96,34,Yes,Atypical Ductal Hyperplasia,4/19/2022,Left,Yes,,Ductal carcinoma in situ,4/19/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,8,,,,,,,,,,,,,,,,
BCSB0710,,,168,96,34,Yes,Atypical Ductal Hyperplasia,4/19/2022,Left,Yes,,Ductal carcinoma in situ,4/19/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,9.9,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0726,,,162.6,85.3,32.3,Yes,Calcifications,10/2/2018,Left,Yes,,Ductal carcinoma in situ,10/2/2018,Left,10/2/2018,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,2,30,High," ER+, PR+, HER2+",90,3,60,3,3+,Unknown,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0726,,,162.6,85.3,32.3,Yes,Calcifications,10/2/2018,Left,Yes,,Ductal carcinoma in situ,10/2/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,,,,,,,,,,,,,,,,
BCSB0726,,,162.6,85.3,32.3,Yes,Calcifications,10/2/2018,Left,Yes,,Ductal carcinoma in situ,10/2/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3.5,1.9,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0727,,,170.2,95.6,33,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/17/2021,Left,9/17/2021,Invasive lobular carcinoma,T3:Tumor >5.0 cm,N2: Ipsilateral axillary LN(s) fixed,M0: No distant metastasis,T3:Tumor >5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage Ib,X,,,X,Lobular,,2,5.71,Low," ER+, PR+, HER2-",94,3,97,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0727,,,170.2,95.6,33,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/17/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,5,,,,,,,,,,,,,,,,
BCSB0727,,,170.2,95.6,33,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/17/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,5,"after surgical intervention, but before chemo or radiation",15.5,2.8,,,,,,,,
BCSB0742,,,162.5,87.9,33.3,No,,,,Yes,,Ductal carcinoma in situ,9/7/2021,Right,9/7/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage IIa,,X,,,Other,Favorable: mucinous,2,,," ER+, PR+, HER2+",100,3,90,3,2,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0742,,,162.5,87.9,33.3,No,,,,Yes,,Ductal carcinoma in situ,9/7/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.7,,,,,,,,,,,,,,,,
BCSB0742,,,162.5,87.9,33.3,No,,,,Yes,,Ductal carcinoma in situ,9/7/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,2.7,"after surgical intervention, after neoadjuvant treatment",1.5,1.5,,,,,,,,
BCSB0749,,,162.5,56.7,21.5,Yes,Breast Cysts,4/1/2021,Bilateral,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/22/2022,"Right, both DCIS and LCIS",4/22/2022,Invasive lobular carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Lobular,,2,2,Low," ER+, PR+, HER2-",95,3,99,0,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,13,,,,,,13 Oncotype for Invasive lobular carcinoma and 19 Oncotype for Invasive Ductal carcinoma
BCSB0749,,,162.5,56.7,21.5,Yes,Breast Cysts,4/1/2021,Bilateral,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/22/2022,"Right, both DCIS and LCIS",4/22/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,5,Low," ER+, PR-, HER2-",99,3,0,0,1,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,13,,,,,,13 Oncotype for Invasive lobular carcinoma and 19 Oncotype for Invasive Ductal carcinoma
BCSB0749,,,162.5,56.7,21.5,Yes,Breast Cysts,4/1/2021,Bilateral,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/22/2022,"Right, both DCIS and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.9,Right,,,,,,,,,13,,,,,,13 Oncotype for Invasive lobular carcinoma and 19 Oncotype for Invasive Ductal carcinoma
BCSB0749,,,162.5,56.7,21.5,Yes,Breast Cysts,4/1/2021,Bilateral,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/22/2022,"Right, both DCIS and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,0.4,Right,,,,,,,,,13,,,,,,13 Oncotype for Invasive lobular carcinoma and 19 Oncotype for Invasive Ductal carcinoma
BCSB0749,,,162.5,56.7,21.5,Yes,Breast Cysts,4/1/2021,Bilateral,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/22/2022,"Right, both DCIS and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.1,0.4,"after surgical intervention, but before chemo or radiation",1.2,0.4,Right,13,,,,,,13 Oncotype for Invasive lobular carcinoma and 19 Oncotype for Invasive Ductal carcinoma
BCSB0749,,,162.5,56.7,21.5,Yes,Breast Cysts,4/1/2021,Bilateral,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/22/2022,"Right, both DCIS and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,1.8,0.4,"after surgical intervention, but before chemo or radiation",0.9,0.3,Right,13,,,,,,13 Oncotype for Invasive lobular carcinoma and 19 Oncotype for Invasive Ductal carcinoma
BCSB0752,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0757,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0712,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0751,,,172.7,77,25.8,No,,,,Yes,,Ductal carcinoma in situ,3/22/2021,Left,3/8/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2+",100,3,75,2,2,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0751,,,172.7,77,25.8,No,,,,Yes,,Ductal carcinoma in situ,3/22/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.9,,,,,,,,,,,,,,,,
BCSB0751,,,172.7,77,25.8,No,,,,Yes,,Ductal carcinoma in situ,3/22/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,0.7,"after surgical intervention, but before chemo or radiation",0.8,0.2,,,,,,,,
BCSB0760,,,152,53,22.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/27/2018,Left,1/4/2018,Invasive lobular carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,X,,,,Lobular,,2,10,Low," ER+, PR+, HER2-",95,3,5,1,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,33,,,,,,
BCSB0760,,,152,53,22.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/27/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.4,,,,,,,,,,33,,,,,,
BCSB0760,,,152,53,22.9,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/27/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,2.4,"after surgical intervention, but before chemo or radiation",3,0.5,,33,,,,,,
BCSB0761,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0763,,,160,65.8,25.7,Yes,Atypical Lobular Hyperplasia,11/8/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",11/8/2022,Left,10/12/2022,Invasive lobular carcinoma,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Lobular,,2,,," ER+, PR+, HER2-",95,3,25,2,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,
BCSB0763,,,160,65.8,25.7,Yes,Atypical Lobular Hyperplasia,11/8/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",11/8/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.4,,,,,,,,,,11,,,,,,
BCSB0763,,,160,65.8,25.7,Yes,Atypical Lobular Hyperplasia,11/8/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",11/8/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,2.4,"after surgical intervention, but before chemo or radiation",2.7,0.1,,11,,,,,,
BCSB0778,,,172.7,63,21.1,No,,,,Yes,,Ductal carcinoma in situ,8/16/2022,Right,6/17/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T3:Tumor >5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage IIIa,,X,,X,Ductal,,2,25,High," ER+, PR+, HER2-",98,3,85,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0778,,,172.7,63,21.1,No,,,,Yes,,Ductal carcinoma in situ,8/16/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.9,,,,,,,,,,,,,,,,
BCSB0778,,,172.7,63,21.1,No,,,,Yes,,Ductal carcinoma in situ,8/16/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,3.7,"after surgical intervention, but before chemo or radiation",5.1,0.3,second focus is 0.6cm,,,,,,,
BCSB0612,,,165.1,75,27.5,No,,,,Yes,,Ductal carcinoma in situ,5/9/2018,Right,12/8/2017,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N2: Ipsilateral axillary LN(s) fixed,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,,,X,,X,Ductal,,2,10,Low," ER+, PR+, HER2-",95,3,90,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0612,,,165.1,75,27.5,No,,,,Yes,,Ductal carcinoma in situ,5/9/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,7,,,,,,,,,,,,,,,,
BCSB0612,,,165.1,75,27.5,No,,,,Yes,,Ductal carcinoma in situ,5/9/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,2.5,"after surgical intervention, after neoadjuvant treatment",3.5,1,"and 1.9cm, 0.9cm",,,,,,,
BCSB0762,,,168,84.9,30.1,Unknown,,,,Yes,,Ductal carcinoma in situ,9/25/2019,Left,9/9/2019,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,X,,,,Ductal,,3,,," ER+, PR+, HER2-",98,3,86,2,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0762,,,168,84.9,30.1,Unknown,,,,Yes,,Ductal carcinoma in situ,9/25/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.7,,,,,,,,,,,,,,,,
BCSB0762,,,168,84.9,30.1,Unknown,,,,Yes,,Ductal carcinoma in situ,9/25/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,2.7,"after surgical intervention, but before chemo or radiation",3.2,0.2,,,,,,,,
BCSB0772,,,165.1,90.7,33.3,Yes,Peripheral Intraductal Papillomas,1/1/2008,Left,Yes,,Ductal carcinoma in situ,11/14/2017,Left,9/27/2017,Invasive ductal carcinoma,,,,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,,Stage IIa,X,,,,Ductal,,3,,," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0772,,,165.1,90.7,33.3,Yes,Peripheral Intraductal Papillomas,1/1/2008,Left,Yes,,Ductal carcinoma in situ,11/14/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.2,,,,,,,,,,,,,,,,
BCSB0772,,,165.1,90.7,33.3,Yes,Peripheral Intraductal Papillomas,1/1/2008,Left,Yes,,Ductal carcinoma in situ,11/14/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.2,"after surgical intervention, but before chemo or radiation",2.4,0,,,,,,,,
BCSB0783,,,156,101.2,41.6,Yes,Breast Cysts,10/20/2021,"Left, and Fibrocystic changes
Intraductal papilloma with Atypical ductal hyperplasia diagnosed on 12/07/2021",Yes,,Ductal carcinoma in situ,10/20/2021,Right,10/20/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage IIa,,X,,X,Ductal,,2,,," ER+, PR+, HER2-",95,3,95,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,23,,,,,,
BCSB0783,,,156,101.2,41.6,Yes,Breast Cysts,10/20/2021,"Left, and Fibrocystic changes
Intraductal papilloma with Atypical ductal hyperplasia diagnosed on 12/07/2021",Yes,,Ductal carcinoma in situ,10/20/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,3.4,second focus 1.5cm,,,,,,,,,23,,,,,,
BCSB0783,,,156,101.2,41.6,Yes,Breast Cysts,10/20/2021,"Left, and Fibrocystic changes
Intraductal papilloma with Atypical ductal hyperplasia diagnosed on 12/07/2021",Yes,,Ductal carcinoma in situ,10/20/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.2,3.4,"after surgical intervention, but before chemo or radiation",3.3,0.5,,23,,,,,,
BCSB0666,,,173.5,61.2,20.3,Yes,Calcifications,1/1/2014,Left,Yes,,Ductal carcinoma in situ,12/16/2020,Left,10/29/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage IIb,X,,,,Ductal,,2,5,Low," ER+, PR+, HER2-",95,3,100,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,6,,,,,,
BCSB0666,,,173.5,61.2,20.3,Yes,Calcifications,1/1/2014,Left,Yes,,Ductal carcinoma in situ,12/16/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.1,,,,,,,,,,6,,,,,,
BCSB0666,,,173.5,61.2,20.3,Yes,Calcifications,1/1/2014,Left,Yes,,Ductal carcinoma in situ,12/16/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,2,"after surgical intervention, but before chemo or radiation",2.1,1,,6,,,,,,
BCSB0744,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0765,,,165,53,19.5,Yes,Fibrocystic Breast Changes,3/31/2020,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/25/2020,Right,2/25/2020,Invasive lobular carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,,X,,,Lobular,,3,,," ER+, PR+, HER2-",80,3,90,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,15,,,,,,
BCSB0765,,,165,53,19.5,Yes,Fibrocystic Breast Changes,3/31/2020,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/25/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.5,,,,,,,,,,15,,,,,,
BCSB0765,,,165,53,19.5,Yes,Fibrocystic Breast Changes,3/31/2020,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/25/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,3.8,"after surgical intervention, but before chemo or radiation",3.7,0.25,,15,,,,,,
BCSB0791,,,162.5,80.7,30.6,Yes,Fibrocystic Breast Changes,4/21/2021,Left,Yes,,Ductal carcinoma in situ,1/28/2021,Right,12/10/2020,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,2,,," ER+, PR+, HER2+",90,3,4,2,3+,Unknown,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0791,,,162.5,80.7,30.6,Yes,Fibrocystic Breast Changes,4/21/2021,Left,Yes,,Ductal carcinoma in situ,1/28/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.1,,,,,,,,,,,,,,,,
BCSB0791,,,162.5,80.7,30.6,Yes,Fibrocystic Breast Changes,4/21/2021,Left,Yes,,Ductal carcinoma in situ,1/28/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,1.1,"after surgical intervention, but before chemo or radiation",1.4,,,,,,,,,
BCSB0565,,,163,84,31.6,No,,,,Yes,,Ductal carcinoma in situ,3/31/2022,Right,3/31/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,15,Low," ER+, PR-, HER2-",100,3,0,0,1,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,23,,,,,,
BCSB0565,,,163,84,31.6,No,,,,Yes,,Ductal carcinoma in situ,3/31/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.9,,,,,,,,,,23,,,,,,
BCSB0565,,,163,84,31.6,No,,,,Yes,,Ductal carcinoma in situ,3/31/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.9,"after surgical intervention, but before chemo or radiation",1,0.5,,23,,,,,,
BCSB0766,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0775,,,170.1,103.9,35.9,Yes,Papillary Apocrine Change,6/20/2017,Atypical Papillary Proliferation in left breast,No,,,,,5/31/2017,Mixed IDC+ILC (50 -90% each component),,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Other,Favorable: tubular,1,,," ER+, PR+, HER2-",95,3,95,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,14,,,,,,
BCSB0775,,,170.1,103.9,35.9,Yes,Papillary Apocrine Change,6/20/2017,Atypical Papillary Proliferation in left breast,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.6,,,,,,,,,,14,,,,,,
BCSB0775,,,170.1,103.9,35.9,Yes,Papillary Apocrine Change,6/20/2017,Atypical Papillary Proliferation in left breast,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,0.6,"after surgical intervention, but before chemo or radiation",0.5,0.2,,14,,,,,,
BCSB0777,,,157.4,68.4,27.6,No,,,,Yes,,Ductal carcinoma in situ,12/28/2020,Right,12/28/2020,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,26,High," ER+, PR+, HER2-",86,3,80,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0777,,,157.4,68.4,27.6,No,,,,Yes,,Ductal carcinoma in situ,12/28/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.6,,,,,,,,,,,,,,,,
BCSB0777,,,157.4,68.4,27.6,No,,,,Yes,,Ductal carcinoma in situ,12/28/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,0.2,"after surgical intervention, but before chemo or radiation",0.5,0.7,,,,,,,,
BCSB0793,,,165.1,86.2,31.6,No,,,,No,,,,,2/10/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,,X,,X,,,2,,," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0793,,,165.1,86.2,31.6,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4,,,,,,,,,,,,,,,,
BCSB0793,,,165.1,86.2,31.6,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.2,4,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0802,,,177.1,124.8,39.8,No,,,,Yes,,Ductal carcinoma in situ,2/5/2021,Right,1/15/2021,Invasive ductal carcinoma,,,MX: cannot be assessed,T1b:>0.5 cm but <=1.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage Ia,,X,,,Ductal,,2,20,High," ER+, PR+, HER2-",60,2,10,2,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,27,,,,,,
BCSB0802,,,177.1,124.8,39.8,No,,,,Yes,,Ductal carcinoma in situ,2/5/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.9,,,,,,,,,,27,,,,,,
BCSB0802,,,177.1,124.8,39.8,No,,,,Yes,,Ductal carcinoma in situ,2/5/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,0.5,"after surgical intervention, but before chemo or radiation",0.9,0.7,,27,,,,,,
BCSB0753,,,158.7,68,27,No,,,,No,,,,,1/31/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,3,30,High," ER-, PR-, HER2-",0,0,0,0,1,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0753,,,158.7,68,27,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.2,,,,,,,,,,,,,,,,
BCSB0753,,,158.7,68,27,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.1,"after surgical intervention, after neoadjuvant treatment",1.1,0.9,,,,,,,,
BCSB0787,,,,,,Yes,Fibroadenoma,7/7/2022,Right,Yes,,Ductal carcinoma in situ,7/7/2022,Right,6/8/2022,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),,T1mic:Microinvasion <=0.1 cm,pN1b: Metastasis any >0.2 cm,,,,X,,X,Ductal,,2,,," ER+, HER2+, PR-",,,0,0,,Unknown,Low ER+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0787,,,,,,Yes,Fibroadenoma,7/7/2022,Right,Yes,,Ductal carcinoma in situ,7/7/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,7.1,,,,,,,,,,,,,,,,
BCSB0787,,,,,,Yes,Fibroadenoma,7/7/2022,Right,Yes,,Ductal carcinoma in situ,7/7/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,7.1,"after surgical intervention, but before chemo or radiation",0,0,,,,,,,,
BCSB0792,,,168,55.6,19.7,Yes,Fibrocystic Breast Changes,12/5/2018,Left,Yes,,Ductal carcinoma in situ,10/15/2018,Right,10/15/2018,Mixed IDC+ILC (50 -90% each component),,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Other,,1,5,Low," ER+, PR+, HER2-",95,3,90,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,Low Risk,,,,,
BCSB0792,,,168,55.6,19.7,Yes,Fibrocystic Breast Changes,12/5/2018,Left,Yes,,Ductal carcinoma in situ,10/15/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,1.8,,,,,,,,,,,Low Risk,,,,,
BCSB0792,,,168,55.6,19.7,Yes,Fibrocystic Breast Changes,12/5/2018,Left,Yes,,Ductal carcinoma in situ,10/15/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.8,"after surgical intervention, but before chemo or radiation",2.5,0.5,,,Low Risk,,,,,
BCSB0794,,,165.9,85.5,31.1,Yes,Calcifications,3/25/2021,Right,Yes,,Ductal carcinoma in situ,3/17/2021,Right,3/17/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,,X,,,Ductal,,3,90,High," ER+, PR+, HER2+",2,1,10,2,3+,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0794,,,165.9,85.5,31.1,Yes,Calcifications,3/25/2021,Right,Yes,,Ductal carcinoma in situ,3/17/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.3,,,,,,,,,,,,,,,,
BCSB0794,,,165.9,85.5,31.1,Yes,Calcifications,3/25/2021,Right,Yes,,Ductal carcinoma in situ,3/17/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.3,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0798,,,160,80.3,31.4,Yes,Fibroadenoma,1/13/2023,Right,Yes,,Ductal carcinoma in situ,11/17/2022,Left,12/12/2022,Mixed IDC+ILC (50 -90% each component),,,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,,X,,,X,,,3,,," ER+, HER2+, PR-",9,1,0,0,3+,Unknown,"ER+ PR- HER2+
MRI showed a large area of abnormality spanning 9.8 cm. it is unknown how much of this is DCIS versus invasive carcinoma (0.8cm or larger).  As a result Clinical and simple stage were not included in the medical records.",,,,,,,,,,,,,,,,,,,,,,,
BCSB0798,,,160,80.3,31.4,Yes,Fibroadenoma,1/13/2023,Right,Yes,,Ductal carcinoma in situ,11/17/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,9.8,MRI breast showed a large area of abnormality spanning 9.8 cm. it is unknown how much of this is DCIS versus invasive carcinoma (0.8cm or larger),,,,,,,,,,,,,,,
BCSB0798,,,160,80.3,31.4,Yes,Fibroadenoma,1/13/2023,Right,Yes,,Ductal carcinoma in situ,11/17/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.7,0.8,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0806,,,154.9,82.5,34.4,No,,,,Yes,,Ductal carcinoma in situ,5/30/2019,Left,5/30/2019,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pNX: Regional LNs cannot be assessed,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,3,,," ER+, PR+, HER2-",90,3,90,3,Unknown,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,12,,,,,,
BCSB0806,,,154.9,82.5,34.4,No,,,,Yes,,Ductal carcinoma in situ,5/30/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,,,,,,,,,,12,,,,,,
BCSB0806,,,154.9,82.5,34.4,No,,,,Yes,,Ductal carcinoma in situ,5/30/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,1.9,"after surgical intervention, but before chemo or radiation",1.8,2.5,,12,,,,,,
BCSB0741,,,165.1,68,24.9,No,,,,Yes,,Ductal carcinoma in situ,4/18/2023,Right,4/18/2023,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,,X,,X,Ductal,,2,13,Low," ER+, PR+, HER2-",100,3,100,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0741,,,165.1,68,24.9,No,,,,Yes,,Ductal carcinoma in situ,4/18/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.4,,,,,,,,,,,,,,,,
BCSB0741,,,165.1,68,24.9,No,,,,Yes,,Ductal carcinoma in situ,4/18/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,2.4,"after surgical intervention, but before chemo or radiation",3.9,0.1,more than 20 foci: 0.1cm to 1.2cm,,,,,,,
BCSB0820,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0825,,,166,67,24.3,Yes,Calcifications,5/7/2021,Right,No,,,,,4/22/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,,X,,,Ductal,,2,79,High," ER-, PR-, HER2-",0.5,1,0,0,1,,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0825,,,166,67,24.3,Yes,Calcifications,5/7/2021,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.5,,,,,,,,,,,,,,,,
BCSB0825,,,166,67,24.3,Yes,Calcifications,5/7/2021,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,3.1,"after surgical intervention, after neoadjuvant treatment",0.3,1.7,,,,,,,,
BCSB0660,,,171,69.5,23.8,Yes,Calcifications,8/8/2017,Right,Yes,,Ductal carcinoma in situ,8/11/2022,Right,8/11/2022,Mixed IDC+ILC (50 -90% each component),,,,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,,,,X,,X,Other,,1,7,Low," ER+, PR+, HER2-",100,3,100,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0660,,,171,69.5,23.8,Yes,Calcifications,8/8/2017,Right,Yes,,Ductal carcinoma in situ,8/11/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,,,,,,,,,,,,,,,,
BCSB0660,,,171,69.5,23.8,Yes,Calcifications,8/8/2017,Right,Yes,,Ductal carcinoma in situ,8/11/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,1.3,"after surgical intervention, but before chemo or radiation",3.3,0.1,and 2.9cm second focus,,,,,,,
BCSB0828,,,157.5,125.6,50.6,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/1/2020,Left,6/1/2020,Invasive lobular carcinoma,,,MX: cannot be assessed,T3:Tumor >5.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage IIb,X,,,X,Lobular,,2,,," ER+, PR+, HER2-",90,3,90,3,Unknown,Non-amplified,"ER+ PR+ HER2- , Stage IIIB after surgery",,,,,,,,,,,,,,,,,12,,,,,,
BCSB0828,,,157.5,125.6,50.6,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/1/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.8,"other foci: 1.2cm, 0.9cm, 0.3cm",,,,,,,,,12,,,,,,
BCSB0828,,,157.5,125.6,50.6,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/1/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,4.8,"after surgical intervention, but before chemo or radiation",7.5,1,"7.5cm tumor is composed of multiple foci of variable sizes, each of which are less than 0.5cm apart",12,,,,,,
BCSB0812,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0799,,,155,66,27.5,No,,,,Yes,,Ductal carcinoma in situ,1/3/2022,Left,11/29/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,,X,,,X,Ductal,,2,,," ER+, PR+, HER2-",99,3,80,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,
BCSB0799,,,155,66,27.5,No,,,,Yes,,Ductal carcinoma in situ,1/3/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,3,,,,,,,,,,11,,,,,,
BCSB0799,,,155,66,27.5,No,,,,Yes,,Ductal carcinoma in situ,1/3/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,3,"after surgical intervention, but before chemo or radiation",3.5,0.1,,11,,,,,,
BCSB0837,,,152.4,63.5,27.3,No,,,,Yes,,Ductal carcinoma in situ,4/25/2019,Right,4/25/2019,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,,X,,X,Ductal,,1,,," ER+, PR+, HER2+",96.5,3,4.9,1,2,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0837,,,152.4,63.5,27.3,No,,,,Yes,,Ductal carcinoma in situ,4/25/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,3,,,,,,,,,,,,,,,,
BCSB0837,,,152.4,63.5,27.3,No,,,,Yes,,Ductal carcinoma in situ,4/25/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,3,"after surgical intervention, but before chemo or radiation",1.2,0.5,second focus 0.2cm,,,,,,,
BCSB0838,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0853,,,161,85.5,33,No,,,,Yes,,Ductal carcinoma in situ,7/29/2021,Left,7/29/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ib,X,,,,Ductal,,2,10,Low," ER+, PR+, HER2+",95,3,67,3,3+,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0853,,,161,85.5,33,No,,,,Yes,,Ductal carcinoma in situ,7/29/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.5,,,,,,,,,,,,,,,,
BCSB0853,,,161,85.5,33,No,,,,Yes,,Ductal carcinoma in situ,7/29/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,2.5,"after surgical intervention, after neoadjuvant treatment",1,1.5,,,,,,,,
BCSB0858,,,165.1,60.3,22.1,Yes,Fibrocystic Breast Changes,8/20/2019,Right,Yes,,Ductal carcinoma in situ,8/12/2019,Right,7/19/2019,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),MX: cannot be assessed,T1a:>0.1 but <=0.5 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage IIb,,X,,X,Ductal,,3,,," ER+, PR+, HER2+",95,3,10,2,Not performed,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0858,,,165.1,60.3,22.1,Yes,Fibrocystic Breast Changes,8/20/2019,Right,Yes,,Ductal carcinoma in situ,8/12/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.5,and several other satellite nodules,,,,,,,,,,,,,,,
BCSB0858,,,165.1,60.3,22.1,Yes,Fibrocystic Breast Changes,8/20/2019,Right,Yes,,Ductal carcinoma in situ,8/12/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,3.5,"after surgical intervention, after neoadjuvant treatment",0.6,0.3,,,,,,,,
BCSB0859,,,145,57.7,27.4,Yes,Fibrocystic Breast Changes,4/10/2020,"Left, and Fibroadenoma",Yes,,Ductal carcinoma in situ,1/13/2020,Left,1/13/2020,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,2,10,Low," ER+, PR+, HER2-",90,3,18,1,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,25,,,,,,
BCSB0859,,,145,57.7,27.4,Yes,Fibrocystic Breast Changes,4/10/2020,"Left, and Fibroadenoma",Yes,,Ductal carcinoma in situ,1/13/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,,,,,,,,,,25,,,,,,
BCSB0859,,,145,57.7,27.4,Yes,Fibrocystic Breast Changes,4/10/2020,"Left, and Fibroadenoma",Yes,,Ductal carcinoma in situ,1/13/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.3,"after surgical intervention, but before chemo or radiation",1.2,0.3,,25,,,,,,
BCSB0587,,,163,57.7,21.7,No,,,,Yes,,Ductal carcinoma in situ,12/12/2017,Left,6/12/2017,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage IIa,X,,,,Ductal,,2,7.9,Low," ER+, PR+, HER2+",96.4,2,95.3,3,3+,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0587,,,163,57.7,21.7,No,,,,Yes,,Ductal carcinoma in situ,12/12/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,4.6,,,,,,,,,,,,,,,,
BCSB0587,,,163,57.7,21.7,No,,,,Yes,,Ductal carcinoma in situ,12/12/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,1,"after surgical intervention, after neoadjuvant treatment",1.2,0.4,,,,,,,,
BCSB0796,,,160,95.2,37.2,Yes,Calcifications,4/15/2022,Right,Yes,,Ductal carcinoma in situ,4/15/2022,Right,4/15/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,3,,," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0796,,,160,95.2,37.2,Yes,Calcifications,4/15/2022,Right,Yes,,Ductal carcinoma in situ,4/15/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.1,,,,,,,,,,,,,,,,
BCSB0796,,,160,95.2,37.2,Yes,Calcifications,4/15/2022,Right,Yes,,Ductal carcinoma in situ,4/15/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.1,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0860,,,162.6,88.5,33.5,Yes,Fibroadenoma,1/1/2006,Right,Yes,,Ductal carcinoma in situ,2/23/2023,Right,2/23/2023,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage IIIa,,X,,X,Ductal,,3,,," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,"ER- PR- HER2+, Right breast cancer was diagnosed after elective breast reduction surgery (No biopsy).",,,,,,,,,,,,,,,,,,,,,,,
BCSB0860,,,162.6,88.5,33.5,Yes,Fibroadenoma,1/1/2006,Right,Yes,,Ductal carcinoma in situ,2/23/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,,Right breast cancer was diagnosed after elective breast reduction surgery (No biopsy),,,,,,,,,,,,,,,
BCSB0860,,,162.6,88.5,33.5,Yes,Fibroadenoma,1/1/2006,Right,Yes,,Ductal carcinoma in situ,2/23/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",0.3,0.1,second focus 0.15cm,,,,,,,
BCSB0759,,,162.5,46.6,17.6,Yes,Breast Cysts,9/2/2021,Left,No,,,,,1/31/2022,Inflammatory breast cancer,T4d:Inflammatory carcinoma,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,N0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIb,X,,,,Ductal,Unfavorable: Inflammatory,3,66,High," ER+, PR-, HER2-",75,2,0,0,2,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0759,,,162.5,46.6,17.6,Yes,Breast Cysts,9/2/2021,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,7,,,,,,,,,,,,,,,,
BCSB0759,,,162.5,46.6,17.6,Yes,Breast Cysts,9/2/2021,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,6.3,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0815,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0819,,,174,77,25.4,Yes,Calcifications,9/8/2018,Left,Yes,,Ductal carcinoma in situ,9/19/2018,Left,9/19/2018,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,3,,," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0819,,,174,77,25.4,Yes,Calcifications,9/8/2018,Left,Yes,,Ductal carcinoma in situ,9/19/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.5,,,,,,,,,,,,,,,,
BCSB0819,,,174,77,25.4,Yes,Calcifications,9/8/2018,Left,Yes,,Ductal carcinoma in situ,9/19/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,2.5,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0823,,,170.2,110.6,38.2,Yes,Fibroadenoma,1/1/2000,Right,Yes,,Ductal carcinoma in situ,7/30/2019,Left,7/30/2019,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,2,,," HER2+, ER-, PR-",0,0,0,0,3+,Amplified,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0823,,,170.2,110.6,38.2,Yes,Fibroadenoma,1/1/2000,Right,Yes,,Ductal carcinoma in situ,7/30/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.3,,,,,,,,,,,,,,,,
BCSB0823,,,170.2,110.6,38.2,Yes,Fibroadenoma,1/1/2000,Right,Yes,,Ductal carcinoma in situ,7/30/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.4,2.3,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0836,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0842,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0876,,,148,67.8,31,No,,,,Yes,,Ductal carcinoma in situ,3/15/2017,Left,2/24/2017,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,2,30,High," ER+, PR+, HER2-",90,3,90,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,10,,,,,,
BCSB0876,,,148,67.8,31,No,,,,Yes,,Ductal carcinoma in situ,3/15/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.5,,,,,,,,,,10,,,,,,
BCSB0876,,,148,67.8,31,No,,,,Yes,,Ductal carcinoma in situ,3/15/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.8,2,"after surgical intervention, but before chemo or radiation",2.5,0.3,,10,,,,,,
BCSB0881,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0832,,,165.1,88.5,32.5,Yes,Atypical Ductal Hyperplasia,7/1/2020,"Left, had Lumpectomy",Yes,,Ductal carcinoma in situ,8/24/2022,Right,8/24/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,10,Low," ER+, PR+, HER2+",100,3,90,2,2,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0832,,,165.1,88.5,32.5,Yes,Atypical Ductal Hyperplasia,7/1/2020,"Left, had Lumpectomy",Yes,,Ductal carcinoma in situ,8/24/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,,,,,,,,,,,,,,,,
BCSB0832,,,165.1,88.5,32.5,Yes,Atypical Ductal Hyperplasia,7/1/2020,"Left, had Lumpectomy",Yes,,Ductal carcinoma in situ,8/24/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,1.1,"after surgical intervention, but before chemo or radiation",1.3,1,,,,,,,,
BCSB0877,,,169.5,80.4,28,Yes,Fibroadenoma,5/21/2021,"Right, and small intraductal papilloma",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/21/2021,Right,4/5/2021,Invasive lobular carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,X,Lobular,,1,5,Low," ER+, PR+, HER2-",91,2,21,2,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,2010 OncotypeDX Score: 23
BCSB0877,,,169.5,80.4,28,Yes,Fibroadenoma,5/21/2021,"Right, and small intraductal papilloma",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/21/2021,Right,3/15/2010,Mixed IDC+ILC (50 -90% each component),,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,,X,,,,Other,,2,,," ER+, PR+, HER2-",,3,,1,Unknown,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,2010 OncotypeDX Score: 23
BCSB0877,,,169.5,80.4,28,Yes,Fibroadenoma,5/21/2021,"Right, and small intraductal papilloma",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/21/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.7,Right,,,,,,,,,11,,,,,,2010 OncotypeDX Score: 23
BCSB0877,,,169.5,80.4,28,Yes,Fibroadenoma,5/21/2021,"Right, and small intraductal papilloma",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/21/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,1.7,"after surgical intervention, but before chemo or radiation",3,0.2,"Right, and 1.5cm",11,,,,,,2010 OncotypeDX Score: 23
BCSB0877,,,169.5,80.4,28,Yes,Fibroadenoma,5/21/2021,"Right, and small intraductal papilloma",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/21/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",1.5,,Left,11,,,,,,2010 OncotypeDX Score: 23
BCSB0883,,,162.6,56.7,21.4,Yes,Fibrocystic Breast Changes,7/17/2023,Bilateral,Yes,,Ductal carcinoma in situ,6/2/2023,Right,6/2/2023,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,,Ductal,,3,,," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,"ER- PR- HER2+,  Grade 1 on Surgical pathology and Grade 3 on biopsy report",,,,,,,,,,,,,,,,,,,,,,,
BCSB0883,,,162.6,56.7,21.4,Yes,Fibrocystic Breast Changes,7/17/2023,Bilateral,Yes,,Ductal carcinoma in situ,6/2/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.1,,,,,,,,,,,,,,,,
BCSB0883,,,162.6,56.7,21.4,Yes,Fibrocystic Breast Changes,7/17/2023,Bilateral,Yes,,Ductal carcinoma in situ,6/2/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.2,1,"after surgical intervention, but before chemo or radiation",0.4,,,,,,,,,
BCSB0814,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0845,,,160,61,23.8,Yes,Fibroadenoma,10/7/2022,Left,No,,,,,1/22/2022,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIb,X,,,,Ductal,,2,,," ER-, PR-, HER2-",0,0,0,0,0,Non-amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0845,,,160,61,23.8,Yes,Fibroadenoma,10/7/2022,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,7,,,,,,,,,,,,,,,,
BCSB0845,,,160,61,23.8,Yes,Fibroadenoma,10/7/2022,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,7,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0847,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0895,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0862,,,166.3,55.3,20,Yes,Fibrocystic Breast Changes,10/31/2019,Left,Yes,,Ductal carcinoma in situ,4/23/2021,Right,4/23/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N2: Ipsilateral axillary LN(s) fixed,M0: No distant metastasis,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,,X,,X,Ductal,,3,,," ER+, PR+, HER2+",100,3,10,2,3+,Unknown,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0862,,,166.3,55.3,20,Yes,Fibrocystic Breast Changes,10/31/2019,Left,Yes,,Ductal carcinoma in situ,4/23/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,3.4,,,,,,,,,,,,,,,,
BCSB0862,,,166.3,55.3,20,Yes,Fibrocystic Breast Changes,10/31/2019,Left,Yes,,Ductal carcinoma in situ,4/23/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0890,,,160,70.3,27.5,Yes,Calcifications,1/19/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/26/2023,"Left, and DCIS",1/26/2023,Invasive lobular carcinoma,T3:Tumor >5.0 cm,N2: Ipsilateral axillary LN(s) fixed,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage IIIb,X,,,,Lobular,,2,,," ER+, PR+, HER2-",90,3,90,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0890,,,160,70.3,27.5,Yes,Calcifications,1/19/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/26/2023,"Left, and DCIS",4/11/2023,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,1,,," ER+, PR+, HER2-",90,3,90,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0890,,,160,70.3,27.5,Yes,Calcifications,1/19/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/26/2023,"Left, and DCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,6.2,Left,,,,,,,,,,,,,,,
BCSB0890,,,160,70.3,27.5,Yes,Calcifications,1/19/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/26/2023,"Left, and DCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,5.5,Right,,,,,,,,,,,,,,,
BCSB0890,,,160,70.3,27.5,Yes,Calcifications,1/19/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/26/2023,"Left, and DCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,6.2,"after surgical intervention, but before chemo or radiation",4.2,0.7,Left,,,,,,,
BCSB0890,,,160,70.3,27.5,Yes,Calcifications,1/19/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/26/2023,"Left, and DCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,3.8,0.25,"after surgical intervention, but before chemo or radiation",0.25,0,Right,,,,,,,
BCSB0894,,,162.6,83.9,31.7,Yes,Atypical Lobular Hyperplasia,6/11/2019,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/15/2019,Left,5/13/2019,Invasive lobular carcinoma,,,,T2:Tumor >2.0 cm but <=5.0 cm,pN0(i+),,Stage IIa,X,,,X,Lobular,,2,,," ER+, PR+, HER2-",90,3,20,2,0,Unknown,"ER+ PR+ HER2-, 3.5cm, 10 o'clock, 8 cm from nipple",,,,,,,,,,,,,,,,,,,,,,,
BCSB0894,,,162.6,83.9,31.7,Yes,Atypical Lobular Hyperplasia,6/11/2019,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/15/2019,Left,6/11/2019,Mixed IDC+ILC (50 -90% each component),,,,T2:Tumor >2.0 cm but <=5.0 cm,pN0(i+),,Stage IIa,X,,,X,Other,,3,,," ER+, PR+, HER2+",90,3,95,3,3+,Unknown,"Triple Positive, 1.5cm, at 12 o'clock, 2 cm from the nipple",,,,,,,,,,,,,,,,,,,,,,,
BCSB0894,,,162.6,83.9,31.7,Yes,Atypical Lobular Hyperplasia,6/11/2019,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/15/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.7,"Invasive lobular carcinoma, 10 o'clock, 8 cm from nipple",,,,,,,,,,,,,,,
BCSB0894,,,162.6,83.9,31.7,Yes,Atypical Lobular Hyperplasia,6/11/2019,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/15/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,1.4,"Invasive carcinoma with mixed ductal and lobular features, at 12 o'clock, 2 cm from the nipple",,,,,,,,,,,,,,,
BCSB0894,,,162.6,83.9,31.7,Yes,Atypical Lobular Hyperplasia,6/11/2019,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/15/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.1,1.7,"after surgical intervention, but before chemo or radiation",3.5,0.1,"Invasive lobular carcinoma, 10 o'clock, 8 cm from nipple",,,,,,,
BCSB0894,,,162.6,83.9,31.7,Yes,Atypical Lobular Hyperplasia,6/11/2019,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/15/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,2.8,1.4,"after surgical intervention, but before chemo or radiation",1.5,0,"Invasive carcinoma with mixed ductal and lobular features, at 12 o'clock, 2 cm from the nipple",,,,,,,
BCSB0901,,,163,78,29.4,No,,,,Yes,,Ductal carcinoma in situ,12/24/2019,Right,12/24/2019,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,,," ER+, PR+, HER2-",90,3,95,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,22,,,,,,
BCSB0901,,,163,78,29.4,No,,,,Yes,,Ductal carcinoma in situ,12/24/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.2,,,,,,,,,,22,,,,,,
BCSB0901,,,163,78,29.4,No,,,,Yes,,Ductal carcinoma in situ,12/24/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,1.2,"after surgical intervention, but before chemo or radiation",1.1,0.6,,22,,,,,,
BCSB0903,,,167.6,80.2,28.6,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/12/2023,"Left, And DCIS",1/12/2023,Invasive lobular carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,X,Lobular,,2,15,Low," ER+, PR+, HER2-",100,,100,,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,
BCSB0903,,,167.6,80.2,28.6,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/12/2023,"Left, And DCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,,,,,,,,,,11,,,,,,
BCSB0903,,,167.6,80.2,28.6,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/12/2023,"Left, And DCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,0.7,"after surgical intervention, but before chemo or radiation",2.7,0.1,And 0.15cm,11,,,,,,
BCSB0864,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0885,,,165.1,64,23.5,Yes,Breast Cysts,9/23/2020,Bilateral,Yes,,Ductal carcinoma in situ,9/24/2020,Left,9/24/2020,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N1: Movable ipsilateral axillary LN(s),,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,,Stage Ib,X,,,X,Ductal,,2,22,High," ER+, PR+, HER2-",90,3,75,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,20,,,,,,
BCSB0885,,,165.1,64,23.5,Yes,Breast Cysts,9/23/2020,Bilateral,Yes,,Ductal carcinoma in situ,9/24/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,second focus 0.9cm,,,,,,,,,20,,,,,,
BCSB0885,,,165.1,64,23.5,Yes,Breast Cysts,9/23/2020,Bilateral,Yes,,Ductal carcinoma in situ,9/24/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1,"after surgical intervention, but before chemo or radiation",1.8,0.7,second focus 0.9cm,20,,,,,,
BCSB0891,,,160,59.9,23.4,Yes,Calcifications,8/17/2020,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/17/2020,Left,8/17/2020,Mixed IDC+ILC (50 -90% each component),T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,,Other,,3,,," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0891,,,160,59.9,23.4,Yes,Calcifications,8/17/2020,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/17/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,,,,,,,
BCSB0891,,,160,59.9,23.4,Yes,Calcifications,8/17/2020,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/17/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1,"after surgical intervention, but before chemo or radiation",1,0.2,,,,,,,,
BCSB0865,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0919,,,170,50,17.3,Yes,Atypical Lobular Hyperplasia,10/19/2021,"Right, and  Atypical Ductal Hyperplasia",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/31/2021,"Right, and DCIS on 10/19/2021",8/31/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ib,,X,,,Ductal,,2,6,Low," ER+, PR+, HER2-",85,3,90,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,16,,,,,,
BCSB0919,,,170,50,17.3,Yes,Atypical Lobular Hyperplasia,10/19/2021,"Right, and  Atypical Ductal Hyperplasia",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/31/2021,"Right, and DCIS on 10/19/2021",10/19/2021,Invasive lobular carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ib,,X,,,Lobular,,2,11,Low," ER+, PR+, HER2-",90,3,80,2,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,16,,,,,,
BCSB0919,,,170,50,17.3,Yes,Atypical Lobular Hyperplasia,10/19/2021,"Right, and  Atypical Ductal Hyperplasia",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/31/2021,"Right, and DCIS on 10/19/2021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2,,,,,,,,,,16,,,,,,
BCSB0919,,,170,50,17.3,Yes,Atypical Lobular Hyperplasia,10/19/2021,"Right, and  Atypical Ductal Hyperplasia",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/31/2021,"Right, and DCIS on 10/19/2021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,2,"after surgical intervention, but before chemo or radiation",2.6,0.2,Invasive ductal carcinoma with lobular features,16,,,,,,
BCSB0919,,,170,50,17.3,Yes,Atypical Lobular Hyperplasia,10/19/2021,"Right, and  Atypical Ductal Hyperplasia",Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/31/2021,"Right, and DCIS on 10/19/2021",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",0.25,0.5,Invasive lobular carcinoma,16,,,,,,
BCSB0922,,,165.1,70.3,25.8,Yes,Breast Cysts,1/1/2018,Right,Yes,,Ductal carcinoma in situ,11/10/2021,Right,11/10/2021,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,,,X,,X,Ductal,,2,,," ER+, PR+, HER2-",40,2,5,1,0,,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0922,,,165.1,70.3,25.8,Yes,Breast Cysts,1/1/2018,Right,Yes,,Ductal carcinoma in situ,11/10/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,5.9,,,,,,,,,,,,,,,,
BCSB0922,,,165.1,70.3,25.8,Yes,Breast Cysts,1/1/2018,Right,Yes,,Ductal carcinoma in situ,11/10/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,5.9,"after surgical intervention, after neoadjuvant treatment",1.5,1,,,,,,,,
BCSB0927,,,155.1,66.2,27.5,Yes,Fibrocystic Breast Changes,5/9/2023,Bilateral,Yes,,Ductal carcinoma in situ,11/16/2022,Right,11/16/2022,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0(i+),M0: No distant metastasis,Stage IIb,,X,,,Ductal,,3,90,High," ER+, PR+, HER2+",99,3,54,1,3+,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0927,,,155.1,66.2,27.5,Yes,Fibrocystic Breast Changes,5/9/2023,Bilateral,Yes,,Ductal carcinoma in situ,11/16/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,8.1,,,,,,,,,,,,,,,,
BCSB0927,,,155.1,66.2,27.5,Yes,Fibrocystic Breast Changes,5/9/2023,Bilateral,Yes,,Ductal carcinoma in situ,11/16/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,8.1,"after surgical intervention, after neoadjuvant treatment",4.4,0.2,,,,,,,,
BCSB0928,,,166.6,79.5,28.6,No,,,,Yes,,Ductal carcinoma in situ,12/23/2019,Right,12/23/2019,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,X,,,X,Ductal,,2,11,Low," ER+, PR+, HER2-",95,3,95,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0928,,,166.6,79.5,28.6,No,,,,Yes,,Ductal carcinoma in situ,12/23/2019,Right,12/23/2019,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,35,High," ER+, PR+, HER2-",82,3,85,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0928,,,166.6,79.5,28.6,No,,,,Yes,,Ductal carcinoma in situ,12/23/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.4,Left,,,,,,,,,,,,,,,
BCSB0928,,,166.6,79.5,28.6,No,,,,Yes,,Ductal carcinoma in situ,12/23/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,1,Right,,,,,,,,,,,,,,,
BCSB0928,,,166.6,79.5,28.6,No,,,,Yes,,Ductal carcinoma in situ,12/23/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.8,1.4,"after surgical intervention, but before chemo or radiation",1.7,0.2,"Left, and 1.6cm",,,,,,,
BCSB0928,,,166.6,79.5,28.6,No,,,,Yes,,Ductal carcinoma in situ,12/23/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,1,1,"after surgical intervention, but before chemo or radiation",1.7,1.1,Right,,,,,,,
BCSB0888,,,175.2,68,22.2,Yes,Fibroadenoma,1/27/2023,Left,No,,,,,12/27/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,10,Low," ER+, PR+, HER2-",100,3,100,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,12,,,,,,
BCSB0888,,,175.2,68,22.2,Yes,Fibroadenoma,1/27/2023,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.3,,,,,,,,,,12,,,,,,
BCSB0888,,,175.2,68,22.2,Yes,Fibroadenoma,1/27/2023,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,3,"after surgical intervention, after neoadjuvant treatment",3.8,0,,12,,,,,,
BCSB0912,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0441,,,167.6,74.4,26.5,No,,,,Yes,,Ductal carcinoma in situ,6/10/2021,Left,6/10/2021,Invasive ductal carcinoma,,,MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage IIb,X,,,,Ductal,Favorable: mucinous,1,,," ER+, PR+, HER2-",100,3,90,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,14,,,,,,
BCSB0441,,,167.6,74.4,26.5,No,,,,Yes,,Ductal carcinoma in situ,6/10/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.1,and 1.8cm,,,,,,,,,14,,,,,,
BCSB0441,,,167.6,74.4,26.5,No,,,,Yes,,Ductal carcinoma in situ,6/10/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,2.1,"after surgical intervention, but before chemo or radiation",4.5,0.2,,14,,,,,,
BCSB0923,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0925,,,170.2,63.5,21.9,Yes,Fibrocystic Breast Changes,1/1/1990,,No,,,,,3/7/2022,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,,Ductal,,3,80,High," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0925,,,170.2,63.5,21.9,Yes,Fibrocystic Breast Changes,1/1/1990,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.4,,,,,,,,,,,,,,,,
BCSB0925,,,170.2,63.5,21.9,Yes,Fibrocystic Breast Changes,1/1/1990,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.1,1.2,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0931,,,154.9,68.5,28.5,No,,,,Yes,,Ductal carcinoma in situ,3/19/2019,Left,10/29/2018,Inflammatory breast cancer,T4d:Inflammatory carcinoma,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage IIIb,X,,,X,Other,Unfavorable: Inflammatory,3,,," ER+, PR+, HER2-",100,3,100,3,Not performed,Non-amplified,"ER+ PR+ HER2- , inflammatory Invasive ductal carcinoma with lobular features",,,,,,,,,,,,,,,,,,,,,,,
BCSB0931,,,154.9,68.5,28.5,No,,,,Yes,,Ductal carcinoma in situ,3/19/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.6,,,,,,,,,,,,,,,,
BCSB0931,,,154.9,68.5,28.5,No,,,,Yes,,Ductal carcinoma in situ,3/19/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,4.6,"after surgical intervention, after neoadjuvant treatment",3.2,1.3,,,,,,,,
BCSB0938,,,157.5,57,23,Yes,Calcifications,6/10/2021,Left,Yes,,Ductal carcinoma in situ,5/26/2022,Left,6/10/2021,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN3: to ipsilateral internal mammary LN(s),MX: cannot be assessed,Stage IIIa,X,,,X,Ductal,,2,,," ER-, PR-, HER2-",0,0,0,0,Unknown,Non-amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0938,,,157.5,57,23,Yes,Calcifications,6/10/2021,Left,Yes,,Ductal carcinoma in situ,5/26/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,8.8,multifocal multi-centric distribution measuring 7.8x7.4x8.8cm,,,,,,,,,,,,,,,
BCSB0938,,,157.5,57,23,Yes,Calcifications,6/10/2021,Left,Yes,,Ductal carcinoma in situ,5/26/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,8.8,"after surgical intervention, after neoadjuvant treatment",1.4,2,,,,,,,,
BCSB0870,,,165.1,59,21.6,,,,,Yes,,Ductal carcinoma in situ,8/26/2019,Left,8/26/2019,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,,Stage Ib,X,,,,Ductal,,1,,," ER+, PR+, HER2+",80,2,80,2,Not performed,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB0870,,,165.1,59,21.6,,,,,Yes,,Ductal carcinoma in situ,8/26/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.8,,,,,,,,,,,,,,,,
BCSB0870,,,165.1,59,21.6,,,,,Yes,,Ductal carcinoma in situ,8/26/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,4.8,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0917,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0941,,,167.6,61.2,21.8,Yes,Breast Cysts,3/31/2020,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/1/2016,Right,5/6/2020,Invasive lobular carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage IIb,,X,,X,Lobular,,2,11,Low," ER+, PR+, HER2-",93,3,97,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,25,,,,,,
BCSB0941,,,167.6,61.2,21.8,Yes,Breast Cysts,3/31/2020,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/1/2016,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,3,,,,,,,,,,25,,,,,,
BCSB0941,,,167.6,61.2,21.8,Yes,Breast Cysts,3/31/2020,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/1/2016,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,3,"after surgical intervention, but before chemo or radiation",3.5,0.3,,25,,,,,,
BCSB0939,,,165.1,72.1,26.5,Yes,Calcifications,6/28/2022,Bilateral,No,,,,,8/3/2022,Invasive lobular carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Lobular,,1,,," ER+, PR-, HER2-",90,3,0,0,0,Unknown,ER+ PR- HER2-,,,,,,,,,,,,,,,,,26,,,,,,
BCSB0939,,,165.1,72.1,26.5,Yes,Calcifications,6/28/2022,Bilateral,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.3,,,,,,,,,,26,,,,,,
BCSB0939,,,165.1,72.1,26.5,Yes,Calcifications,6/28/2022,Bilateral,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,,"after surgical intervention, but before chemo or radiation",4.8,,,26,,,,,,
BCSB0945,,,158.1,65.8,26.3,Yes,Atypical Lobular Hyperplasia,9/16/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/16/2022,Left,8/4/2022,Invasive lobular carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Lobular,,2,10,Low," ER+, PR+, HER2-",90,3,70,2,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,23,,,,,,
BCSB0945,,,158.1,65.8,26.3,Yes,Atypical Lobular Hyperplasia,9/16/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/16/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,,,,,,,,,,23,,,,,,
BCSB0945,,,158.1,65.8,26.3,Yes,Atypical Lobular Hyperplasia,9/16/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/16/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.2,"after surgical intervention, but before chemo or radiation",2.1,0.2,,23,,,,,,
BCSB0863,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0934,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0942,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0953,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0957,,,162.6,62.1,23.5,Yes,Atypical Ductal Hyperplasia,12/2/2021,"Left, and Fibroadenoma in Right Breast 11/22/2021",Yes,,Ductal carcinoma in situ,11/22/2021,Left,11/22/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",95,3,95,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,8,,,,,,
BCSB0957,,,162.6,62.1,23.5,Yes,Atypical Ductal Hyperplasia,12/2/2021,"Left, and Fibroadenoma in Right Breast 11/22/2021",Yes,,Ductal carcinoma in situ,11/22/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.4,,,,,,,,,,8,,,,,,
BCSB0957,,,162.6,62.1,23.5,Yes,Atypical Ductal Hyperplasia,12/2/2021,"Left, and Fibroadenoma in Right Breast 11/22/2021",Yes,,Ductal carcinoma in situ,11/22/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,1.4,"after surgical intervention, but before chemo or radiation",0.7,0.3,,8,,,,,,
BCSB0959,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0971,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0972,,,162.5,64.8,24.5,Yes,Breast Cysts,11/8/2021,Right,Yes,,Ductal carcinoma in situ,4/29/2022,Right,4/29/2022,Papillary carcinoma,T3:Tumor >5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,,X,,,Other,Favorable: papillary,2,,," ER+, PR+, HER2-",95,3,95,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,0,,,,,,
BCSB0972,,,162.5,64.8,24.5,Yes,Breast Cysts,11/8/2021,Right,Yes,,Ductal carcinoma in situ,4/29/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,Local,9/11/2024,,Right breast chest wall skin,,,,,,,,,,,,,0,,,,,,
BCSB0972,,,162.5,64.8,24.5,Yes,Breast Cysts,11/8/2021,Right,Yes,,Ductal carcinoma in situ,4/29/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,6.9,,,,,,,,,,0,,,,,,
BCSB0972,,,162.5,64.8,24.5,Yes,Breast Cysts,11/8/2021,Right,Yes,,Ductal carcinoma in situ,4/29/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,3.7,"after surgical intervention, but before chemo or radiation",4.3,1.2,,0,,,,,,
BCSB0713,,,167.6,95.7,34.1,Yes,Breast Cysts,10/25/2016,Bilateral,Yes,,Ductal carcinoma in situ,7/22/2019,Right,7/22/2019,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,X,Ductal,Favorable: tubular,1,10,Low," ER+, PR+, HER2-",95,3,90,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,7,,,,,,
BCSB0713,,,167.6,95.7,34.1,Yes,Breast Cysts,10/25/2016,Bilateral,Yes,,Ductal carcinoma in situ,7/22/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.9,other foci: 1.5cm and 0.8cm,,,,,,,,,7,,,,,,
BCSB0713,,,167.6,95.7,34.1,Yes,Breast Cysts,10/25/2016,Bilateral,Yes,,Ductal carcinoma in situ,7/22/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,1.9,"after surgical intervention, but before chemo or radiation",1.5,0.15,,7,,,,,,
BCSB0943,,,160,57.1,22.3,Yes,Fibrocystic Breast Changes,8/5/2021,Left,Yes,,Ductal carcinoma in situ,8/5/2021,Left,1/13/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,,X,,,,Ductal,,3,95,High," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0943,,,160,57.1,22.3,Yes,Fibrocystic Breast Changes,8/5/2021,Left,Yes,,Ductal carcinoma in situ,8/5/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,,,,,,,,,,,,,,,,
BCSB0943,,,160,57.1,22.3,Yes,Fibrocystic Breast Changes,8/5/2021,Left,Yes,,Ductal carcinoma in situ,8/5/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3.3,1.9,"after surgical intervention, after neoadjuvant treatment",1.9,0.2,,,,,,,,
BCSB0958,,,154.9,54.4,22.7,No,,,,No,,,,,11/30/2017,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,3,,," ER+, PR+, HER2-",90,3,90,3,2,Unknown,"ER+ PR+ HER2-, HER2 ratio 1.6 copy 4.5",,,,,,,,,,,,,,,,,30,,,,,,
BCSB0958,,,154.9,54.4,22.7,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.7,,,,,,,,,,30,,,,,,
BCSB0958,,,154.9,54.4,22.7,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,2.7,"after surgical intervention, but before chemo or radiation",3.5,0.3,,30,,,,,,
BCSB0973,,,172.7,60,20.1,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/28/2018,Left,9/4/2018,Invasive lobular carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,X,Lobular,,3,,," ER+, PR+, HER2-",97,3,88,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,15,,,,,,
BCSB0973,,,172.7,60,20.1,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/28/2018,Left,9/28/2018,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",97,,92,,Unknown,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,15,,,,,,
BCSB0973,,,172.7,60,20.1,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/28/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,,,,,,,,,,15,,,,,,
BCSB0973,,,172.7,60,20.1,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/28/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.7,"after surgical intervention, but before chemo or radiation",2.1,0.7,"Left ILC, and 0.4cc",15,,,,,,
BCSB0973,,,172.7,60,20.1,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/28/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,,,,"after surgical intervention, but before chemo or radiation",1.1,,Left IDC,15,,,,,,
BCSB0981,,,157.5,50.8,20.5,Yes,Calcifications,9/8/2021,Right,Yes,,Ductal carcinoma in situ,9/18/2021,"Right,  LCIS on 10/13/2021 (Mastectomy)",9/18/2021,Invasive ductal carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,X,Ductal,,1,13,Low," ER+, PR+, HER2-",90,3,20,2,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,10,,,,,,
BCSB0981,,,157.5,50.8,20.5,Yes,Calcifications,9/8/2021,Right,Yes,,Ductal carcinoma in situ,9/18/2021,"Right,  LCIS on 10/13/2021 (Mastectomy)",10/13/2021,Invasive lobular carcinoma,,,,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,X,Lobular,,2,5,Low," ER+, PR-, HER2-",90,3,0,0,0,Unknown,ER+ PR- HER2-,,,,,,,,,,,,,,,,,10,,,,,,
BCSB0981,,,157.5,50.8,20.5,Yes,Calcifications,9/8/2021,Right,Yes,,Ductal carcinoma in situ,9/18/2021,"Right,  LCIS on 10/13/2021 (Mastectomy)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.5,,,,,,,,,,10,,,,,,
BCSB0981,,,157.5,50.8,20.5,Yes,Calcifications,9/8/2021,Right,Yes,,Ductal carcinoma in situ,9/18/2021,"Right,  LCIS on 10/13/2021 (Mastectomy)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.5,"after surgical intervention, but before chemo or radiation",1.2,1,Invasive Ductal Carcinoma,10,,,,,,
BCSB0981,,,157.5,50.8,20.5,Yes,Calcifications,9/8/2021,Right,Yes,,Ductal carcinoma in situ,9/18/2021,"Right,  LCIS on 10/13/2021 (Mastectomy)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",0.4,0.1,Invasive Lobular Carcinoma,10,,,,,,
BCSB0605,,,160,87.1,34,Yes,Calcifications,1/25/2023,Left,Yes,,Ductal carcinoma in situ,7/26/2023,"and LCIS, Left breast",2/28/2023,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,3,,," ER+, HER2+, PR-",95,3,0,0,3+,Unknown,ER+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0605,,,160,87.1,34,Yes,Calcifications,1/25/2023,Left,Yes,,Ductal carcinoma in situ,7/26/2023,"and LCIS, Left breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.7,,,,,,,,,,,,,,,,
BCSB0605,,,160,87.1,34,Yes,Calcifications,1/25/2023,Left,Yes,,Ductal carcinoma in situ,7/26/2023,"and LCIS, Left breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,2.7,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0950,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0964,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0965,,,154.9,58,24.2,Yes,Atypical Ductal Hyperplasia,7/18/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/13/2023,Right,6/13/2023,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Lobular,,1,5,Low," ER+, PR+, HER2-",100,,80,,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,14,,,,,,
BCSB0965,,,154.9,58,24.2,Yes,Atypical Ductal Hyperplasia,7/18/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/13/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.8,,,,,,,,,,14,,,,,,
BCSB0965,,,154.9,58,24.2,Yes,Atypical Ductal Hyperplasia,7/18/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/13/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.6,"after surgical intervention, but before chemo or radiation",1.5,0.7,,14,,,,,,
BCSB0966,,,165.1,68,24.9,Yes,Fibroadenoma,7/6/2018,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/1/2021,Right,6/22/2022,Invasive lobular carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T3:Tumor >5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ib,X,,,X,Lobular,,2,3,Low," ER+, PR+, HER2-",100,3,98,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0966,,,165.1,68,24.9,Yes,Fibroadenoma,7/6/2018,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/1/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.3,,,,,,,,,,,,,,,,
BCSB0966,,,165.1,68,24.9,Yes,Fibroadenoma,7/6/2018,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/1/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,3.3,"after surgical intervention, but before chemo or radiation",10.2,0.5,,,,,,,,
BCSB0967,,,170.2,65.3,22.5,Yes,Atypical Lobular Hyperplasia,4/24/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/24/2023,Left,3/7/2023,Invasive lobular carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,X,Lobular,,2,21,High," ER+, PR+, HER2-",90,3,95,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,
BCSB0967,,,170.2,65.3,22.5,Yes,Atypical Lobular Hyperplasia,4/24/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/24/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.4,second tumor: 0.6cm,,,,,,,,,11,,,,,,
BCSB0967,,,170.2,65.3,22.5,Yes,Atypical Lobular Hyperplasia,4/24/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/24/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.4,"after surgical intervention, but before chemo or radiation",2.4,0.3,second tumor: 1.0cm,11,,,,,,
BCSB0975,,,163,85.2,32.1,Yes,Fibrocystic Breast Changes,8/26/2021,Left,No,,,,,1/29/2021,Invasive lobular carcinoma,T3:Tumor >5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T3:Tumor >5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage IIIa,,X,,,Lobular,,1,15,Low," ER+, PR+, HER2-",91,2,98,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0975,,,163,85.2,32.1,Yes,Fibrocystic Breast Changes,8/26/2021,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,9.8,,,,,,,,,,,,,,,,
BCSB0975,,,163,85.2,32.1,Yes,Fibrocystic Breast Changes,8/26/2021,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.2,6.8,"after surgical intervention, after neoadjuvant treatment",5.2,0.2,,,,,,,,
BCSB0977,,,165.1,74.8,27.4,Yes,Fibrocystic Breast Changes,5/23/2018,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/16/2017,Left,10/16/2017,Invasive lobular carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIIa,X,,,,Lobular,,1,1,Low," ER+, PR+, HER2-",100,3,100,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0977,,,165.1,74.8,27.4,Yes,Fibrocystic Breast Changes,5/23/2018,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/16/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,8.5,,,,,,,,,,,,,,,,
BCSB0977,,,165.1,74.8,27.4,Yes,Fibrocystic Breast Changes,5/23/2018,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/16/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,8.5,"after surgical intervention, after neoadjuvant treatment",1.8,0.2,,,,,,,,
BCSB0983,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0665,,,162.5,83.4,31.6,No,,,,Yes,,Ductal carcinoma in situ,12/23/2020,Right,12/23/2020,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1mic:Microinvasion <=0.1 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,,," ER+, PR-, HER2-",5,1,0,0,0,Unknown,ER+ PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0665,,,162.5,83.4,31.6,No,,,,Yes,,Ductal carcinoma in situ,12/23/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.8,"imaging post NAC: Significant interval decrease in size of the known right breast
neoplasm such that it is barely perceptible.",,,,,,,,,,,,,,,
BCSB0665,,,162.5,83.4,31.6,No,,,,Yes,,Ductal carcinoma in situ,12/23/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,1.8,"after surgical intervention, after neoadjuvant treatment",0.1,1,,,,,,,,
BCSB0813,,,175.2,81.6,26.6,Yes,Fibroadenoma,2/3/2022,Left,Yes,,Ductal carcinoma in situ,12/30/2021,Left,12/30/2021,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage Ib,X,,,X,Ductal,,1,,," ER+, PR+, HER2+",,3,,3,2,Amplified,"Triple Positive, Allred score ER: 8/8   PR 6/8
Initially thought to be HER2 negative. Oncotype DX testing revealed HER2 positive.",,,,,,,,,,,,,,,,,24,,,,,,
BCSB0813,,,175.2,81.6,26.6,Yes,Fibroadenoma,2/3/2022,Left,Yes,,Ductal carcinoma in situ,12/30/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1,,,,,,,,,,24,,,,,,
BCSB0813,,,175.2,81.6,26.6,Yes,Fibroadenoma,2/3/2022,Left,Yes,,Ductal carcinoma in situ,12/30/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.1,1,"after surgical intervention, but before chemo or radiation",1.5,0.5,other focus 1.3cm,24,,,,,,
BCSB0932,,,175.2,81.2,26.5,Yes,Central Intraductal Papilloma,2/20/2023,Right,Yes,,Ductal carcinoma in situ,8/4/2023,Left,10/25/2023,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0(i+),M0: No distant metastasis,Stage Ia,X,,,X,Ductal,,2,10,Low," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0932,,,175.2,81.2,26.5,Yes,Central Intraductal Papilloma,2/20/2023,Right,Yes,,Ductal carcinoma in situ,8/4/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,,,,,,,,,,,,,,,,,
BCSB0932,,,175.2,81.2,26.5,Yes,Central Intraductal Papilloma,2/20/2023,Right,Yes,,Ductal carcinoma in situ,8/4/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,,"after surgical intervention, but before chemo or radiation",0.3,1,other 2 foci 0.05cm and 0.09cm,,,,,,,
BCSB0947,,,167.6,92.1,32.8,No,,,,Yes,,Ductal carcinoma in situ,2/28/2022,Left,2/28/2022,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,17,Low," ER+, PR+, HER2-",100,3,100,3,1,Non-amplified,,,,,,,,,,,,,,,,,,12,,,,,,
BCSB0947,,,167.6,92.1,32.8,No,,,,Yes,,Ductal carcinoma in situ,2/28/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.6,,,,,,,,,,12,,,,,,
BCSB0947,,,167.6,92.1,32.8,No,,,,Yes,,Ductal carcinoma in situ,2/28/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.6,"after surgical intervention, but before chemo or radiation",1.3,,Negative margins,12,,,,,,
BCSB0613,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0681,,,167.6,87.5,31.2,,,,,,,,,,,Invasive ductal carcinoma,,,,,,,,X,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0681,,,167.6,87.5,31.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,
BCSB0960,,,162.5,78.4,29.7,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/9/2023,Left,1/19/2023,Invasive lobular carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,1,16,Low," ER+, PR+, HER2-",56,3,4,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,26,,,,,,
BCSB0960,,,162.5,78.4,29.7,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/9/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,1.8,,,,,,,,,,26,,,,,,
BCSB0960,,,162.5,78.4,29.7,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",3/9/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.8,"after surgical intervention, but before chemo or radiation",1.6,,,26,,,,,,
BCSB0961,,,165.1,53.5,19.6,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/26/2021,Left,1/26/2021,Invasive lobular carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Lobular,,2,63,High," ER+, PR+, HER2-",100,3,99,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,19,,,,,,
BCSB0961,,,165.1,53.5,19.6,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/26/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,,,,,,,,,,19,,,,,,
BCSB0961,,,165.1,53.5,19.6,No,,,,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",1/26/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.9,"after surgical intervention, but before chemo or radiation",3.4,0.2,,19,,,,,,
BCSB0716,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0952,,,167.6,106.6,37.9,No,,,,Yes,,Ductal carcinoma in situ,1/25/2021,Right,1/25/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,,X,,,Ductal,,2,70,High," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB0952,,,167.6,106.6,37.9,No,,,,Yes,,Ductal carcinoma in situ,1/25/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.8,,,,,,,,,,,,,,,,
BCSB0952,,,167.6,106.6,37.9,No,,,,Yes,,Ductal carcinoma in situ,1/25/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.6,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1000,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0986,,,177.8,68,21.5,No,,,,Yes,,Ductal carcinoma in situ,3/12/2020,Left,3/12/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,3,,," ER+, PR+, HER2-",90,3,70,2,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,28,,,,,,
BCSB0986,,,177.8,68,21.5,No,,,,Yes,,Ductal carcinoma in situ,3/12/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.7,,,,,,,,,,28,,,,,,
BCSB0986,,,177.8,68,21.5,No,,,,Yes,,Ductal carcinoma in situ,3/12/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,1.9,"after surgical intervention, after neoadjuvant treatment",1.9,0.1,,28,,,,,,
BCSB0997,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0816,,,161.3,71.6,27.5,No,,,,Yes,,Ductal carcinoma in situ,9/16/2022,Left,9/16/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,X,,,X,Ductal,,2,15,Low," ER+, PR+, HER2-",100,3,90,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,17,,,,,,
BCSB0816,,,161.3,71.6,27.5,No,,,,Yes,,Ductal carcinoma in situ,9/16/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,2.2,,,,,,,,,,17,,,,,,
BCSB0816,,,161.3,71.6,27.5,No,,,,Yes,,Ductal carcinoma in situ,9/16/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,2.2,"after surgical intervention, after neoadjuvant treatment",2.5,1.6,other focus 0.5cm,17,,,,,,
BCSB0970,,,182.8,114.7,34.3,Yes,Atypical Lobular Hyperplasia,9/6/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/6/2023,Right,3/15/2023,Invasive lobular carcinoma,T3:Tumor >5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,X,,,,Lobular,,2,1,Low," ER+, PR-, HER2-",92,3,0,0,2,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,14,,,,,,
BCSB0970,,,182.8,114.7,34.3,Yes,Atypical Lobular Hyperplasia,9/6/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/6/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,7,,,,,,,,,,14,,,,,,
BCSB0970,,,182.8,114.7,34.3,Yes,Atypical Lobular Hyperplasia,9/6/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/6/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.5,4.9,"after surgical intervention, after neoadjuvant treatment",3.4,1,,14,,,,,,
BCSB1004,,,167.6,78,27.8,Yes,Atypical Lobular Hyperplasia,5/15/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/15/2023,Right,5/15/2023,Invasive lobular carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Lobular,,1,,," ER+, PR+, HER2-",100,3,90,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,8,,,,,,
BCSB1004,,,167.6,78,27.8,Yes,Atypical Lobular Hyperplasia,5/15/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/15/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,0.7,,,,,,,,,,8,,,,,,
BCSB1004,,,167.6,78,27.8,Yes,Atypical Lobular Hyperplasia,5/15/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/15/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.7,"after surgical intervention, but before chemo or radiation",2,0.2,,8,,,,,,
BCSB1005,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1003,,,172.7,86.1,28.9,Yes,Fibroadenoma,1/1/1999,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/7/2023,Left,9/7/2023,Invasive lobular carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,2,1,Low," ER+, PR+, HER2-",80,3,70,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1003,,,172.7,86.1,28.9,Yes,Fibroadenoma,1/1/1999,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/7/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.6,,,,,,,,,,,,,,,,
BCSB1003,,,172.7,86.1,28.9,Yes,Fibroadenoma,1/1/1999,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",9/7/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,0.6,"after surgical intervention, but before chemo or radiation",1.4,0.4,,,,,,,,
BCSB1009,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1013,,,180.3,83.9,25.8,Yes,Atypical Lobular Hyperplasia,11/3/2020,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",11/3/2020,"Left, Right breast on 12/14/2020",11/3/2020,Invasive lobular carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,1,5,Low," ER+, PR+, HER2-",85,3,85,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,8,,,,,,
BCSB1013,,,180.3,83.9,25.8,Yes,Atypical Lobular Hyperplasia,11/3/2020,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",11/3/2020,"Left, Right breast on 12/14/2020",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.9,,,,,,,,,,8,,,,,,
BCSB1013,,,180.3,83.9,25.8,Yes,Atypical Lobular Hyperplasia,11/3/2020,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",11/3/2020,"Left, Right breast on 12/14/2020",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,0.9,"after surgical intervention, but before chemo or radiation",1.7,0.15,,8,,,,,,
BCSB1018,,,165.1,56.7,20.8,No,,,,Yes,,Ductal carcinoma in situ,1/13/2021,Left,1/13/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,X,,,X,Ductal,,3,35,High," ER+, PR+, HER2-",80,3,20,2,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1018,,,165.1,56.7,20.8,No,,,,Yes,,Ductal carcinoma in situ,1/13/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.4,and a 0.4cm focus,,,,,,,,,,,,,,,
BCSB1018,,,165.1,56.7,20.8,No,,,,Yes,,Ductal carcinoma in situ,1/13/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,2.4,"after surgical intervention, after neoadjuvant treatment",1.3,0.5,,,,,,,,
BCSB1014,,,172.7,58.1,19.5,Yes,Breast Cysts,4/8/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/25/2023,Left,8/25/2023,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,2,10,Low," ER+, PR+, HER2-",99,3,80,3,2,Non-amplified,"ER+ PR+ HER2- ,  Biopsy report indicated HER2 Positive (FISH: Amplified)",,,,,,,,,,,,,,,,,18,,,,,,
BCSB1014,,,172.7,58.1,19.5,Yes,Breast Cysts,4/8/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/25/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.1,,,,,,,,,,18,,,,,,
BCSB1014,,,172.7,58.1,19.5,Yes,Breast Cysts,4/8/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/25/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,1.2,"after surgical intervention, but before chemo or radiation",0.7,0.4,,18,,,,,,
BCSB1023,,,167.6,79.4,28.3,No,,,,Yes,,Ductal carcinoma in situ,2/7/2023,Left,5/10/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,X,,,,Ductal,,3,80,High," ER-, PR-, HER2-",0,0,0,0,0,Non-amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB1023,,,167.6,79.4,28.3,No,,,,Yes,,Ductal carcinoma in situ,2/7/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,2.7,,,,,,,,,,,,,,,,
BCSB1023,,,167.6,79.4,28.3,No,,,,Yes,,Ductal carcinoma in situ,2/7/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,2.7,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB0738,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0984,,,152.4,74.8,32.2,Yes,Breast Cysts,1/21/2020,Left,Yes,,Ductal carcinoma in situ,1/20/2021,Left,1/20/2021,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,X,,,,Ductal,,2,,," ER+, PR+, HER2-",95,3,60,2,Unknown,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0984,,,152.4,74.8,32.2,Yes,Breast Cysts,1/21/2020,Left,Yes,,Ductal carcinoma in situ,1/20/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.2,,,,,,,,,,,,,,,,
BCSB0984,,,152.4,74.8,32.2,Yes,Breast Cysts,1/21/2020,Left,Yes,,Ductal carcinoma in situ,1/20/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,2.2,"after surgical intervention, after neoadjuvant treatment",2,2.5,,,,,,,,
BCSB0991,,,162.5,65.3,24.7,No,,,,No,,,,,10/9/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,3,50,High," ER-, PR-, HER2-",3,1,0,0,0,Unknown,"Triple Negative, ER low positive",,,,,,,,,,,,,,,,,59,,,,,,
BCSB0991,,,162.5,65.3,24.7,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.2,,,,,,,,,,59,,,,,,
BCSB0991,,,162.5,65.3,24.7,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.4,2.2,"after surgical intervention, but before chemo or radiation",2.2,0.3,,59,,,,,,
BCSB1017,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1033,,,157.4,56.7,22.9,No,,,,No,,,,,6/8/2023,Invasive lobular carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,3,20,High," ER+, PR-, HER2-",90,3,0,0,2,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,37,,,,,,
BCSB1033,,,157.4,56.7,22.9,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.6,,,,,,,,,,37,,,,,,
BCSB1033,,,157.4,56.7,22.9,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.6,"after surgical intervention, but before chemo or radiation",1.9,0.2,,37,,,,,,
BCSB1012,,,162.6,89.8,34,Yes,Atypical Lobular Hyperplasia,10/14/2018,Left,Yes,,Ductal carcinoma in situ,6/28/2018,Left,6/4/2018,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,3,70,High," HER2+, ER-, PR-",0,0,0,0,2,Amplified,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB1012,,,162.6,89.8,34,Yes,Atypical Lobular Hyperplasia,10/14/2018,Left,Yes,,Ductal carcinoma in situ,6/28/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.9,,,,,,,,,,,,,,,,
BCSB1012,,,162.6,89.8,34,Yes,Atypical Lobular Hyperplasia,10/14/2018,Left,Yes,,Ductal carcinoma in situ,6/28/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,2.1,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1016,,,170.2,69.9,24.1,Yes,Calcifications,11/23/2021,Right,Yes,,Ductal carcinoma in situ,11/23/2021,Right,11/23/2021,Invasive ductal carcinoma,,,,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,X,Ductal,,2,30,High," ER+, PR+, HER2-",100,3,95,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,0,,,,,,
BCSB1016,,,170.2,69.9,24.1,Yes,Calcifications,11/23/2021,Right,Yes,,Ductal carcinoma in situ,11/23/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.8,,,,,,,,,,0,,,,,,
BCSB1016,,,170.2,69.9,24.1,Yes,Calcifications,11/23/2021,Right,Yes,,Ductal carcinoma in situ,11/23/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3,0.4,"after surgical intervention, but before chemo or radiation",0.9,0.6,Second tumor: 0.7cm,0,,,,,,
BCSB1026,,,162.6,60.8,23,Yes,Fibrocystic Breast Changes,1/3/2023,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/1/2022,Right,12/1/2022,Invasive lobular carcinoma,,,,T3:Tumor >5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,,Stage IIIb,,X,,,Lobular,,2,,," ER+, PR+, HER2-",95,3,95,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,9,,,,,,
BCSB1026,,,162.6,60.8,23,Yes,Fibrocystic Breast Changes,1/3/2023,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/1/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,9.2,,,,,,,,,,9,,,,,,
BCSB1026,,,162.6,60.8,23,Yes,Fibrocystic Breast Changes,1/3/2023,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/1/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,9,"after surgical intervention, but before chemo or radiation",6.9,1.1,,9,,,,,,
BCSB1036,,,162.6,52.6,19.9,Yes,Calcifications,12/8/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/8/2023,Right,12/8/2023,Invasive lobular carcinoma,,,,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,,Stage IIa,,X,,,Lobular,,2,,," ER+, PR+, HER2-",91,3,91,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,12,,,,,,
BCSB1036,,,162.6,52.6,19.9,Yes,Calcifications,12/8/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/8/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,1.3,,,,,,,,,,12,,,,,,
BCSB1036,,,162.6,52.6,19.9,Yes,Calcifications,12/8/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",12/8/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.3,"after surgical intervention, but before chemo or radiation",3.2,0.5,,12,,,,,,
BCSB1038,,,147.3,54.4,25.1,No,,,,Yes,,Ductal carcinoma in situ,5/1/2023,"Left, and LCIS",5/1/2023,Mixed IDC+ILC (50 -90% each component),T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,X,,,X,Other,,2,20,High," ER+, PR+, HER2-",100,3,100,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,13,,,,,,
BCSB1038,,,147.3,54.4,25.1,No,,,,Yes,,Ductal carcinoma in situ,5/1/2023,"Left, and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,,,,,,,,,,13,,,,,,
BCSB1038,,,147.3,54.4,25.1,No,,,,Yes,,Ductal carcinoma in situ,5/1/2023,"Left, and LCIS",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.3,"after surgical intervention, but before chemo or radiation",1.2,0,"plus 4 more foci: 0.3cm, 0.3cm, 0.35cm, 0.6cm",13,,,,,,
BCSB1007,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1034,,,160,67.6,26.4,Yes,Fibroadenoma,6/29/2023,Right,Yes,,Ductal carcinoma in situ,6/2/2023,Left,6/2/2023,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,X,Ductal,,3,30,High," ER+, PR+, HER2+",20,2,20,1,3+,Unknown,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB1034,,,160,67.6,26.4,Yes,Fibroadenoma,6/29/2023,Right,Yes,,Ductal carcinoma in situ,6/2/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,"Biopsy-proven malignancies in the lateral left breast span up to 5.5
cm",,,,,,,,,,,,,,,
BCSB1034,,,160,67.6,26.4,Yes,Fibroadenoma,6/29/2023,Right,Yes,,Ductal carcinoma in situ,6/2/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.4,"after surgical intervention, after neoadjuvant treatment",0,0,second focus: 1.2cm,,,,,,,
BCSB1030,,,172.7,77.4,26,Yes,Breast Cysts,1/29/2020,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/17/2020,Right,2/17/2020,Invasive lobular carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,,Lobular,,2,,," ER+, PR+, HER2-",90,3,90,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,
BCSB1030,,,172.7,77.4,26,Yes,Breast Cysts,1/29/2020,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/17/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.2,,,,,,,,,,11,,,,,,
BCSB1030,,,172.7,77.4,26,Yes,Breast Cysts,1/29/2020,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/17/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.3,1.1,"after surgical intervention, but before chemo or radiation",1.5,0.2,,11,,,,,,
BCSB1037,,,170.2,113.4,39.1,No,,,,Yes,,Ductal carcinoma in situ,6/14/2023,Right,4/11/2023,Invasive ductal carcinoma,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ib,,X,,,Ductal,,2,21.82,High," ER+, PR+, HER2-",96.45,3,95.66,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,4,,,,,,
BCSB1037,,,170.2,113.4,39.1,No,,,,Yes,,Ductal carcinoma in situ,6/14/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.43,,,,,,,,,,4,,,,,,
BCSB1037,,,170.2,113.4,39.1,No,,,,Yes,,Ductal carcinoma in situ,6/14/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.4,0.43,"after surgical intervention, but before chemo or radiation",0.75,0.475,,4,,,,,,
BCSB1062,,,160,77.5,30.3,Yes,Flat Epithelial Atypia,11/1/2019,Left,Yes,,Ductal carcinoma in situ,11/1/2019,Left,11/1/2019,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,X,Ductal,,1,,," ER+, PR+, HER2-",75,2,80,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,10,,,,,,
BCSB1062,,,160,77.5,30.3,Yes,Flat Epithelial Atypia,11/1/2019,Left,Yes,,Ductal carcinoma in situ,11/1/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.3,,,,,,,,,,10,,,,,,
BCSB1062,,,160,77.5,30.3,Yes,Flat Epithelial Atypia,11/1/2019,Left,Yes,,Ductal carcinoma in situ,11/1/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,1.3,"after surgical intervention, but before chemo or radiation",1.7,1,,10,,,,,,
BCSB0999,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1002,,,162,102.2,38.9,No,,,,Yes,,Ductal carcinoma in situ,1/16/2023,Bilateral,1/16/2023,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,,X,,X,Ductal,,2,25,High," ER+, PR+, HER2-",95,3,95,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,15,,,,,,
BCSB1002,,,162,102.2,38.9,No,,,,Yes,,Ductal carcinoma in situ,1/16/2023,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.9,and 1.5cm,,,,,,,,,15,,,,,,
BCSB1002,,,162,102.2,38.9,No,,,,Yes,,Ductal carcinoma in situ,1/16/2023,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,1.9,"after surgical intervention, but before chemo or radiation",4.3,1,second focus: 2.9cm,15,,,,,,
BCSB1015,,,175.3,104.3,33.9,Yes,Fibrocystic Breast Changes,8/15/2016,Right,No,,,,,2/5/2016,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,X,,,,Ductal,,2,,," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB1015,,,175.3,104.3,33.9,Yes,Fibrocystic Breast Changes,8/15/2016,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,1.4,,,,,,,,,,,,,,,,
BCSB1015,,,175.3,104.3,33.9,Yes,Fibrocystic Breast Changes,8/15/2016,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.2,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1042,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1045,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1067,,,175.3,70.3,22.9,Yes,Fibroadenoma,1/17/2020,Left,Yes,,Ductal carcinoma in situ,12/21/2023,Left,12/21/2023,Noninvasive carcinoma (NOS),Tis:DCIS/LCIS/Paget's dis w/o associated tumor,N0: No regional LNs metastasis,,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,NX: Regional LNs cannot be assessed,,Stage 0,X,,,,Ductal,,,,," ER+, PR+",95,3,95,3,,,"ER+ PR+,  No invasive carcinoma was diagnosed.  The participant was diagnosed with DCIS.",,,,,,,,,,,,,,,,,,,,,,,
BCSB1067,,,175.3,70.3,22.9,Yes,Fibroadenoma,1/17/2020,Left,Yes,,Ductal carcinoma in situ,12/21/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.7,,,,,,,,,,,,,,,,
BCSB1067,,,175.3,70.3,22.9,Yes,Fibroadenoma,1/17/2020,Left,Yes,,Ductal carcinoma in situ,12/21/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3,0.7,"after surgical intervention, but before chemo or radiation",1,1,DCIS tumor,,,,,,,
BCSB1072,,,165.1,86.2,31.6,No,,,,Yes,,Ductal carcinoma in situ,2/16/2023,Right,2/16/2023,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,,," ER+, PR+, HER2-",97.4,3,79.8,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1072,,,165.1,86.2,31.6,No,,,,Yes,,Ductal carcinoma in situ,2/16/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.65,,,,,,,,,,,,,,,,
BCSB1072,,,165.1,86.2,31.6,No,,,,Yes,,Ductal carcinoma in situ,2/16/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.3,0.8,"after surgical intervention, but before chemo or radiation",1.1,0.5,,,,,,,,
BCSB1083,,,158.7,84.3,33.5,Yes,Central Intraductal Papilloma,7/19/2021,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/26/2021,Right,5/26/2021,Invasive lobular carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,,X,,,Lobular,,2,13,Low," ER+, PR+, HER2-",90,3,98,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,16,,,,,,
BCSB1083,,,158.7,84.3,33.5,Yes,Central Intraductal Papilloma,7/19/2021,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/26/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.9,,,,,,,,,,16,,,,,,
BCSB1083,,,158.7,84.3,33.5,Yes,Central Intraductal Papilloma,7/19/2021,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/26/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,4,0.9,"after surgical intervention, but before chemo or radiation",2.5,1,,16,,,,,,
BCSB1039,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0649,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1035,,,167.6,79.4,28.3,No,,,,No,,,,,8/17/2023,Invasive lobular carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,2,18,Low," ER+, PR+, HER2-",95,3,93,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,
BCSB1035,,,167.6,79.4,28.3,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.6,,,,,,,,,,11,,,,,,
BCSB1035,,,167.6,79.4,28.3,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,0.65,"after surgical intervention, but before chemo or radiation",1.5,2,,11,,,,,,
BCSB1058,,,152.4,68.5,29.5,Yes,Fibrocystic Breast Changes,6/27/2017,Right,No,,,,,3/27/2023,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,2,10,Low," ER+, PR+, HER2-",80,2,30,1,0,Unknown,"ER+ PR+ HER2- , Simple stage after surgery: 1B",,,,,,,,,,,,,,,,,16,,,,,,
BCSB1058,,,152.4,68.5,29.5,Yes,Fibrocystic Breast Changes,6/27/2017,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,16,,,,,,
BCSB1058,,,152.4,68.5,29.5,Yes,Fibrocystic Breast Changes,6/27/2017,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,1.1,"after surgical intervention, but before chemo or radiation",2.2,0.2,,16,,,,,,
BCSB1073,,,162.6,57.6,21.8,Yes,Breast Cysts,5/10/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/26/2023,Left,4/26/2023,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,X,Lobular,,2,20,High," ER+, PR+, HER2-",91,3,91,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,17,,,,,,other focus Oncotype 15
BCSB1073,,,162.6,57.6,21.8,Yes,Breast Cysts,5/10/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/26/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,,,,,,,,,,17,,,,,,other focus Oncotype 15
BCSB1073,,,162.6,57.6,21.8,Yes,Breast Cysts,5/10/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/26/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,1.5,"after surgical intervention, but before chemo or radiation",2.5,0.1,other foci: from 0.4cm - 1.5cm,17,,,,,,other focus Oncotype 15
BCSB1076,,,165.1,72.1,26.5,Yes,Calcifications,7/25/2022,Right,Yes,,Ductal carcinoma in situ,8/15/2022,Right,10/13/2022,Invasive ductal carcinoma,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,28,High," ER+, PR-, HER2-",90,3,0,0,1,Unknown,"ER+ PR- HER2- , Invasive ductal carcinoma (IDC) was diagnosed during surgery to remove ductal carcinoma in situ (DCIS)",,,,,,,,,,,,,,,,,33,,,,,,
BCSB1076,,,165.1,72.1,26.5,Yes,Calcifications,7/25/2022,Right,Yes,,Ductal carcinoma in situ,8/15/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,,Invasive ductal carcinoma (IDC) was diagnosed during surgery to remove ductal carcinoma in situ (DCIS),,,,,,,,,33,,,,,,
BCSB1076,,,165.1,72.1,26.5,Yes,Calcifications,7/25/2022,Right,Yes,,Ductal carcinoma in situ,8/15/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",1.1,0.1,Invasive ductal carcinoma (IDC) was diagnosed during surgery to remove ductal carcinoma in situ (DCIS),33,,,,,,
BCSB1080,,,170.2,78,26.9,Yes,Calcifications,12/9/2021,Right,Yes,,Ductal carcinoma in situ,11/8/2021,Right,11/8/2021,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIa,,X,,X,Ductal,,3,,," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB1080,,,170.2,78,26.9,Yes,Calcifications,12/9/2021,Right,Yes,,Ductal carcinoma in situ,11/8/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,8.2,other masses: 2.8cm,,,,,,,,,,,,,,,
BCSB1080,,,170.2,78,26.9,Yes,Calcifications,12/9/2021,Right,Yes,,Ductal carcinoma in situ,11/8/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,8.2,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1081,,,172.7,68,22.8,Yes,Fibroadenoma,6/21/2023,Right,Yes,,Ductal carcinoma in situ,8/3/2023,Left,6/21/2023,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,X,,,X,Ductal,,2,10,Low," ER+, PR+, HER2-",95,3,95,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,8,,,,,,
BCSB1081,,,172.7,68,22.8,Yes,Fibroadenoma,6/21/2023,Right,Yes,,Ductal carcinoma in situ,8/3/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,8,,,,,,
BCSB1081,,,172.7,68,22.8,Yes,Fibroadenoma,6/21/2023,Right,Yes,,Ductal carcinoma in situ,8/3/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,1,"after surgical intervention, but before chemo or radiation",5,0.5,,8,,,,,,
BCSB1091,,,137.2,72,38.2,Yes,Breast Cysts,7/31/2019,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/24/2021,Right,5/24/2021,Invasive lobular carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,X,Lobular,,2,,," ER+, PR+, HER2-",90,3,2,1,Not performed,Non-amplified,"ER+ PR+ HER2- , Stage 2a after surgery",,,,,,,,,,,,,,,,,21,,,,,,
BCSB1091,,,137.2,72,38.2,Yes,Breast Cysts,7/31/2019,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/24/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,21,,,,,,
BCSB1091,,,137.2,72,38.2,Yes,Breast Cysts,7/31/2019,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/24/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,1,"after surgical intervention, but before chemo or radiation",3.5,0.1,,21,,,,,,
BCSB1066,,,151,65.8,28.9,Unknown,,,,No,,,,,9/30/2020,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIa,,X,,X,Ductal,,3,,," HER2+, ER-, PR-",0,0,0,0,3+,Amplified,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB1066,,,151,65.8,28.9,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,9,,,,,,,,,,,,,,,,
BCSB1066,,,151,65.8,28.9,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,9,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1053,,,167.6,83.9,29.9,Unknown,,,,Yes,,Ductal carcinoma in situ,8/24/2021,Right,8/24/2021,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIa,,X,,,Ductal,,3,90,High," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB1053,,,167.6,83.9,29.9,Unknown,,,,Yes,,Ductal carcinoma in situ,8/24/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,7.7,,,,,,,,,,,,,,,,
BCSB1053,,,167.6,83.9,29.9,Unknown,,,,Yes,,Ductal carcinoma in situ,8/24/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,7,"after surgical intervention, after neoadjuvant treatment",0.15,0.1,,,,,,,,
BCSB1054,,,175.3,59,19.2,Yes,Atypical Lobular Hyperplasia,2/9/2021,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/23/2021,Bilateral,2/9/2021,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,,T1b:>0.5 cm but <=1.0 cm,pN0(i+),,Stage Ia,,X,,X,Ductal,,2,17,Low," ER+, PR+, HER2-",100,3,30,2,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1054,,,175.3,59,19.2,Yes,Atypical Lobular Hyperplasia,2/9/2021,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/23/2021,Bilateral,2/9/2021,Invasive lobular carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,,T1b:>0.5 cm but <=1.0 cm,pN0(i+),,Stage Ia,,X,,X,Lobular,,2,9,Low," ER+, PR+, HER2-",100,3,70,2,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1054,,,175.3,59,19.2,Yes,Atypical Lobular Hyperplasia,2/9/2021,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/23/2021,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.9,Invasive Ductal Carcinoma,,,,,,,,,,,,,,,
BCSB1054,,,175.3,59,19.2,Yes,Atypical Lobular Hyperplasia,2/9/2021,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/23/2021,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,0.5,Invasive Lobular Carcinoma,,,,,,,,,,,,,,,
BCSB1054,,,175.3,59,19.2,Yes,Atypical Lobular Hyperplasia,2/9/2021,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/23/2021,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,0.9,"after surgical intervention, but before chemo or radiation",0.9,0.2,Invasive Ductal Carcinoma,,,,,,,
BCSB1054,,,175.3,59,19.2,Yes,Atypical Lobular Hyperplasia,2/9/2021,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",4/23/2021,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,1.5,0.5,"after surgical intervention, but before chemo or radiation",0.5,0.5,"Invasive Lobular Carcinoma, other focus 0.4cm",,,,,,,
BCSB1074,,,180.3,61.2,18.8,No,,,,Yes,,Ductal carcinoma in situ,1/25/2023,in Right breast and LCIS in Left breast,1/25/2023,Inflammatory breast cancer,T4d:Inflammatory carcinoma,N2: Ipsilateral axillary LN(s) fixed,M0: No distant metastasis,T4d:Inflammatory carcinoma,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIc,,X,,X,Other,Unfavorable: Inflammatory,2,29,High," ER+, HER2+, PR-",49,2,0.2,1,3+,Amplified,"ER+ PR- HER2+ , Ductal",,,,,,,,,,,,,,,,,,,,,,,
BCSB1074,,,180.3,61.2,18.8,No,,,,Yes,,Ductal carcinoma in situ,1/25/2023,in Right breast and LCIS in Left breast,2/22/2023,Invasive lobular carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,X,,,X,Lobular,,1,16,Low," ER+, PR+, HER2-",65,2,90,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1074,,,180.3,61.2,18.8,No,,,,Yes,,Ductal carcinoma in situ,1/25/2023,in Right breast and LCIS in Left breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,,Right,,,,,,,,,,,,,,,
BCSB1074,,,180.3,61.2,18.8,No,,,,Yes,,Ductal carcinoma in situ,1/25/2023,in Right breast and LCIS in Left breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,4.9,Left,,,,,,,,,,,,,,,
BCSB1074,,,180.3,61.2,18.8,No,,,,Yes,,Ductal carcinoma in situ,1/25/2023,in Right breast and LCIS in Left breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,,"after surgical intervention, after neoadjuvant treatment",,0.9,Right,,,,,,,
BCSB1074,,,180.3,61.2,18.8,No,,,,Yes,,Ductal carcinoma in situ,1/25/2023,in Right breast and LCIS in Left breast,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,1.5,4.9,"after surgical intervention, after neoadjuvant treatment",3.5,0.5,Left,,,,,,,
BCSB1085,,,162.6,78.9,29.8,No,,,,Yes,,Ductal carcinoma in situ,12/14/2019,Left,12/27/2018,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,1,42,High," ER+, PR+, HER2-",93,2,84,2,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,LOW RISK LUMINAL-TYPE A,,,,,
BCSB1085,,,162.6,78.9,29.8,No,,,,Yes,,Ductal carcinoma in situ,12/14/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,,LOW RISK LUMINAL-TYPE A,,,,,
BCSB1085,,,162.6,78.9,29.8,No,,,,Yes,,Ductal carcinoma in situ,12/14/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.4,1,"after surgical intervention, but before chemo or radiation",1.2,0.3,,,LOW RISK LUMINAL-TYPE A,,,,,
BCSB1095,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1105,,,167.6,77.1,27.4,No,,,,Yes,,Ductal carcinoma in situ,8/4/2022,Left,8/4/2022,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIa,X,,,X,Ductal,,3,,," HER2+, ER-, PR-",0,0,0,0,3+,Amplified,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB1105,,,167.6,77.1,27.4,No,,,,Yes,,Ductal carcinoma in situ,8/4/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,9.4,,,,,,,,,,,,,,,,
BCSB1105,,,167.6,77.1,27.4,No,,,,Yes,,Ductal carcinoma in situ,8/4/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.4,9.4,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1086,,,167.6,85.7,30.5,Yes,Breast Cysts,1/1/2016,Left,Yes,,Ductal carcinoma in situ,12/30/2019,Left,7/9/2019,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",90,3,90,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,
BCSB1086,,,167.6,85.7,30.5,Yes,Breast Cysts,1/1/2016,Left,Yes,,Ductal carcinoma in situ,12/30/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.8,,,,,,,,,,11,,,,,,
BCSB1086,,,167.6,85.7,30.5,Yes,Breast Cysts,1/1/2016,Left,Yes,,Ductal carcinoma in situ,12/30/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.3,1.1,"after surgical intervention, but before chemo or radiation",2,1.1,,11,,,,,,
BCSB0395,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1025,,,157.5,98.4,39.7,No,,,,Yes,,Ductal carcinoma in situ,5/25/2023,Left,5/25/2023,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,0,Low," ER+, PR+, HER2-",100,3,60,2,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,14,,,,,,
BCSB1025,,,157.5,98.4,39.7,No,,,,Yes,,Ductal carcinoma in situ,5/25/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.6,,,,,,,,,,14,,,,,,
BCSB1025,,,157.5,98.4,39.7,No,,,,Yes,,Ductal carcinoma in situ,5/25/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,0.6,"after surgical intervention, but before chemo or radiation",0.9,0.5,,14,,,,,,
BCSB1043,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1098,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0519,,,166,94.7,34.4,Yes,Breast Cysts,1/1/1999,"Right, and 2006",Yes,,Ductal carcinoma in situ,12/11/2018,Right,4/11/2019,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,,," ER+, PR+, HER2-",80,3,60,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0519,,,166,94.7,34.4,Yes,Breast Cysts,1/1/1999,"Right, and 2006",Yes,,Ductal carcinoma in situ,12/11/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,,Biopsy indicated DCIS. IDC was diagnosed during surgery.,,,,,,,,,,,,,,,
BCSB0519,,,166,94.7,34.4,Yes,Breast Cysts,1/1/1999,"Right, and 2006",Yes,,Ductal carcinoma in situ,12/11/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",0.2,0.5,,,,,,,,
BCSB1046,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1096,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1099,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1101,,,157.5,54.4,21.9,No,,,,Yes,,Ductal carcinoma in situ,6/16/2023,Left,6/16/2023,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,X,,,X,Ductal,,2,15,Low," ER+, PR+, HER2-",90,3,10,1,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1101,,,157.5,54.4,21.9,No,,,,Yes,,Ductal carcinoma in situ,6/16/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2,,,,,,,,,,,,,,,,
BCSB1101,,,157.5,54.4,21.9,No,,,,Yes,,Ductal carcinoma in situ,6/16/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,1.2,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1041,,,167.6,81.6,29,Yes,Fibrocystic Breast Changes,5/11/2020,Right,Yes,,Ductal carcinoma in situ,3/16/2020,Right,3/16/2020,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,,Stage Ib,,X,,,Ductal,,2,8,Low," ER+, PR+, HER2-",85,3,100,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,"Low risk, luminal type A",,,,,
BCSB1041,,,167.6,81.6,29,Yes,Fibrocystic Breast Changes,5/11/2020,Right,Yes,,Ductal carcinoma in situ,3/16/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.7,,,,,,,,,,,"Low risk, luminal type A",,,,,
BCSB1041,,,167.6,81.6,29,Yes,Fibrocystic Breast Changes,5/11/2020,Right,Yes,,Ductal carcinoma in situ,3/16/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,0.7,"after surgical intervention, but before chemo or radiation",1.5,0.3,,,"Low risk, luminal type A",,,,,
BCSB1103,,,167.6,79.4,28.3,No,,,,Yes,,Ductal carcinoma in situ,12/18/2020,Left,12/18/2020,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,X,Ductal,,2,,," ER+, PR+, HER2-",95,3,87,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,6,,,,,,
BCSB1103,,,167.6,79.4,28.3,No,,,,Yes,,Ductal carcinoma in situ,12/18/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.9,and 0.85cm,,,,,,,,,6,,,,,,
BCSB1103,,,167.6,79.4,28.3,No,,,,Yes,,Ductal carcinoma in situ,12/18/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,0.9,"after surgical intervention, but before chemo or radiation",1.8,,second focus: 1cm,6,,,,,,
BCSB0884,,,175.3,72.6,23.6,Yes,Fibrocystic Breast Changes,,Left,No,,,,,8/12/2020,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,,Stage IIa,,X,,,Ductal,,2,90,High," ER+, HER2+, PR-",25,1,0,0,3+,Amplified,ER+ PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB0884,,,175.3,72.6,23.6,Yes,Fibrocystic Breast Changes,,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,4.4,MRI,,,,,,,,,,,,,,,
BCSB0884,,,175.3,72.6,23.6,Yes,Fibrocystic Breast Changes,,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.3,2.4,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1077,,,172.7,77.6,26,Yes,Atypical Lobular Hyperplasia,10/5/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/17/2022,Left,8/17/2022,Invasive lobular carcinoma,,,,T2:Tumor >2.0 cm but <=5.0 cm,pN3: to ipsilateral internal mammary LN(s),,Stage IIIb,X,,,X,Lobular,,2,5,Low," ER+, PR-, HER2-",100,3,0,0,0,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,13,,,,,,
BCSB1077,,,172.7,77.6,26,Yes,Atypical Lobular Hyperplasia,10/5/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/17/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.5,"other masses: 1.4cm, 1.1cm",,,,,,,,,13,,,,,,
BCSB1077,,,172.7,77.6,26,Yes,Atypical Lobular Hyperplasia,10/5/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/17/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.5,"after surgical intervention, but before chemo or radiation",3.4,0.1,Tumor size: Ranging from 3.4 cm - 1.2 cm,13,,,,,,
BCSB1116,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1119,,,154.9,63,26.3,Yes,Fibrocystic Breast Changes,12/26/2017,Left,Yes,,Ductal carcinoma in situ,11/24/2017,Left,11/24/2017,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,Favorable: mucinous,3,,," ER+, PR-, HER2-",100,3,0,0,0,Unknown,ER+ PR- HER2-,,,,,,,,,,,,,,,,,31,,,,,,
BCSB1119,,,154.9,63,26.3,Yes,Fibrocystic Breast Changes,12/26/2017,Left,Yes,,Ductal carcinoma in situ,11/24/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.9,,,,,,,,,,31,,,,,,
BCSB1119,,,154.9,63,26.3,Yes,Fibrocystic Breast Changes,12/26/2017,Left,Yes,,Ductal carcinoma in situ,11/24/2017,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,2.9,"after surgical intervention, but before chemo or radiation",2.8,0.4,,31,,,,,,
BCSB1070,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1107,,,165.1,113.4,41.6,Yes,Calcifications,7/28/2017,Right,Yes,,Ductal carcinoma in situ,1/9/2018,Right,3/19/2018,Invasive ductal carcinoma,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,,M0: No distant metastasis,TX:Primary tumor cannot be assessed,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,50,High," ER+, PR+, HER2-",99,3,10,2,0,Non-amplified,"ER+ PR+ HER2-
Metastatic adenocarcinoma in one Lymph node, consistent with breast primary by immunohistochemistry and measuring 0.6 x 0.3 cm. There is no evidence of invasive carcinoma in the breast specimen. There was a high amount of inflammation from the post biopsy changes. The pathologist thought that it is possible that the invasive component was obscured with the inflammation.",,,,,,,,,,,,,,,,,,,,,,,
BCSB1107,,,165.1,113.4,41.6,Yes,Calcifications,7/28/2017,Right,Yes,,Ductal carcinoma in situ,1/9/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,,,,,,,,,,,,,,,,,
BCSB1107,,,165.1,113.4,41.6,Yes,Calcifications,7/28/2017,Right,Yes,,Ductal carcinoma in situ,1/9/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",,,"No invasive cancer on final pathology but 1.2cm DCIS with inflammatory changes and multiple foci of lymphovascular space involvement, Metastatic adenocarcinoma in one Lymph node, consistent with breast primary by immunohistochemistry and measuring 0.6 x 0.3 cm",,,,,,,
BCSB1104,,,157.5,61.2,24.7,Yes,Atypical Ductal Hyperplasia,2/15/2023,Right,Yes,,Ductal carcinoma in situ,2/15/2023,Right,4/4/2023,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,X,Ductal,,1,15,Low," ER+, PR+, HER2-",90,3,99,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,
BCSB1104,,,157.5,61.2,24.7,Yes,Atypical Ductal Hyperplasia,2/15/2023,Right,Yes,,Ductal carcinoma in situ,2/15/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.9,,,,,,,,,,11,,,,,,
BCSB1104,,,157.5,61.2,24.7,Yes,Atypical Ductal Hyperplasia,2/15/2023,Right,Yes,,Ductal carcinoma in situ,2/15/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.9,"after surgical intervention, but before chemo or radiation",0.8,0.13,second focus: 0.12cm,11,,,,,,
BCSB1111,,,154.9,53.1,22.1,Yes,Breast Cysts,1/1/2014,Right,Yes,,Ductal carcinoma in situ,4/25/2022,Right,4/25/2022,Molecular Apocrine breast cancer,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,,X,,,Ductal,,3,17,Low," ER-, PR-, HER2-",0,0,0,0,2,Non-amplified,"Triple Negative, androgen receptor 100% positive",,,,,,,,,,,,,,,,,,,,,,,
BCSB1111,,,154.9,53.1,22.1,Yes,Breast Cysts,1/1/2014,Right,Yes,,Ductal carcinoma in situ,4/25/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,,,,,,,
BCSB1111,,,154.9,53.1,22.1,Yes,Breast Cysts,1/1/2014,Right,Yes,,Ductal carcinoma in situ,4/25/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.9,1,"after surgical intervention, but before chemo or radiation",1.2,0.65,,,,,,,,
BCSB1115,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1118,,,168.9,86.2,30.2,No,,,,No,,,,,8/7/2023,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,,Ductal,,2,,," ER+, PR+, HER2+",100,3,3,2,3+,Unknown,Triple Positive,,,,,,,,,,,,,,,,,,,,,,1,"MRD Monitoring with Signatera: Negative 02/09/24, Negative 07/06/24"
BCSB1118,,,168.9,86.2,30.2,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.6,,,,,,,,,,,,,,,1,"MRD Monitoring with Signatera: Negative 02/09/24, Negative 07/06/24"
BCSB1118,,,168.9,86.2,30.2,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.45,"after surgical intervention, but before chemo or radiation",0.7,0.7,,,,,,,1,"MRD Monitoring with Signatera: Negative 02/09/24, Negative 07/06/24"
BCSB1131,,,172.7,64.4,21.6,No,,,,No,,,,,9/29/2020,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,,Ductal,,3,,," ER+, PR-, HER2-",80,3,0,0,1,Unknown,ER+ PR- HER2-,,,,,,,,,,,,,,,,,43,,,,,,
BCSB1131,,,172.7,64.4,21.6,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.4,,,,,,,,,,43,,,,,,
BCSB1131,,,172.7,64.4,21.6,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.1,1.4,"after surgical intervention, but before chemo or radiation",1.4,0.2,,43,,,,,,
BCSB1135,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1141,,,160,69.4,27.1,No,,,,Yes,,Ductal carcinoma in situ,4/26/2023,Left,4/26/2023,Invasive ductal carcinoma,,,,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,,Ductal,,2,14,Low," ER+, PR+, HER2-",80,2,100,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,18,,,,,,
BCSB1141,,,160,69.4,27.1,No,,,,Yes,,Ductal carcinoma in situ,4/26/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.7,,,,,,,,,,18,,,,,,
BCSB1141,,,160,69.4,27.1,No,,,,Yes,,Ductal carcinoma in situ,4/26/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.5,"after surgical intervention, but before chemo or radiation",0.6,0.1,,18,,,,,,
BCSB1142,,,162.6,74.8,28.3,Yes,Fibroadenoma,2/12/2019,"Right, Calcifications on 01/16/2019",Yes,,Ductal carcinoma in situ,2/21/2019,Right,1/16/2019,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,,X,,X,Ductal,,3,15,Low," ER+, PR+, HER2-",100,3,90,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,high risk luminal type B,,,,,
BCSB1142,,,162.6,74.8,28.3,Yes,Fibroadenoma,2/12/2019,"Right, Calcifications on 01/16/2019",Yes,,Ductal carcinoma in situ,2/21/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,3.4,,,,,,,,,,,high risk luminal type B,,,,,
BCSB1142,,,162.6,74.8,28.3,Yes,Fibroadenoma,2/12/2019,"Right, Calcifications on 01/16/2019",Yes,,Ductal carcinoma in situ,2/21/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,3.3,"after surgical intervention, but before chemo or radiation",4,0.1,,,high risk luminal type B,,,,,
BCSB1150,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1132,,,165.1,90.7,33.3,Yes,Calcifications,6/6/2022,Right,Yes,,Ductal carcinoma in situ,7/25/2022,Right,7/25/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,10,Low," ER+, PR+, HER2-",90,3,80,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1132,,,165.1,90.7,33.3,Yes,Calcifications,6/6/2022,Right,Yes,,Ductal carcinoma in situ,7/25/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.4,,,,,,,,,,,,,,,,
BCSB1132,,,165.1,90.7,33.3,Yes,Calcifications,6/6/2022,Right,Yes,,Ductal carcinoma in situ,7/25/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.4,0.4,"after surgical intervention, but before chemo or radiation",0.4,0.5,,,,,,,,
BCSB1122,,,167.6,60.8,21.6,Yes,Fibrocystic Breast Changes,1/25/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/23/2024,Left,2/23/2024,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,1,,," ER+, PR+, HER2-",100,3,94,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,"Ultra Low Risk, Index +0.569",,,,,
BCSB1122,,,167.6,60.8,21.6,Yes,Fibrocystic Breast Changes,1/25/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/23/2024,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.4,,,,,,,,,,,"Ultra Low Risk, Index +0.569",,,,,
BCSB1122,,,167.6,60.8,21.6,Yes,Fibrocystic Breast Changes,1/25/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/23/2024,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,1.4,"after surgical intervention, but before chemo or radiation",0.5,1.5,,,"Ultra Low Risk, Index +0.569",,,,,
BCSB0647,,,175.3,99.8,32.5,Yes,Fibroadenoma,1/22/2019,Left,Yes,,Ductal carcinoma in situ,3/13/2019,Left,1/22/2019,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,X,Ductal,,2,,," ER+, PR+, HER2-",90,2,98,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,18,,,,,,
BCSB0647,,,175.3,99.8,32.5,Yes,Fibroadenoma,1/22/2019,Left,Yes,,Ductal carcinoma in situ,3/13/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.6,,,,,,,,,,18,,,,,,
BCSB0647,,,175.3,99.8,32.5,Yes,Fibroadenoma,1/22/2019,Left,Yes,,Ductal carcinoma in situ,3/13/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,1.6,"after surgical intervention, but before chemo or radiation",1.4,0.16,other focus 0.41cm,18,,,,,,
BCSB0840,,,167.6,68,24.2,No,,,,Yes,,Ductal carcinoma in situ,8/16/2022,Left,5/16/2022,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,,Ductal,,2,,," ER+, PR-, HER2-",100,3,0,0,0,Unknown,ER+ PR- HER2-,,,,,,,,,,,,,,,,,25,,,,,,
BCSB0840,,,167.6,68,24.2,No,,,,Yes,,Ductal carcinoma in situ,8/16/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2,,,,,,,,,,25,,,,,,
BCSB0840,,,167.6,68,24.2,No,,,,Yes,,Ductal carcinoma in situ,8/16/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,1.2,"after surgical intervention, but before chemo or radiation",2.6,0.8,,25,,,,,,
BCSB1126,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1124,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1143,,,172.7,64.4,21.6,Yes,Breast Cysts,1/1/2009,,Yes,,Ductal carcinoma in situ,5/30/2019,Right,5/30/2019,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ib,,X,,,Ductal,,3,,," ER+, PR+, HER2+",100,3,80,2,3+,Unknown,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB1143,,,172.7,64.4,21.6,Yes,Breast Cysts,1/1/2009,,Yes,,Ductal carcinoma in situ,5/30/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,2.5,,,,,,,,,,,,,,,,
BCSB1143,,,172.7,64.4,21.6,Yes,Breast Cysts,1/1/2009,,Yes,,Ductal carcinoma in situ,5/30/2019,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.5,"after surgical intervention, after neoadjuvant treatment",0.2,,,,,,,,,
BCSB1162,,,160,70.8,27.7,Yes,Calcifications,7/13/2016,Left,Yes,,Ductal carcinoma in situ,10/4/2019,Left,8/16/2019,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",100,3,90,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,3,,,,,,
BCSB1162,,,160,70.8,27.7,Yes,Calcifications,7/13/2016,Left,Yes,,Ductal carcinoma in situ,10/4/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,3,,,,,,
BCSB1162,,,160,70.8,27.7,Yes,Calcifications,7/13/2016,Left,Yes,,Ductal carcinoma in situ,10/4/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,1.1,"after surgical intervention, but before chemo or radiation",0.9,0.3,,3,,,,,,
BCSB1166,,,157.4,78,31.5,Yes,Calcifications,8/12/2021,Left,Yes,,Ductal carcinoma in situ,8/12/2021,Left,8/12/2021,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N3: Ipsilateral internal mammary LN(s),M0: No distant metastasis,T1mic:Microinvasion <=0.1 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIc,X,,,,Ductal,,3,83,High," HER2+, ER-, PR-",0.5,1,0.3,1,3+,Amplified,ER- PR- HER2+,,,,,,,,,,,,,,,,,,,,,,,
BCSB1166,,,157.4,78,31.5,Yes,Calcifications,8/12/2021,Left,Yes,,Ductal carcinoma in situ,8/12/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,5.2,,,,,,,,,,,,,,,,
BCSB1166,,,157.4,78,31.5,Yes,Calcifications,8/12/2021,Left,Yes,,Ductal carcinoma in situ,8/12/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,5.2,"after surgical intervention, after neoadjuvant treatment",0.04,1,,,,,,,,
BCSB1144,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1145,,,167.6,93.9,33.4,No,,,,No,,,,,3/5/2018,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,X,,,,Ductal,,3,37,High," ER+, PR+, HER2+",73,2,85,2,3+,Unknown,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB1145,,,167.6,93.9,33.4,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,5.2,,,,,,,,,,,,,,,,
BCSB1145,,,167.6,93.9,33.4,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1,5.2,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1159,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1185,,,160,64.4,25.2,No,,,,Yes,,Ductal carcinoma in situ,10/6/2022,Right,11/11/2021,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),MX: cannot be assessed,T1mic:Microinvasion <=0.1 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage IIIa,,X,,X,Ductal,,3,67,High," ER-, PR-, HER2-",0,0,0,0,0,Non-amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB1185,,,160,64.4,25.2,No,,,,Yes,,Ductal carcinoma in situ,10/6/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,5.5,3.9cm and 1.6cm,,,,,,,,,,,,,,,
BCSB1185,,,160,64.4,25.2,No,,,,Yes,,Ductal carcinoma in situ,10/6/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,5.5,"after surgical intervention, after neoadjuvant treatment",0.1,0.75,,,,,,,,
BCSB1186,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0715,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0951,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1187,,,152.4,63.5,27.3,No,,,,No,,,,,1/23/2019,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,3,30,High," ER+, PR+, HER2-",98,3,25,1,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,34,,,,,,
BCSB1187,,,152.4,63.5,27.3,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.7,,,,,,,,,,34,,,,,,
BCSB1187,,,152.4,63.5,27.3,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.7,"after surgical intervention, but before chemo or radiation",2.2,0.5,,34,,,,,,
BCSB0756,,,160,68,26.6,No,,,,Yes,,Ductal carcinoma in situ,12/8/2021,Right,12/8/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,1,23,High," ER+, PR+, HER2-",98,3,95,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,5,,,,,,
BCSB0756,,,160,68,26.6,No,,,,Yes,,Ductal carcinoma in situ,12/8/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.6,,,,,,,,,,5,,,,,,
BCSB0756,,,160,68,26.6,No,,,,Yes,,Ductal carcinoma in situ,12/8/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3,2.2,"after surgical intervention, but before chemo or radiation",4,0.1,,5,,,,,,
BCSB1136,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1195,,,160,60.8,23.7,Yes,Fibrocystic Breast Changes,3/17/2020,Right,Yes,,Ductal carcinoma in situ,3/17/2020,Right,3/17/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIa,,X,,X,Ductal,,2,,," ER+, PR+, HER2-",95,2,95,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1195,,,160,60.8,23.7,Yes,Fibrocystic Breast Changes,3/17/2020,Right,Yes,,Ductal carcinoma in situ,3/17/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,and 0.9cm,,,,,,,,,,,,,,,
BCSB1195,,,160,60.8,23.7,Yes,Fibrocystic Breast Changes,3/17/2020,Right,Yes,,Ductal carcinoma in situ,3/17/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,2.2,"after surgical intervention, but before chemo or radiation",3.1,0.2,,,,,,,,
BCSB1027,,,170.2,79.4,27.4,No,,,,Yes,,Ductal carcinoma in situ,1/4/2024,Right,11/28/2023,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,,," ER+, PR+, HER2-",90,3,90,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,20,,,,,,
BCSB1027,,,170.2,79.4,27.4,No,,,,Yes,,Ductal carcinoma in situ,1/4/2024,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.5,,,,,,,,,,20,,,,,,
BCSB1027,,,170.2,79.4,27.4,No,,,,Yes,,Ductal carcinoma in situ,1/4/2024,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.4,"after surgical intervention, but before chemo or radiation",1.1,,,20,,,,,,
BCSB1198,,,167.6,78.9,28.1,Yes,Calcifications,1/23/2023,Left,Yes,,Ductal carcinoma in situ,1/23/2023,Left,1/23/2023,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,10,Low," ER+, PR+, HER2-",98,3,30,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,17,,,,,,
BCSB1198,,,167.6,78.9,28.1,Yes,Calcifications,1/23/2023,Left,Yes,,Ductal carcinoma in situ,1/23/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.6,,,,,,,,,,17,,,,,,
BCSB1198,,,167.6,78.9,28.1,Yes,Calcifications,1/23/2023,Left,Yes,,Ductal carcinoma in situ,1/23/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.1,0.6,"after surgical intervention, but before chemo or radiation",0.75,0.85,,17,,,,,,
BCSB1203,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1210,,,157.5,71.6,28.9,No,,,,Yes,,Ductal carcinoma in situ,2/7/2022,Left,10/28/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,,," ER+, PR+, HER2-",90,3,90,3,Unknown,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,2,,,,,,
BCSB1210,,,157.5,71.6,28.9,No,,,,Yes,,Ductal carcinoma in situ,2/7/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,,,,,,,,,,2,,,,,,
BCSB1210,,,157.5,71.6,28.9,No,,,,Yes,,Ductal carcinoma in situ,2/7/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,1.3,"after surgical intervention, but before chemo or radiation",1.8,0.2,,2,,,,,,
BCSB1212,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1204,,,162.6,84.4,31.9,Yes,Calcifications,9/1/2020,Right,Yes,,Ductal carcinoma in situ,1/1/2007,"Right, had lumpectomy",9/1/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,3,,," ER+, PR-, HER2-",90,3,0,0,2,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,39,,,,,,
BCSB1204,,,162.6,84.4,31.9,Yes,Calcifications,9/1/2020,Right,Yes,,Ductal carcinoma in situ,1/1/2007,"Right, had lumpectomy",9/1/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",90,3,30,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,39,,,,,,
BCSB1204,,,162.6,84.4,31.9,Yes,Calcifications,9/1/2020,Right,Yes,,Ductal carcinoma in situ,1/1/2007,"Right, had lumpectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.4,Right,,,,,,,,,39,,,,,,
BCSB1204,,,162.6,84.4,31.9,Yes,Calcifications,9/1/2020,Right,Yes,,Ductal carcinoma in situ,1/1/2007,"Right, had lumpectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,0.9,Left,,,,,,,,,39,,,,,,
BCSB1204,,,162.6,84.4,31.9,Yes,Calcifications,9/1/2020,Right,Yes,,Ductal carcinoma in situ,1/1/2007,"Right, had lumpectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,21.2,1.4,"after surgical intervention, but before chemo or radiation",1.6,0.3,Right,39,,,,,,
BCSB1204,,,162.6,84.4,31.9,Yes,Calcifications,9/1/2020,Right,Yes,,Ductal carcinoma in situ,1/1/2007,"Right, had lumpectomy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,1.3,0.9,"after surgical intervention, but before chemo or radiation",0.6,0.7,Left,39,,,,,,
BCSB1192,,,160,88,34.4,Unknown,,,,Yes,,Ductal carcinoma in situ,6/7/2018,Left,6/7/2018,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N3: Ipsilateral internal mammary LN(s),MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage IIIa,X,,,X,Ductal,,1,,," ER+, PR+, HER2-",95,3,40,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1192,,,160,88,34.4,Unknown,,,,Yes,,Ductal carcinoma in situ,6/7/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,10.6,,,,,,,,,,,,,,,,
BCSB1192,,,160,88,34.4,Unknown,,,,Yes,,Ductal carcinoma in situ,6/7/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,7.6,"after surgical intervention, after neoadjuvant treatment",1.7,1,,,,,,,,
BCSB1218,,,154.9,47.6,19.8,Yes,Calcifications,10/21/2022,Left,No,,,,,11/1/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,X,,,,Ductal,,3,70,High," ER-, PR-, HER2-",0,0,0,0,0,Unknown,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB1218,,,154.9,47.6,19.8,Yes,Calcifications,10/21/2022,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.8,,,,,,,,,,,,,,,,
BCSB1218,,,154.9,47.6,19.8,Yes,Calcifications,10/21/2022,Left,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.3,2.8,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1219,,,165.1,86.2,31.6,Yes,Fibroadenoma,12/13/2018,Right,Yes,,Ductal carcinoma in situ,4/21/2020,Right,3/31/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,,Ductal,,2,1,Low," ER+, PR+, HER2-",95,3,50,2,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,23,,,,,,
BCSB1219,,,165.1,86.2,31.6,Yes,Fibroadenoma,12/13/2018,Right,Yes,,Ductal carcinoma in situ,4/21/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.9,,,,,,,,,,23,,,,,,
BCSB1219,,,165.1,86.2,31.6,Yes,Fibroadenoma,12/13/2018,Right,Yes,,Ductal carcinoma in situ,4/21/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.1,1.9,"after surgical intervention, but before chemo or radiation",2.2,1.4,,23,,,,,,
BCSB1164,,,149.9,79.2,35.2,Yes,Fibrocystic Breast Changes,1/31/2022,Right,No,,,,,1/31/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N3: Ipsilateral internal mammary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIc,X,,,,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,Not performed,Non-amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB1164,,,149.9,79.2,35.2,Yes,Fibrocystic Breast Changes,1/31/2022,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.6,,,,,,,,,,,,,,,,
BCSB1164,,,149.9,79.2,35.2,Yes,Fibrocystic Breast Changes,1/31/2022,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,2.6,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1225,,,170.2,90.7,31.3,Yes,Calcifications,10/20/2021,Left,Yes,,Ductal carcinoma in situ,11/9/2021,"Left, Right Breast DCIS on 02/23/2022",2/23/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,,," ER+, PR+, HER2+",99,3,100,3,Not performed,Amplified,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB1225,,,170.2,90.7,31.3,Yes,Calcifications,10/20/2021,Left,Yes,,Ductal carcinoma in situ,11/9/2021,"Left, Right Breast DCIS on 02/23/2022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1,,,,,,,,,,,,,,,,
BCSB1225,,,170.2,90.7,31.3,Yes,Calcifications,10/20/2021,Left,Yes,,Ductal carcinoma in situ,11/9/2021,"Left, Right Breast DCIS on 02/23/2022",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.4,0.75,"after surgical intervention, but before chemo or radiation",0.95,0.1,,,,,,,,
BCSB1224,,,167.6,99.8,35.5,No,,,,No,,,,,3/3/2023,Invasive lobular carcinoma,,,,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,,Lobular,,2,10,Low," ER+, PR+, HER2-",95,3,90,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,11,,,,,,
BCSB1224,,,167.6,99.8,35.5,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.4,,,,,,,,,,11,,,,,,
BCSB1224,,,167.6,99.8,35.5,No,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.4,"after surgical intervention, but before chemo or radiation",3.2,0.7,,11,,,,,,
BCSB1227,,,160,54,21.1,Yes,Breast Cysts,1/1/1992,Left,Yes,,Ductal carcinoma in situ,3/26/2024,Right,10/9/2023,Other(s) (specify),T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,,X,,,Ductal,,2,35,High," HER2+, ER-, PR-",0,0,0,0,Not performed,Amplified,"ER- PR- HER2+, IDC subtype: Invasive carcinoma with apocrine differentiation",,,,,,,,,,,,,,,,,,,,,,,
BCSB1227,,,160,54,21.1,Yes,Breast Cysts,1/1/1992,Left,Yes,,Ductal carcinoma in situ,3/26/2024,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.3,,,,,,,,,,,,,,,,
BCSB1227,,,160,54,21.1,Yes,Breast Cysts,1/1/1992,Left,Yes,,Ductal carcinoma in situ,3/26/2024,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.9,3.3,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1231,,,152.4,68,29.3,No,,,,Yes,,Ductal carcinoma in situ,7/17/2020,Right,7/17/2020,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,X,Ductal,,2,,," ER+, PR+, HER2-",99,3,98,3,1,Non-amplified,"ER+ PR+ HER2- , 1.1cm",,,,,,,,,,,,,,,,,11,,,,,,
BCSB1231,,,152.4,68,29.3,No,,,,Yes,,Ductal carcinoma in situ,7/17/2020,Right,7/17/2020,Papillary carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,X,Other,Favorable: papillary,3,,," ER+, PR+, HER2-",98,3,95,2,1,Non-amplified,"ER+ PR+ HER2- , 1.0cm",,,,,,,,,,,,,,,,,11,,,,,,
BCSB1231,,,152.4,68,29.3,No,,,,Yes,,Ductal carcinoma in situ,7/17/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.1,,,,,,,,,,11,,,,,,
BCSB1231,,,152.4,68,29.3,No,,,,Yes,,Ductal carcinoma in situ,7/17/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,2.1,"after surgical intervention, but before chemo or radiation",1.1,1,second focus 1.0cm,11,,,,,,
BCSB1233,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1234,,,149.9,72.6,32.3,Yes,Calcifications,8/13/2019,"Left, Mammogram",Yes,,Ductal carcinoma in situ,4/6/2023,Left,1/3/2023,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,2,,," ER+, PR-, HER2-",5,1,0,0,Not performed,Non-amplified,ER+ (Low Positive) PR- HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1234,,,149.9,72.6,32.3,Yes,Calcifications,8/13/2019,"Left, Mammogram",Yes,,Ductal carcinoma in situ,4/6/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.8,,,,,,,,,,,,,,,,
BCSB1234,,,149.9,72.6,32.3,Yes,Calcifications,8/13/2019,"Left, Mammogram",Yes,,Ductal carcinoma in situ,4/6/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,0.8,"after surgical intervention, but before chemo or radiation",1,2.5,,,,,,,,
BCSB1235,,,152.4,112.5,48.4,Yes,Fibroadenoma,9/27/2021,Left,Yes,,Ductal carcinoma in situ,7/26/2022,Left,9/27/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),MX: cannot be assessed,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage IIb,X,,,X,Ductal,,3,3,Low," ER+, PR+, HER2-",90,3,80,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,High Risk,,,,,
BCSB1235,,,152.4,112.5,48.4,Yes,Fibroadenoma,9/27/2021,Left,Yes,,Ductal carcinoma in situ,7/26/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,3.7,other focus 3.3cm,,,,,,,,,,High Risk,,,,,
BCSB1235,,,152.4,112.5,48.4,Yes,Fibroadenoma,9/27/2021,Left,Yes,,Ductal carcinoma in situ,7/26/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,3.7,"after surgical intervention, after neoadjuvant treatment",2.1,1.5,,,High Risk,,,,,
BCSB1239,,,167.6,94.8,33.7,Yes,Peripheral Intraductal Papillomas,5/5/2021,Left,Yes,,Ductal carcinoma in situ,9/29/2023,Left,9/29/2023,Invasive ductal carcinoma,,,MX: cannot be assessed,T1mic:Microinvasion <=0.1 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+",90,3,70,3,Not performed,Unknown,"ER+ PR+ , HER2 test not performed due to insufficient tissue 0.1cm",,,,,,,,,,,,,,,,,,,,,,,
BCSB1239,,,167.6,94.8,33.7,Yes,Peripheral Intraductal Papillomas,5/5/2021,Left,Yes,,Ductal carcinoma in situ,9/29/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.6,0.6 cm of grouped coarse heterogenous calcifications.,,,,,,,,,,,,,,,
BCSB1239,,,167.6,94.8,33.7,Yes,Peripheral Intraductal Papillomas,5/5/2021,Left,Yes,,Ductal carcinoma in situ,9/29/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,3.5,0.6,"after surgical intervention, but before chemo or radiation",0.1,1.3,,,,,,,,
BCSB1241,,,160,88.5,34.6,No,,,,Yes,,Ductal carcinoma in situ,5/9/2022,Left,5/9/2022,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,Tis:DCIS/LCIS/Paget's dis w/o associated tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIIa,X,,,X,Ductal,,2,15,Low," ER+, PR+, HER2-",90,3,40,2,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1241,,,160,88.5,34.6,No,,,,Yes,,Ductal carcinoma in situ,5/9/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,8.8,,,,,,,,,,,,,,,,
BCSB1241,,,160,88.5,34.6,No,,,,Yes,,Ductal carcinoma in situ,5/9/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,8.8,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1217,,,162.6,90.7,34.3,No,,,,Yes,,Ductal carcinoma in situ,11/5/2020,Right,10/5/2020,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,X,Ductal,,1,13,Low," ER+, PR+, HER2-",93,3,47,3,1,Non-amplified,"ER+ PR+ HER2-, Grade 2 on surgical report",,,,,,,,,,,,,,,,,4,,,,,,
BCSB1217,,,162.6,90.7,34.3,No,,,,Yes,,Ductal carcinoma in situ,11/5/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.6,,,,,,,,,,4,,,,,,
BCSB1217,,,162.6,90.7,34.3,No,,,,Yes,,Ductal carcinoma in situ,11/5/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.5,1.6,"after surgical intervention, but before chemo or radiation",1.8,0.2,"other foci: 0.9cm,0.5cm,0.3cm",4,,,,,,
BCSB1230,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1246,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1248,,,160,100.4,39.2,Yes,Fibrocystic Breast Changes,9/7/2023,Bilateral,No,,,,,9/7/2023,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,1,,," ER+, PR+, HER2-",90,3,90,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,10,,,,,,
BCSB1248,,,160,100.4,39.2,Yes,Fibrocystic Breast Changes,9/7/2023,Bilateral,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.1,,,,,,,,,,10,,,,,,
BCSB1248,,,160,100.4,39.2,Yes,Fibrocystic Breast Changes,9/7/2023,Bilateral,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.3,1.1,"after surgical intervention, but before chemo or radiation",1.5,0.2,,10,,,,,,
BCSB1249,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1226,,,152.4,60.3,26,Yes,Breast Cysts,8/1/2023,Left,Yes,,Ductal carcinoma in situ,8/3/2023,"Right, LCIS on 10/04/2023",8/3/2023,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,,X,,,Ductal,,2,32,High," ER+, PR+, HER2+",80,3,49,2,3+,Unknown,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB1226,,,152.4,60.3,26,Yes,Breast Cysts,8/1/2023,Left,Yes,,Ductal carcinoma in situ,8/3/2023,"Right, LCIS on 10/04/2023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,,,,,,,,,,,,,,,,
BCSB1226,,,152.4,60.3,26,Yes,Breast Cysts,8/1/2023,Left,Yes,,Ductal carcinoma in situ,8/3/2023,"Right, LCIS on 10/04/2023",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,1.5,"after surgical intervention, but before chemo or radiation",1.8,0.5,,,,,,,,
BCSB1245,,,160,79.4,31,No,,,,Yes,,Ductal carcinoma in situ,9/22/2021,Left,9/22/2021,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,3,,," ER+, PR+, HER2-",80,3,80,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,27,,,,,,
BCSB1245,,,160,79.4,31,No,,,,Yes,,Ductal carcinoma in situ,9/22/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.3,,,,,,,,,,27,,,,,,
BCSB1245,,,160,79.4,31,No,,,,Yes,,Ductal carcinoma in situ,9/22/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,2.3,"after surgical intervention, but before chemo or radiation",0.9,0.9,,27,,,,,,
BCSB1247,,,149.9,56.7,25.2,No,,,,Yes,,Ductal carcinoma in situ,8/30/2022,Right,8/30/2022,Invasive ductal carcinoma,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,,," ER+, PR+, HER2-",95,3,95,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1247,,,149.9,56.7,25.2,No,,,,Yes,,Ductal carcinoma in situ,8/30/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.5,,,,,,,,,,,,,,,,
BCSB1247,,,149.9,56.7,25.2,No,,,,Yes,,Ductal carcinoma in situ,8/30/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.3,0.5,"after surgical intervention, but before chemo or radiation",0.3,1.3,,,,,,,,
BCSB0703,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1252,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1253,,,165.1,89.8,32.9,Yes,Central Intraductal Papilloma,7/31/2017,Left,Yes,,Ductal carcinoma in situ,2/22/2018,Left,2/22/2018,Invasive ductal carcinoma,,,MX: cannot be assessed,T1b:>0.5 cm but <=1.0 cm,pNX: Regional LNs cannot be assessed,MX: cannot be assessed,Stage Ia,X,,,X,Ductal,,1,,," ER+, PR-, HER2-",80,2,0,0,Not performed,Non-amplified,ER+ PR- HER2-,,,,,,,,,,,,,,,,,26,,,,,,
BCSB1253,,,165.1,89.8,32.9,Yes,Central Intraductal Papilloma,7/31/2017,Left,Yes,,Ductal carcinoma in situ,2/22/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,,"There is no Biopsy or Tumor imaging, Tumor was diagnosed during size reduction/intraductal papilloma surgery.",,,,,,,,,26,,,,,,
BCSB1253,,,165.1,89.8,32.9,Yes,Central Intraductal Papilloma,7/31/2017,Left,Yes,,Ductal carcinoma in situ,2/22/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,"after surgical intervention, but before chemo or radiation",0.8,0.1,"There is no Biopsy or Tumor imaging, Tumor was diagnosed during size reduction/intraductal papilloma surgery.",26,,,,,,
BCSB1254,,,162.6,57.6,21.8,Yes,Atypical Ductal Hyperplasia,12/6/2022,Left,Yes,,Ductal carcinoma in situ,12/12/2022,Left,12/12/2022,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,,T1mic:Microinvasion <=0.1 cm,pN0: No regional LNs metastasis,,Stage IIa,X,,,X,Ductal,,2,25,High," ER+, PR+, HER2+",80,,90,,3+,Amplified,"Triple Positive, residual tumor T1mi ER+, PR-, HER2- disease that is distinct, G1, and low Ki-67",,,,,,,,,,,,,,,,,,,,,,,
BCSB1254,,,162.6,57.6,21.8,Yes,Atypical Ductal Hyperplasia,12/6/2022,Left,Yes,,Ductal carcinoma in situ,12/12/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,5,"There are at least 6 masses.
Extent of disease is difficult to determine, the disease may very well span to 5 cm or greater.",,,,,,,,,,,,,,,
BCSB1254,,,162.6,57.6,21.8,Yes,Atypical Ductal Hyperplasia,12/6/2022,Left,Yes,,Ductal carcinoma in situ,12/12/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,5,"after surgical intervention, after neoadjuvant treatment",1,0.8,"at least 6 masses diagnosed: 1.4cm, 0.6cm, .",,,,,,,
BCSB1255,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0781,,,164.5,59.9,22.1,Yes,Breast Cysts,1/19/2022,Bilateral,Yes,,Ductal carcinoma in situ,12/19/2022,Left,11/10/2022,Invasive ductal carcinoma,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T3:Tumor >5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage IIIa,X,,,,Ductal,Favorable: mucinous,2,40,High," ER+, PR+, HER2-",95,3,75,2,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB0781,,,164.5,59.9,22.1,Yes,Breast Cysts,1/19/2022,Bilateral,Yes,,Ductal carcinoma in situ,12/19/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,5.8,,,,,,,,,,,,,,,,
BCSB0781,,,164.5,59.9,22.1,Yes,Breast Cysts,1/19/2022,Bilateral,Yes,,Ductal carcinoma in situ,12/19/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,5.8,"after surgical intervention, but before chemo or radiation",9.1,0.1,,,,,,,,
BCSB1236,,,157.5,70.3,28.3,Yes,Calcifications,11/25/2019,Left,Yes,,Ductal carcinoma in situ,11/25/2019,Left,11/25/2019,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,X,Ductal,,2,,," ER+, PR+, HER2+",80,2,40,2,3+,Unknown,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB1236,,,157.5,70.3,28.3,Yes,Calcifications,11/25/2019,Left,Yes,,Ductal carcinoma in situ,11/25/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,with 9cm tumor bed according to the MRI,,,,,,,,,,,,,,,
BCSB1236,,,157.5,70.3,28.3,Yes,Calcifications,11/25/2019,Left,Yes,,Ductal carcinoma in situ,11/25/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.5,"after surgical intervention, after neoadjuvant treatment",0,0,with 9cm tumor bed according to the MRI,,,,,,,
BCSB1228,,,162.6,77.1,29.2,No,,,,Yes,,Ductal carcinoma in situ,2/2/2021,Left,8/6/2020,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,X,,,,Ductal,,2,47,High," HER2+, ER-, PR-",0,0,0,0,3+,Unknown,"ER- PR- HER2+
Left Axilla biopsy: ER+ 30%,  PR+ 20%, HER2+ (Amplified)",,,,,,,,,,,,,,,,,,,,,,,
BCSB1228,,,162.6,77.1,29.2,No,,,,Yes,,Ductal carcinoma in situ,2/2/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,4.3,,,,,,,,,,,,,,,,
BCSB1228,,,162.6,77.1,29.2,No,,,,Yes,,Ductal carcinoma in situ,2/2/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.8,3.4,"after surgical intervention, after neoadjuvant treatment",4.5,0.1,,,,,,,,
BCSB1243,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1258,,,162.6,59.9,22.7,Yes,Calcifications,10/10/2019,Right,No,,,,,7/20/2020,Invasive lobular carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Lobular,,2,,," ER+, PR+, HER2-",90,3,90,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,21,,,,,,
BCSB1258,,,162.6,59.9,22.7,Yes,Calcifications,10/10/2019,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.2,,,,,,,,,,21,,,,,,
BCSB1258,,,162.6,59.9,22.7,Yes,Calcifications,10/10/2019,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,1.2,"after surgical intervention, but before chemo or radiation",1.1,0.2,,21,,,,,,
BCSB1263,,,152.4,72.6,31.3,No,,,,Yes,,Ductal carcinoma in situ,7/3/2019,Left,7/3/2019,Invasive ductal carcinoma,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",95,3,95,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1263,,,152.4,72.6,31.3,No,,,,Yes,,Ductal carcinoma in situ,7/3/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.5,,,,,,,,,,,,,,,,
BCSB1263,,,152.4,72.6,31.3,No,,,,Yes,,Ductal carcinoma in situ,7/3/2019,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,0.5,"after surgical intervention, but before chemo or radiation",0.2,1.2,,,,,,,,
BCSB1269,,,157.5,55.8,22.5,Yes,Calcifications,9/2/2022,Right,Yes,,Ductal carcinoma in situ,9/2/2022,Right,11/29/2022,Mixed IDC+ILC (50 -90% each component),,,,T1b:>0.5 cm but <=1.0 cm,pNX: Regional LNs cannot be assessed,,Stage Ia,,X,,,Ductal,,2,17,Low," ER+, PR+, HER2-",99,3,3,1,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,27,,,,,,
BCSB1269,,,157.5,55.8,22.5,Yes,Calcifications,9/2/2022,Right,Yes,,Ductal carcinoma in situ,9/2/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.8,,,,,,,,,,27,,,,,,
BCSB1269,,,157.5,55.8,22.5,Yes,Calcifications,9/2/2022,Right,Yes,,Ductal carcinoma in situ,9/2/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,0.8,"after surgical intervention, but before chemo or radiation",0.9,0.85,,27,,,,,,
BCSB1271,,,165.1,61.2,22.5,Yes,Breast Cysts,6/1/2017,,Yes,,Ductal carcinoma in situ,4/16/2021,Right,4/16/2021,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,,X,,X,Ductal,,1,,," ER+, PR+, HER2-",95,3,95,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,9,,,,,,
BCSB1271,,,165.1,61.2,22.5,Yes,Breast Cysts,6/1/2017,,Yes,,Ductal carcinoma in situ,4/16/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.6,,,,,,,,,,9,,,,,,
BCSB1271,,,165.1,61.2,22.5,Yes,Breast Cysts,6/1/2017,,Yes,,Ductal carcinoma in situ,4/16/2021,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,0.6,"after surgical intervention, but before chemo or radiation",1.5,0.3,multiple foci (at least 20 foci) varying in size from 0.2 - 1.5 cm,9,,,,,,
BCSB0913,,,154,55.1,23.2,Yes,Calcifications,6/30/2021,Right,Yes,,Ductal carcinoma in situ,9/19/2022,Right,10/4/2022,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,,X,,X,Ductal,,1,,," ER+, PR+, HER2-",100,3,50,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,12,,,,,,
BCSB0913,,,154,55.1,23.2,Yes,Calcifications,6/30/2021,Right,Yes,,Ductal carcinoma in situ,9/19/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,"6.5cm Area with a total of at least 3 masses.  Other foci: 1.6cm, 1.1cm",,,,,,,,,12,,,,,,
BCSB0913,,,154,55.1,23.2,Yes,Calcifications,6/30/2021,Right,Yes,,Ductal carcinoma in situ,9/19/2022,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.9,"after surgical intervention, but before chemo or radiation",2.3,0.5,"Other foci: 1.7cm, 1.5cm and 3 additional foci",12,,,,,,
BCSB1286,,,165.1,99.8,36.6,Yes,Adenosis,3/29/2024,"Right, and Fibrocystic changes",No,,,,,8/7/2023,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N1: Movable ipsilateral axillary LN(s),,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,,Stage IIb,,X,,,Ductal,Unfavorable: squamous,3,72,High," ER-, PR-, HER2-",0,0,0,0,Not performed,Non-amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB1286,,,165.1,99.8,36.6,Yes,Adenosis,3/29/2024,"Right, and Fibrocystic changes",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.7,,,,,,,,,,,,,,,,
BCSB1286,,,165.1,99.8,36.6,Yes,Adenosis,3/29/2024,"Right, and Fibrocystic changes",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,4.5,2.7,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1288,,,165.1,89.8,32.9,Yes,Calcifications,3/17/2020,Right,Yes,,Ductal carcinoma in situ,3/17/2020,Right,3/17/2020,Inflammatory breast cancer,T4d:Inflammatory carcinoma,N0: No regional LNs metastasis,,T2:Tumor >2.0 cm but <=5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,,Stage IIIb,,X,,,Ductal,,1,5,Low," ER+, PR+, HER2-",90,3,50,2,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1288,,,165.1,89.8,32.9,Yes,Calcifications,3/17/2020,Right,Yes,,Ductal carcinoma in situ,3/17/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,3.4,,,,,,,,,,,,,,,,
BCSB1288,,,165.1,89.8,32.9,Yes,Calcifications,3/17/2020,Right,Yes,,Ductal carcinoma in situ,3/17/2020,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,3.4,"after surgical intervention, after neoadjuvant treatment",4,3.2,,,,,,,,
BCSB1287,,,157.5,58.1,23.4,No,,,,Yes,,Ductal carcinoma in situ,4/11/2023,Left,2/7/2023,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage IIb,X,,,X,Ductal,,2,20,High," ER+, PR+, HER2-",95,3,95,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,23,,,,,,
BCSB1287,,,157.5,58.1,23.4,No,,,,Yes,,Ductal carcinoma in situ,4/11/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.8,,,,,,,,,,23,,,,,,
BCSB1287,,,157.5,58.1,23.4,No,,,,Yes,,Ductal carcinoma in situ,4/11/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.6,1.8,"after surgical intervention, but before chemo or radiation",4.6,0.4,"other 2 foci: 0.7cm, 0.6cm",23,,,,,,
BCSB0935,,,167.6,75.7,26.9,Yes,Fibrocystic Breast Changes,3/20/2018,Bilateral,No,,,,,2/7/2018,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,10,Low," ER+, PR+, HER2-",97,,85,,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,"-0.341, High Risk",,,,,
BCSB0935,,,167.6,75.7,26.9,Yes,Fibrocystic Breast Changes,3/20/2018,Bilateral,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.4,,,,,,,,,,,"-0.341, High Risk",,,,,
BCSB0935,,,167.6,75.7,26.9,Yes,Fibrocystic Breast Changes,3/20/2018,Bilateral,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,0.8,"after surgical intervention, but before chemo or radiation",1.4,0.6,,,"-0.341, High Risk",,,,,
BCSB1137,,,157.5,68.9,27.8,Unknown,,,,Yes,,Ductal carcinoma in situ,7/16/2021,Left,7/16/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage IIIa,X,,,,Ductal,,2,1,Low," ER+, PR+, HER2-",90,3,80,3,2,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1137,,,157.5,68.9,27.8,Unknown,,,,Yes,,Ductal carcinoma in situ,7/16/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.2,,,,,,,,,,,,,,,,
BCSB1137,,,157.5,68.9,27.8,Unknown,,,,Yes,,Ductal carcinoma in situ,7/16/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,2.2,"after surgical intervention, but before chemo or radiation",2.3,0.7,,,,,,,,
BCSB1296,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1299,,,152.4,113.4,48.8,Yes,Fibrocystic Breast Changes,10/11/2018,Right,Yes,,Ductal carcinoma in situ,10/11/2018,Left,10/11/2018,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,,," ER+, PR+, HER2-",95,3,90,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,12,,,,,,
BCSB1299,,,152.4,113.4,48.8,Yes,Fibrocystic Breast Changes,10/11/2018,Right,Yes,,Ductal carcinoma in situ,10/11/2018,Left,10/11/2018,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,,," ER+, PR+, HER2-",100,3,90,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,12,,,,,,
BCSB1299,,,152.4,113.4,48.8,Yes,Fibrocystic Breast Changes,10/11/2018,Right,Yes,,Ductal carcinoma in situ,10/11/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.6,Left Breast,,,,,,,,,12,,,,,,
BCSB1299,,,152.4,113.4,48.8,Yes,Fibrocystic Breast Changes,10/11/2018,Right,Yes,,Ductal carcinoma in situ,10/11/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,1.5,Right Breast,,,,,,,,,12,,,,,,
BCSB1299,,,152.4,113.4,48.8,Yes,Fibrocystic Breast Changes,10/11/2018,Right,Yes,,Ductal carcinoma in situ,10/11/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,1,"after surgical intervention, but before chemo or radiation",1.5,0.4,Left Breast,12,,,,,,
BCSB1299,,,152.4,113.4,48.8,Yes,Fibrocystic Breast Changes,10/11/2018,Right,Yes,,Ductal carcinoma in situ,10/11/2018,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,4,1.4,"after surgical intervention, but before chemo or radiation",1.7,1.4,Right Breast,12,,,,,,
BCSB1301,,,162.6,87.1,32.9,Yes,Atypical Ductal Hyperplasia,5/10/2023,Right,Yes,,Ductal carcinoma in situ,6/26/2023,"Right, LCIS was diagnosed on 07/21/2023 Right breast",6/26/2023,Invasive ductal carcinoma,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN1: movable ipsilateral axillary LN(s),M0: No distant metastasis,Stage Ia,,X,,,Ductal,,2,9,Low," ER+, PR+, HER2-",100,3,100,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,15,,,,,,
BCSB1301,,,162.6,87.1,32.9,Yes,Atypical Ductal Hyperplasia,5/10/2023,Right,Yes,,Ductal carcinoma in situ,6/26/2023,"Right, LCIS was diagnosed on 07/21/2023 Right breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.4,,,,,,,,,,15,,,,,,
BCSB1301,,,162.6,87.1,32.9,Yes,Atypical Ductal Hyperplasia,5/10/2023,Right,Yes,,Ductal carcinoma in situ,6/26/2023,"Right, LCIS was diagnosed on 07/21/2023 Right breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.1,0.4,"after surgical intervention, but before chemo or radiation",0.52,0.5,,15,,,,,,
BCSB1305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1310,,,162.6,59.9,22.7,Yes,Fibroadenoma,4/3/2018,Left,Yes,,Ductal carcinoma in situ,2/21/2018,Right,2/21/2018,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,,Ductal,,3,25,High," ER-, PR-, HER2-",0,0,0,0,0,Non-amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB1310,,,162.6,59.9,22.7,Yes,Fibroadenoma,4/3/2018,Left,Yes,,Ductal carcinoma in situ,2/21/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,0.8,,,,,,,,,,,,,,,,
BCSB1310,,,162.6,59.9,22.7,Yes,Fibroadenoma,4/3/2018,Left,Yes,,Ductal carcinoma in situ,2/21/2018,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.7,0.2,"after surgical intervention, but before chemo or radiation",0.4,0.1,,,,,,,,
BCSB1312,,,165.1,59.9,22,Yes,Calcifications,3/5/2021,Left,Yes,,Ductal carcinoma in situ,3/26/2021,Left,3/26/2021,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,49,High," ER+, PR+, HER2-",26,1,91,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,27,,,,,,
BCSB1312,,,165.1,59.9,22,Yes,Calcifications,3/5/2021,Left,Yes,,Ductal carcinoma in situ,3/26/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.9,,,,,,,,,,27,,,,,,
BCSB1312,,,165.1,59.9,22,Yes,Calcifications,3/5/2021,Left,Yes,,Ductal carcinoma in situ,3/26/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.3,0.9,"after surgical intervention, but before chemo or radiation",1.05,0.15,,27,,,,,,
BCSB1313,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1315,,,154.9,65.3,27.2,Yes,Fibrocystic Breast Changes,12/8/2022,Right,Yes,,Ductal carcinoma in situ,11/11/2022,Left,11/11/2022,Invasive ductal carcinoma,,,,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,,Ductal,,2,10,Low," ER+, PR+, HER2-",95,3,5,1,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,31,,,,,,
BCSB1315,,,154.9,65.3,27.2,Yes,Fibrocystic Breast Changes,12/8/2022,Right,Yes,,Ductal carcinoma in situ,11/11/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.8,,,,,,,,,,31,,,,,,
BCSB1315,,,154.9,65.3,27.2,Yes,Fibrocystic Breast Changes,12/8/2022,Right,Yes,,Ductal carcinoma in situ,11/11/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.2,0.6,"after surgical intervention, but before chemo or radiation",0.9,0.75,,31,,,,,,
BCSB1318,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1323,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB0852,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1008,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1328,,,154.9,80.7,33.6,No,,,,Yes,,Ductal carcinoma in situ,5/13/2022,"Left, and LCIS in the Right breast",3/11/2022,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N1: Movable ipsilateral axillary LN(s),,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,,X,,,Lobular,,2,,," ER+, PR+, HER2-",97,3,99,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,15,,,,,,Right breast Oncotype
BCSB1328,,,154.9,80.7,33.6,No,,,,Yes,,Ductal carcinoma in situ,5/13/2022,"Left, and LCIS in the Right breast",4/26/2022,Invasive ductal carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,,Ductal,,1,9,Low," ER+, PR+, HER2-",91,3,91,3,0,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,15,,,,,,Right breast Oncotype
BCSB1328,,,154.9,80.7,33.6,No,,,,Yes,,Ductal carcinoma in situ,5/13/2022,"Left, and LCIS in the Right breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.3,Right,,,,,,,,,15,,,,,,Right breast Oncotype
BCSB1328,,,154.9,80.7,33.6,No,,,,Yes,,Ductal carcinoma in situ,5/13/2022,"Left, and LCIS in the Right breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,0.9,Left,,,,,,,,,15,,,,,,Right breast Oncotype
BCSB1328,,,154.9,80.7,33.6,No,,,,Yes,,Ductal carcinoma in situ,5/13/2022,"Left, and LCIS in the Right breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2,1.3,"after surgical intervention, but before chemo or radiation",1.2,1.5,Right,15,,,,,,Right breast Oncotype
BCSB1328,,,154.9,80.7,33.6,No,,,,Yes,,Ductal carcinoma in situ,5/13/2022,"Left, and LCIS in the Right breast",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,1.3,0.9,"after surgical intervention, but before chemo or radiation",1.3,2.1,Left,15,,,,,,Right breast Oncotype
BCSB1329,,,160,92.1,36,Yes,Fibrocystic Breast Changes,5/23/2023,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/23/2023,Left,5/23/2023,Invasive lobular carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,MX: cannot be assessed,T0:No evidence of primary tumor,pN1a:Only micrometastasis <=0.2 cm,MX: cannot be assessed,Stage Ia,X,,,,Lobular,,1,,," ER+, PR-, HER2-",90,3,0,0,Not performed,Non-amplified,"ER+ PR- HER2-
All disease may have been removed with core biopsy. No residual cancer in surgical pathology.",,,,,,,,,,,,,,,,,19,,,,,,
BCSB1329,,,160,92.1,36,Yes,Fibrocystic Breast Changes,5/23/2023,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/23/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.8,,,,,,,,,,19,,,,,,
BCSB1329,,,160,92.1,36,Yes,Fibrocystic Breast Changes,5/23/2023,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",5/23/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.1,0.6,"after surgical intervention, but before chemo or radiation",0,0,All disease may have been removed with core biopsy. No residual cancer in surgical pathology.,19,,,,,,
BCSB1330,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1320,,,162.6,80.3,30.4,Yes,Fibrocystic Breast Changes,5/21/2020,Left,Yes,,Ductal carcinoma in situ,5/21/2020,Left,3/23/2020,Invasive ductal carcinoma,,,MX: cannot be assessed,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,MX: cannot be assessed,Stage Ia,X,,,,Ductal,,2,,," ER+, PR+, HER2-",95,3,95,3,Not performed,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,5,,,,,,
BCSB1320,,,162.6,80.3,30.4,Yes,Fibrocystic Breast Changes,5/21/2020,Left,Yes,,Ductal carcinoma in situ,5/21/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.2,,,,,,,,,,5,,,,,,
BCSB1320,,,162.6,80.3,30.4,Yes,Fibrocystic Breast Changes,5/21/2020,Left,Yes,,Ductal carcinoma in situ,5/21/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.7,2.2,"after surgical intervention, but before chemo or radiation",1.5,0.6,,5,,,,,,
BCSB1331,,,162.6,65.8,24.9,Yes,Atypical Lobular Hyperplasia,10/6/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/27/2022,Bilateral,8/27/2022,Invasive lobular carcinoma,T3:Tumor >5.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIb,,X,,X,Lobular,,3,50,High," ER+, PR+, HER2+",80,3,90,3,3+,Unknown,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB1331,,,162.6,65.8,24.9,Yes,Atypical Lobular Hyperplasia,10/6/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/27/2022,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,6.3,,,,,,,,,,,,,,,,
BCSB1331,,,162.6,65.8,24.9,Yes,Atypical Lobular Hyperplasia,10/6/2022,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",8/27/2022,Bilateral,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,6.3,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1339,,,167.6,99.8,35.5,Yes,Fibroadenoma,7/30/2019,Right,No,,,,,2/12/2019,Invasive ductal carcinoma,T2:Tumor >2.0 cm but <=5.0 cm,NX: Regional LNs cannot be assessed,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage IIa,,X,,,Ductal,,3,,," ER-, PR-, HER2-",0,0,0,0,Unknown,Non-amplified,Triple Negative,,,,,,,,,,,,,,,,,,,,,,,
BCSB1339,,,167.6,99.8,35.5,Yes,Fibroadenoma,7/30/2019,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,2.4,,,,,,,,,,,,,,,,
BCSB1339,,,167.6,99.8,35.5,Yes,Fibroadenoma,7/30/2019,Right,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2.4,"after surgical intervention, after neoadjuvant treatment",1.3,0.5,,,,,,,,
BCSB1333,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1341,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1350,,,162.6,52.2,19.7,Yes,Fibroadenoma,9/1/2021,Right,Yes,,Ductal carcinoma in situ,12/17/2020,Left,11/27/2020,Invasive ductal carcinoma,,,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ib,X,,,,Ductal,,2,50,High," ER+, PR+, HER2-",95,3,10,3,2,Non-amplified,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1350,,,162.6,52.2,19.7,Yes,Fibroadenoma,9/1/2021,Right,Yes,,Ductal carcinoma in situ,12/17/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.5,,,,,,,,,,,,,,,,
BCSB1350,,,162.6,52.2,19.7,Yes,Fibroadenoma,9/1/2021,Right,Yes,,Ductal carcinoma in situ,12/17/2020,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,1.5,"after surgical intervention, but before chemo or radiation",1.5,0.3,,,,,,,,
BCSB1347,,,165.1,84.8,31.1,Yes,Adenosis,2/18/2021,Bilateral,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/18/2021,Left,1/21/2021,Invasive lobular carcinoma,,,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0(i+),M0: No distant metastasis,Stage Ib,X,,,X,Lobular,,2,,," ER+, PR+, HER2-",90,3,90,3,1,Unknown,,,,,,,,,,,,,,,,,,13,,,,,,
BCSB1347,,,165.1,84.8,31.1,Yes,Adenosis,2/18/2021,Bilateral,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/18/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,Local,1/27/2025,,"reported on 05/06/25, 6 month follow up, DCIS Left grade 3 1.1cm",,,,,,,,,,,,,13,,,,,,
BCSB1347,,,165.1,84.8,31.1,Yes,Adenosis,2/18/2021,Bilateral,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/18/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,,,,,,,,,,13,,,,,,
BCSB1347,,,165.1,84.8,31.1,Yes,Adenosis,2/18/2021,Bilateral,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",2/18/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",2.4,,"other foci: 1.1cm, 0.8cm, 0.2cm
Positive Margins",13,,,,,,
BCSB1349,,,165.1,104.3,38.3,Yes,Atypical Ductal Hyperplasia,5/16/2022,Left,Yes,,Ductal carcinoma in situ,8/19/2022,Left,8/19/2022,Invasive ductal carcinoma,T1mic:Microinvasion <=0.1 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1b:>0.5 cm but <=1.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,2,30,High," ER+, PR+, HER2-",100,3,100,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,22,,,,,,
BCSB1349,,,165.1,104.3,38.3,Yes,Atypical Ductal Hyperplasia,5/16/2022,Left,Yes,,Ductal carcinoma in situ,8/19/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Unknown,,,,,,,,,,,22,,,,,,
BCSB1349,,,165.1,104.3,38.3,Yes,Atypical Ductal Hyperplasia,5/16/2022,Left,Yes,,Ductal carcinoma in situ,8/19/2022,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",0.8,0.2,,22,,,,,,
BCSB1351,,,154.9,63.5,26.5,No,,,,Yes,,Ductal carcinoma in situ,2/2/2024,Right,12/20/2023,Invasive ductal carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage IIa,,X,,X,Ductal,,2,3,Low," ER+, PR+, HER2-",70,2,100,3,0,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1351,,,154.9,63.5,26.5,No,,,,Yes,,Ductal carcinoma in situ,2/2/2024,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.6,,,,,,,,,,,,,,,,
BCSB1351,,,154.9,63.5,26.5,No,,,,Yes,,Ductal carcinoma in situ,2/2/2024,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,1.5,1.6,"after surgical intervention, but before chemo or radiation",2.2,0.5,and 0.9cm,,,,,,,
BCSB1352,,,160,69.4,27.1,Yes,Calcifications,10/20/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/20/2023,Right,11/28/2023,Invasive lobular carcinoma,,,,T1b:>0.5 cm but <=1.0 cm,pNX: Regional LNs cannot be assessed,,Stage Ia,,X,,,Lobular,,2,8,Low," ER+, PR+, HER2-",85,2,85,3,1,Non-amplified,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,20,,,,,,
BCSB1352,,,160,69.4,27.1,Yes,Calcifications,10/20/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/20/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,,Invasive tumor was diagnosed during lumpectomy surgery of LCIS.,,,,,,,,,20,,,,,,
BCSB1352,,,160,69.4,27.1,Yes,Calcifications,10/20/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",10/20/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,,,,"after surgical intervention, but before chemo or radiation",0.95,0.6,Invasive tumor was diagnosed during lumpectomy surgery of LCIS,20,,,,,,
BCSB0768,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1355,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1357,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1357,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Distant,7/7/2025,Bone,"Spinal biopsy. reported on 6/16/25, 6 month follow up",,,,,,,,,,,,,,,,,,,
BCSB1362,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1363,,,162.6,65.3,24.7,Yes,Fibrocystic Breast Changes,3/8/2022,Left,Yes,,Ductal carcinoma in situ,3/17/2023,Left,3/17/2023,Invasive ductal carcinoma,,,,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,,Stage Ia,X,,,X,Ductal,,3,60,High," ER+, PR+, HER2+",95,2,95,3,3+,Unknown,Triple Positive,,,,,,,,,,,,,,,,,,,,,,,
BCSB1363,,,162.6,65.3,24.7,Yes,Fibrocystic Breast Changes,3/8/2022,Left,Yes,,Ductal carcinoma in situ,3/17/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1,second focus 0.3cm,,,,,,,,,,,,,,,
BCSB1363,,,162.6,65.3,24.7,Yes,Fibrocystic Breast Changes,3/8/2022,Left,Yes,,Ductal carcinoma in situ,3/17/2023,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,0.7,0.9,"after surgical intervention, but before chemo or radiation",1.3,0.4,other focus: 0.15cm,,,,,,,
BCSB1365,,,170.2,92.5,31.9,Yes,Fibrocystic Breast Changes,7/7/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/5/2023,Right,6/5/2023,Invasive lobular carcinoma,T1b:>0.5 cm but <=1.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN2: to ipsilateral axillaryLN(s) fixed,M0: No distant metastasis,Stage IIb,,X,,,Lobular,,2,24,High," ER+, PR+, HER2-",90,,96,,0,Unknown,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1365,,,170.2,92.5,31.9,Yes,Fibrocystic Breast Changes,7/7/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/5/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,0.5,,,,,,,,,,,,,,,,
BCSB1365,,,170.2,92.5,31.9,Yes,Fibrocystic Breast Changes,7/7/2023,Right,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",6/5/2023,Right,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,0.8,"after surgical intervention, but before chemo or radiation",1.4,,,,,,,,,
BCSB1368,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1370,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1369,,,165.1,72.6,26.6,Yes,Atypical Lobular Hyperplasia,11/16/2021,Left,Yes,,Ductal carcinoma in situ,11/16/2021,Left,11/16/2021,Invasive ductal carcinoma,T1a:>0.1 but <=0.5 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T1c:>1.0 cm but <=2.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,X,Ductal,,2,5,Low," ER+, PR+, HER2-",90,2,80,2,2,Non-amplified,"ER+ PR+ HER2-, (ER 60%, PR 80%, HER2- , IHC 1+ on surgical pathology)",,,,,,,,,,,,,,,,,,,,,,,
BCSB1369,,,165.1,72.6,26.6,Yes,Atypical Lobular Hyperplasia,11/16/2021,Left,Yes,,Ductal carcinoma in situ,11/16/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,0.5,,,,,,,,,,,,,,,,
BCSB1369,,,165.1,72.6,26.6,Yes,Atypical Lobular Hyperplasia,11/16/2021,Left,Yes,,Ductal carcinoma in situ,11/16/2021,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,2.7,0.5,"after surgical intervention, but before chemo or radiation",1.3,0.1,second focus: 0.15cm,,,,,,,
BCSB1079,,,167.6,81.2,28.9,Yes,Atypical Ductal Hyperplasia,6/1/2016,Right,Yes,,Ductal carcinoma in situ,3/6/2019,"And LCIS, Bilateral",3/20/2019,Invasive lobular carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN1a:Only micrometastasis <=0.2 cm,M0: No distant metastasis,Stage IIb,X,,,X,Lobular,,1,2.4,Low," ER+, PR+, HER2-",74,3,71,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1079,,,167.6,81.2,28.9,Yes,Atypical Ductal Hyperplasia,6/1/2016,Right,Yes,,Ductal carcinoma in situ,3/6/2019,"And LCIS, Bilateral",4/24/2019,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,,X,,,Ductal,,1,2.4,Low," ER+, PR+, HER2-",100,3,100,3,1,Unknown,ER+ PR+ HER2-,,,,,,,,,,,,,,,,,,,,,,,
BCSB1079,,,167.6,81.2,28.9,Yes,Atypical Ductal Hyperplasia,6/1/2016,Right,Yes,,Ductal carcinoma in situ,3/6/2019,"And LCIS, Bilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,1.2,Left,,,,,,,,,,,,,,,
BCSB1079,,,167.6,81.2,28.9,Yes,Atypical Ductal Hyperplasia,6/1/2016,Right,Yes,,Ductal carcinoma in situ,3/6/2019,"And LCIS, Bilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,No,0.4,Right,,,,,,,,,,,,,,,
BCSB1079,,,167.6,81.2,28.9,Yes,Atypical Ductal Hyperplasia,6/1/2016,Right,Yes,,Ductal carcinoma in situ,3/6/2019,"And LCIS, Bilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",0.3,1,Left,,,,,,,
BCSB1079,,,167.6,81.2,28.9,Yes,Atypical Ductal Hyperplasia,6/1/2016,Right,Yes,,Ductal carcinoma in situ,3/6/2019,"And LCIS, Bilateral",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",0.5,1,Right,,,,,,,
BCSB1371,,,170.2,96.6,33.3,Yes,Atypical Lobular Hyperplasia,7/22/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/22/2024,Left,7/22/2024,Invasive lobular carcinoma,T1c:>1.0 cm but <=2.0 cm,N0: No regional LNs metastasis,M0: No distant metastasis,T2:Tumor >2.0 cm but <=5.0 cm,pN0: No regional LNs metastasis,M0: No distant metastasis,Stage Ia,X,,,,Lobular,,2,15,Low," ER+, PR+, HER2-",100,3,100,3,2,Non-amplified,,,,,,,,,,,,,,,,,,14,,,,,,
BCSB1371,,,170.2,96.6,33.3,Yes,Atypical Lobular Hyperplasia,7/22/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/22/2024,Left,9/6/2024,Invasive ductal carcinoma,,,M0: No distant metastasis,T1a:>0.1 but <=0.5 cm,pNX: Regional LNs cannot be assessed,M0: No distant metastasis,Stage Ia,X,,,,Ductal,,1,4,Low," ER+, PR+, HER2-",90,3,100,3,1,Non-amplified,,,,,,,,,,,,,,,,,,14,,,,,,
BCSB1371,,,170.2,96.6,33.3,Yes,Atypical Lobular Hyperplasia,7/22/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/22/2024,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,Yes,1.9,Invasive Lobular Carcinoma,,,,,,,,,14,,,,,,
BCSB1371,,,170.2,96.6,33.3,Yes,Atypical Lobular Hyperplasia,7/22/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/22/2024,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,Yes,0.4,Invasive Ductal Carcinoma,,,,,,,,,14,,,,,,
BCSB1371,,,170.2,96.6,33.3,Yes,Atypical Lobular Hyperplasia,7/22/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/22/2024,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,2,"after surgical intervention, but before chemo or radiation",2.2,3.1,Invasive Lobular Carcinoma,14,,,,,,
BCSB1371,,,170.2,96.6,33.3,Yes,Atypical Lobular Hyperplasia,7/22/2024,Left,Yes,,"Lobular carcinoma in situ (benign, increased risk for breast cancer)",7/22/2024,Left,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2,prior to ANY treatment including surgery,,,"after surgical intervention, but before chemo or radiation",0.35,1,Invasive Ductal Carcinoma,14,,,,,,
BCSB1376,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1377,,,170.2,123.4,42.6,Unknown,,,,No,,,,,3/31/2023,Inflammatory breast cancer,T3:Tumor >5.0 cm,N1: Movable ipsilateral axillary LN(s),,T0:No evidence of primary tumor,pN0: No regional LNs metastasis,,Stage IIIa,,X,,,Ductal,Unfavorable: Inflammatory,2,,," HER2+, ER-, PR-",0,0,0,0,Unknown,Unknown,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1377,,,170.2,123.4,42.6,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,No,5.3,,,,,,,,,,,,,,,,
BCSB1377,,,170.2,123.4,42.6,Unknown,,,,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1,prior to ANY treatment including surgery,,5.3,"after surgical intervention, after neoadjuvant treatment",0,0,,,,,,,,
BCSB1358,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1382,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1384,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1391,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1393,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1395,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1387,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1399,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCC1401,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1394,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1403,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1427,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1429,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1432,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1435,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1436,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1437,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1440,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
BCSB1401,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
